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SUMMARY OF THESIS
Aspects of Glucose Metabolism in Uraemia
This thesis takes the form of a tripartite study on aspects of 
glucose metabolism in uraemia. The work examines certain biochemical 
aspects of glucose metabolism in a clinical context.
Continuous ambulatory peritoneal dialysis (CAPD) is a relatively 
new but now established mode of renal replacement therapy, that 
presents an unique clinical situation in that glucose is continuously 
self-administered intraperitoneally to control fluid balance. The 
metabolic consequences are thus clinically important.
The first 4 chapters review the background to the work and include 
the topics of glucose homeostasis, glucose metabolism in uraemia, CAPD 
and glycosylated haemoglobin. Chapter 5 describes the biochemical 
methods and chapters 6, 7 and 8 detail the three projects performed.
1. The first project "Pancreatic Beta Cell Function in Uraemia" 
evaluated beta cell function in renal failure. The specific 
objective was to determine if CAPD adversely affected the beta 
cell secretory capacity. Beta cell integrity was also 
investigated in diabetics to assess the effect of uraemia and 
dialysis.
2. Residual beta cell function was assessed, in 70 patients, by 
using intravenous glucagon stimulation and measuring in the 
peripheral blood the beta cell peptide response.
Fasting glucose and insulin concentrations were normal in uraemic 
patients but c-peptide was grossly elevated due to impaired renal 
catabolism. Following glucagon stimulation, an exaggerated blood 
glucose response with delayed glucose peak was observed, while 
the peak insulin response was normal, but the return to basal 
concentrations was delayed. The c-peptide response was 
exaggerated and peak concentrations were greatly increased. 
Responses were similar in all non-diabetic uraemic patients. The 
above features reflect glucose intolerance in uraemia which 
persisted despite dialysis therapy.
The glucagon challenge showed significant increments in the beta 
cell peptides reflecting adequate residual pancreatic function. 
The response was similar in both new and established CAPD 
patients compared to non-dialysed uraemics and haemodialysis 
subjects. Thus, it can be concluded, that despite continuous 
glucose administration, CAPD does not‘adversely affect pancreatic 
beta cell function.
Type I insulin-dependent diabetics had no beta cell response to 
glucagon, but type II uraemic diabetics had raised fasting 
c-peptide concentrations which might suggest hypersecretion of 
the beta cell. However, absolute concentrations can be 
misleading as the increase was largely due to renal impairment. 
This was confirmed by the lack of response to glucagon challenge, 
indicating no significant residual beta cell function. The 
effect of long-standing diabetes overshadowed any discernible 
effect of uraemia or dialysis.
The second project "Glucoregulatory Hormones and Intermediary 
Metabolites in CAPD" assessed the acute metabolic consequences of 
intraperitoneal glucose administration. Fasting hormones and 
metabolites were evaluated in non-dialysed uraemic and
haemodialysis patients for comparison with CAPD subjects.
Metabolic profiles were monitored during a CAPD cycle comparing 
high and low dextrose dialysate solutions. Specific groups of 
CAPD patients were studied including diabetics, the elderly and 
patients with peritonitis.
In the fasting state blood glucose and insulin were normal in
most uraemic patients, but c-peptide was grossly elevated and
glucagon moderately increased. Growth hormone was normal and 
cortisol, although normal in CAPD patients was increased in other 
uraemic subjects. The gluconeogenic precursors lactate, pyruvate 
and alanine were normal, but ketone bodies and glycerol tended to 
be elevated particularly in the elderly CAPD patient.
The hormone and metabolite profiles during a CAPD cycle showed 
greater changes x^ ith high dextrose solutions, particularly during 
the first two hours of dialysate dwell. Peritoneal glucose 
absorption induced hyperglycaemia, hyperinsulinaemia and a 
transient fall in glucagon, while growth hormone and cortisol 
were unchanged. Lactate increased, largely due to absorption 
from the dialysate, rather than via endogenous glycolysis, as the 
blood lactate increment was independent of dialysate glucose 
concentration. Ketone bodies and glycerol were suppressed in the 
early part of the cycle during the period of maximum glucose 
absorption. In general, the metabolic variables returned to
their basal state by the end of the 6 hour cycle. Thus 
peritoneal glucose absorption causes hyperglycaemia which induces 
hyperinsulinaemia, which in turn stimulates glycolysis, inhibits 
gluconeogenesis and suppresses ketogenesis and lipolysis.
9. Peritonitis increased the rate of glucose and lactate absorption 
from the dialysate due to increased permeability of the 
peritoneum. Elderly patients had similar profiles to younger 
CAPD subjects.
10. The effect of peritoneal glucose absorption in a state of insulin 
deficiency was evaluated in diabetics deprived of insulin. 
Dialysate glucose absorption induced hyperglycaemia but no beta 
cell response and glucagon, growth hormone and cortisol were 
unchanged. Lactate increased but pyruvate and alanine were 
essentially unaltered. Ketone bodies and glycerol remained 
elevated and were not suppressed despite the ambient 
hyperglycaemia. Thus in a state of insulin deficiency peritoneal 
glucose absorption failed to stimulate glycolysis or inhibit 
gluconeogenesis and ketogenesis and lipolysis were maintained.
11. The third project evaluated "Glycosylated and Carbamylated 
Haemoglobin in Uraemia". Glycosylated haemoglobin in renal 
failure is a controversial subject and was reappraised in a 
uraemic population of over 200 patients, including non-dialysis, 
dialysis, transplants, diabetics with and without renal failure.
12. The study confirmed that glycosylated haemoglobin was increased 
in non-diabetics with uraemia, when measured by mini-column
. ion-exchange chromatography, but was normal when total ketoamine 
glycosylation of the red cell was measured by colorimetry.
13. In diabetics glycosylated haemoglobin was increased independent 
of methodology and both techniques showed excellent correlation. 
Although colorimetry is unaffected by uraemia and may be the 
method of choice, the chromatographic method was still useful for 
assessing glycaemic control in diabetics with renal failure.
14. All chromatographic HbA^ fractions increased in uraemia, but the 
HbA-^ c component was more influenced by diabetes and the HbA^a+  ^
component by uraemia.
15. Carbamylated haemoglobin was detected in all subjects but was 
grossly elevated in renal failure. The increase paralleled the 
rise in the HbA^ fractions in non-diabetic uraemics and 
correlated with the severity of uraemia.
16. The concept that carbamylated haemoglobin in uraemia is analogous 
to glycosylated haemoglobin in diabetes warrants further 
investigation. From the work of this thesis further research is 
being done to assess the clinical usefulness and possible 
pathophysiological significance of carbamylated haemoglobin.
PREFACE
In the early 1980fs, while a registrar in renal medicine in 
Glasgow, I developed an interest in continuous ambulatory peritoneal 
dialysis (CAPD). At that time, CAPD was a new mode of treatment and 
clinical experience was limited, but from this my interest grew. An 
increasing number of young diabetic patients with end stage renal 
disease were also being treated, particularly with CAPD. This 
nurtured my interest in diabetics with renal failure and initiated my 
plans to study glucose metabolism in uraemia. While thinking about a 
research project in the field of glucose metabolism I was attracted to 
a research post in Sheffield.
On arrival in Sheffield in 1984, I was full of enthusiasm to get
started only to realise that no formal research programme or expertise
existed in this busy department of nephrology. However, with an
abundance of renal failure patients, particularly a large CAPD 
population, and encouragement and cooperation from many departments in 
the Royal Hallamshire Hospital, Sheffield and the metabolic 
departments in Newcastle, I set about designing and exploring certain 
aspects of glucose metabolism in uraemia.
The first project, "Pancreatic beta cell function in uraemia" was 
designed to determine if CAPD treatment, which involves continuous 
glucose administration, had an adverse effect on the beta cell 
secretory function. This seemed to me an obvious, yet unanswered 
question of great clinical significance.
The second project followed, that continuous intraperitoneal 
glucose administration was a unique clinical situation, with possible 
metabolic consequences and yet, the physiological or
pathophysiological effects had not been investigated. This stimulated
me to study glucoregulatory hormones and intermediary metabolites 
during CAPD treatment in a variety of patients including diabetics and 
the elderly.
The third project, "Glycosylated and carbamylated haemoglobin in 
uraemia" originated from both, my endeavours to achieve good blood 
glucose control in uraemic diabetics, and the confusing and 
conflicting data on glycosylated haemoglobin in the literature. The 
suggestion that uraemia interfered with the analysis of glycosylated 
haemoglobin directed me to measure carbamylated haemoglobin. From the 
work of this thesis, I believe that carbamylated haemoglobin may have 
a clinical usefulness as well as a pathophysiological significance and 
in 1987 this continues to be an ongoing research interest.
CHAPTER 1
GLUCOSE METABOLISM AND HOMEOSTASIS
1. INTRODUCTION
Glucose is the major energy source for the human body and is the 
only metabolic fuel utilized by the brain under most conditions 
encountered in normal life. The brain cannot synthesize or store 
glucose and thus the maintenance of blood glucose concentration is 
critical. The concentration of glucose in the blood is kept within a 
narrow range although there is some variation as circumstances change, 
such as feeding or fasting. The blood glucose concentration depends 
on the balance between glucose entering or leaving the extracellular 
compartment.
Glucose entry into the circulation results from absorption of 
glucose derived from digested dietary carbohydrates and release of 
endogenous glucose from the liver. Endogenous glucose is derived from 
hepatic glycogen (glycogenolysis) and glucose synthesized in the liver 
(gluconeogenesis). Gluconeogenic precursors include lactate and 
pyruvate transported to the liver from a variety of extrahepatic 
tissues and carbon skeleton intermediates which are derived from amino 
acids, principally alanine from muscle and to a smaller extent 
glycerol from adipose tissue.
Glucose exits from the circulation into a variety of tissues where 
it is rapidly metabolized. Glucose has several metabolic fates. It 
can be stored in the liver and muscle as glycogen, undergo glycolysis 
to pyruvate which can be reduced to lactate, transaminated to alanine 
or converted to acetyl-CoA. Acetyl-CoA can be oxidized to carbon 
dioxide and water via the tricarboxylic acid cycle (Krebs or citric 
acid cycle), converted to fatty acids (lipogenesis) and stored as 
triglycerides, or utilized for ketone body synthesis (ketogenesis). A 
schematic presentation of glucose metabolism is summarized in Figures
Figure 1 
Figure 1.
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2. THE LIVER
The liver is central in the role of glucose metabolism and 
flexible depending on the metabolic demands at any given time, such as 
fasting or feeding. It is the single most important organ ensuring a 
constant energy supply to other tissues (see Figures 1.3 and 1.4).
The liver can store excess glucose as glycogen (glycogenesis). The 
rate of glycogen synthesis from glucose 6-phosphate is modulated by 
insulin, which is secreted from the pancreatic beta cells in response 
to systemic hyperglycaemia. The excess of glucose, following a meal, 
results in the hepatic conversion to fatty acids which are ultimately 
stored as triglyceride in adipose tissue. The entry of glucose into 
hepatic cells (as well as cerebral cells) is not affected directly by 
insulin but depends on the extracellular glucose concentration. The 
conversion of glucose 6-phosphate, the first step in glucose 
metabolism in all cells, is catalysed in the liver by the enzyme 
glucokinase, which has a low affinity for glucose compared to that of 
hexokinase found in most tissues. Glucokinase activity is induced by 
insulin secreted in response to systemic hyperglycaemia. Thus 
proportionately less glucose is extracted by hepatic cells during 
fasting compared to the post prandial state. This helps maintain a 
fasting glucose supply to vulnerable tissues such as the brain.
Under aerobic conditions the liver can synthesize glucose by 
gluconeogenesis using lactate, glycerol or carbon chains resulting 
from deamination of most amino acids (mainly alanine) which are 
products of metabolism of other tissues. The liver contains the 
enzyme glucose 6-phophatase, which hydrolyses glucose 6-phosphate
yielded from glycogen breakdown or by gluconeogenesis to produce 
glucose and maintain extracellular glucose homeostasis. Hepatic 
glycogenolysis is stimulated by glucagon from the alpha cells of the 
pancreas.
During fasting the liver can convert fatty acids released from 
adipose tissue to ketones which can be used by other tissues, 
including the brain, as an energy source when glucose is in short 
supply (Figure 1.4). The renal cortex is also capable of 
gluconeogenesis and of converting glucose 6-*phosphate to glucose, but 
this is generally only significant under certain conditions such as 
prolonged fasting. Although other tissues, such as skeletal muscle, 
store glycogen it can only be utilized locally in that tissue as 
muscle does not have the necessary enzyme glucose 6-phosphatase. Thus 
muscle glycogen cannot directly maintain blood glucose concentration.
The effects of an oral glucose load are schematically presented in 
Figure 1.3. The liver modifies the potential hyperglycaemic effect of 
a high carbohydrate meal by extracting relatively more glucose from 
the portal blood than in the fasting state. Some glucose passes 
through the liver unchanged and a rise in the systemic concentration 
stimulates the pancreas to secrete insulin which further stimulates 
hepatic and muscle glycogenesis. The entry of glucose into adipose 
tissue and muscle cells, unlike that of liver and brain, is stimulated 
by insulin, and the blood glucose falls rapidly to near fasting 
levels. This does not happen if there is a relative or absolute 
insulin deficiency (as in diabetes mellitus). Conversion of 
intracellular glucose into glucose 6-phosphate in adipose and muscle 
cells is catalysed by hexokinase which, because its affinity for 
glucose is greater than that of hepatic glucokinase, ensures that 
glucose enters the metabolic pathways in these tissues at lower
Figure 1.
B R A i n
GLUCOSE
LUCOS
GLYCOGEN
fifty *CK) *  Glycerol •  )  -  P Feny K id  • Glycerol - J • P
TRIGLYCERI DE
vioi
3 Post-prandial state - feeding
Gl ucose
KE T ONE S  ♦ H
FFA
FA
ADIPOSE* TISSUE
Figure 1. 4 Post-absorptive state - fasting
concentrations than in liver. Muscle and adipose tissue store the 
excess post-prandial glucose although the mode and function of each is 
very different.
3. ADIPOSE TISSUE AND THE LIVER
Adipose tissue triglyceride is the most important long term energy 
store in the body and increased utilization of fat stores can be 
associated with ketosis.
Adipose tissue, in conjunction with the liver, converts excess 
glucose to triglyceride and stores it in this form rather than 
conversion to glycogen. The component fatty acids are derived from 
glucose entering the liver and the component glycerol from glucose 
entering adipose tissue cells. In the liver triglycerides are formed 
from glycerol 3-phosphate (from triose phosphate) and fatty acids 
(from acetyl-CoA). This triglyeride is transported to adipose tissue 
in VLDL (very low density lipoprotein), where it is hydrolysed by 
lipoprotein lipase. The released fatty acids (of hepatic origin) 
condense with glycerol 3-phosphate derived from glucose entering 
adipose tissue under the influence of insulin and the resultant 
triglyceride is stored. More energy can be stored as triglyceride 
than glycogen.
During fasting, when exogenous glucose is unavailable, endogenous 
adipose tissue triglyceride is reconverted to free fatty acids (FFA) 
and glycerol by lipolysis (Figure 1.4). These are transported to the 
liver where glycerol enters the gluconeogenic pathway at the triose 
phosphate stage. The glucose synthesized can be released into the 
circulation to maintain the blood glucose concentration. Most tissues 
other than the brain use the FFA as a metabolic fuel after conversion 
to acetyl-CoA. The liver can also form acetoacetate by enzymatic
conversion of acetyl-CoA, acetoacetate in turn can be reduced to 
3-hydroxybutyrate and decarboxylated to acetone. The ketone bodies 
can be used as an energy source by brain and other tissue when glucose 
supply is reduced.
Ketosis occurs when fat stores are the main energy source and can 
be seen in conditions such as fasting and reduced nutrient absorption 
due to vomiting. Mild ketosis may occur after 12 hours of fasting, 
but is not usually associated with acidosis unless the fasting is 
prolonged. Diabetic ketoacidosis is accompanied by hyperglycaemia 
unlike the ketotic hypoglycaemia seen in prolonged fasting such as in 
anorexia nervosa. However the mechanism of ketosis is similar. In 
starvation ketosis the supply of glucose to cells of adipose tissue is 
insufficient for normal glycolysis and lipogenesis. In diabetes the 
insulin deficiency induces intracellular glucose deficiency due to 
impaired entry of high extracellular concentrations of glucose into 
the fat cells. The high extracellular concentrations of glucose is 
thus a misleading index of intracellular events.
4. MUSCLE AND THE LIVER
Glucose enters skeletal muscle post-prandially under the influence 
of insulin and is stored as glycogen (Figure 1.3). The glycogen 
cannot be reconverted to glucose due to the absence of glucose 
6-phosphatase and therefore muscle glycogen can only supply local 
needs.
During muscle activity (Figure 1.5) glycogenolysis is stimulated 
by adrenaline and the resultant glucose 6-phosphate undergoes 
glycolysis to pyruvate and lactate. Under aerobic conditions pyruvate 
is oxidized via the tricarboxylic acid cycle. However, the oxygen 
availability during exercise is readily depleted and anaerobic
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glycolysis with production of lactate becomes important. Lactate is 
transported from muscle to liver in the circulation where it can be 
used for gluconeogenesis (Cori cycle) and provides further glucose for 
muscle activity. Alanine can also be transported from muscle to liver 
where it serves as a gluconeogenic precursor (glucose-alanine cycle). 
During gluconeogenesis hydrogen ion is also neutralized. Under 
aerobic conditions the liver consumes more lactate than it produces. 
The physiological accumulation of lactate during increased muscle 
activity is temporary and disappears at rest when slowing of anaerobic 
glycolysis allows the aerobic processes to equilibrate.
5. LACTIC ACIDOSIS
Lactic acid produced by anaerobic glycolysis may be oxidized to 
carbon dioxide and water in the tricarboxylic acid cycle or be 
reconverted to glucose by gluconeogenesis in the liver. Pathological 
accumulation of lactate can occur due to increased production or 
decreased utilization. This may be due to increased production by 
anaerobic glycolysis and decreased utilization by impaired 
gluconeogenesis or impairment of the tricarboxylic acid cycle. This 
is seen in tissue hypoxia due to poor tissue perfusion. The 
combination of impaired gluconeogenesis and increased anaerobic 
glycolysis converts the liver from a lactate consuming to a lactate 
producing organ (Figure 1.6).
6. GLUCOSE HOMEOSTASIS AND INTERMEDIARY METABOLISM
In the post-absorptive state (after an overnight fast) blood 
glucose concentrations are stable indicating that production and 
utilization are equivalent. The brain accounts for 60% of glucose 
utilization (Sherwin, 1980) and the remainder is used for other
glycolysing tissues such as red blood cells, renal medulla, muscle and 
fat. Hepatic glucose production after an overnight fast is largely 
from glycogenolysis (75%) and the remainder from gluconeogenesis 
(25%). Gluconeogenesis from lactate, pyruvate, alanine and glycerol 
is estimated to represent 13, 1, 4 and 4% of endogenous glucose 
production respectively and, therefore, 52, 4, 16 and 16% of 
gluconeogenesis respectively (Cryer, 1985).
Gluconeogenesis is important in providing new glucose and 
replenishing hepatic glycogen storage in the post-absorptive state due 
to the limited availability of preformed glucose. The glucose pool 
consists of free glucose in the extracellular fluid and in the cells 
of some tissues especially the liver, but also small amounts in the 
kidney, blood cells, pancreatic islets, brain and intestinal mucosa. 
The glucose pool amounts to 15 to 20 g in the normal adult (Searle, 
1976) and glycogen can be mobilized to provide 70 g of glucose 
(Nilsson, 1973). In more prolonged fasting plasma glucose falls and 
then stabilizes, hepatic glycogen falls and gluconeogenesis becomes 
the only source of glucose production. Muscle protein is degraded 
providing amino acid substrate and glucose utilization by muscle and 
fat is inhibited. Lipolysis and ketogenesis accelerate and 
circulating ketone concentrations increase with ketone bodies becoming 
the major fuel for the brain.
After a meal, in the post-prandial state, glucose absorption 
results in a large increase in exogenous glucose delivery to the 
circulation, often doubling the rate of post-absorptive glucose 
production. As glucose is absorbed, endogenous glucose production is 
suppressed and glucose utilization by the liver, muscle and adipose 
tissue increases. Thus exogenous glucose is assimilated and blood 
glucose returns towards the post-absorptive state.
In this way glucose homeostatic mechanisms result in keeping blood 
glucose within a relatively narrow range. The regulation of systemic 
blood glucose involves hormonal, neural, and autoregulatory factors.
7. HORMONAL GLUCOREGULATORY FACTORS
Glucoregulatory hormones include insulin, glucagon, adrenaline, 
growth hormone and cortisol (Figure 1.7). Insulin is the dominant 
glucose lowering hormone. It suppresses endogenous glucose production 
and stimulates glucose utilization. Insulin inhibits hepatic 
glycogenolysis and gluconeogenesis and in association with other 
factors, including hyperglycaemia and hypoglucagonaemia converts the 
liver into an organ of glucose consumption and fuel storage in the 
form of glycogen and triglycerides. Insulin stimulates glucose 
uptake, storage and utilization by other tissues such as muscle and 
fat. Insulin also increases fatty acid and triglyceride synthesis and 
triglyceride transport via VLDL, increases fatty acid uptake and 
incorporation into triglyceride in adipose tissue and suppresses 
tissue lipolysis. The latter results in decreased fatty acid flux to 
the liver which coupled with direct hepatic effects of insulin results 
in decreased ketogenesis. Insulin also stimulates amino acid uptake 
and net protein synthesis in muscle. Thus insulin promotes the 
storage of carbohydrate, fat and protein.
Glucose-raising or counterregulatory hormones include glucagon, 
adrenaline, growth hormone and cortisol. Glucagon is secreted by the 
alpha cells of the pancreas into the portal circulation and acts 
predominantly on the liver under physiological conditions. Glucagon 
is a potent stimulator of glycogenolysis and gluconeogenesis and 
rapidly increases hepatic glucose production. Glucagon also 
stimulates hepatic ketogenesis particularly when insulin
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concentrations are low. However, hepatic glucose production induced 
by hyperglucagonaemia is only transient and other factors such as 
glucose induced insulin release and autoregulation due to 
hyperglycaemia may also be involved (Cryer, 1985).
The hyperglycaemic effect of adrenaline is complex. Adrenaline 
stimulates hepatic glucose production and restricts utilization and 
these effects are mediated via alpha and beta adrenergic mechanisms 
(Rizza etal., 1980). Adrenaline can also increase hepatic 
glycogenolysis and gluconeogenesis independently of other hormones. 
Adrenaline, like glucagon, acts rapidly and produces a transient 
increase in glucose production and continues to support glucose 
production even in the fasting state. In contrast to glucagon, 
adrenaline also limits glucose utilization. Sustained increases in 
adrenaline causes persistent hyperglycaemia due to reduced glucose 
utilization.
Long term elevation of growth hormone limits glucose transport 
into cells and can produce an insulin resistant state. Growth hormone 
may have a glucose lowering effect but it is not obvious for hours 
(MacGorman et al., 1981). Thus growth hormone is unlikely to be 
important for rapid glucose counter-regulation. Infusion of cortisol 
does not increase glucose production by limiting glucose utilization 
(Shamoon et_al., 1981) and thus, like growth hormone, cortisol does 
not appear to have a major role in the short term glucose control. In 
the long term growth hormone and cortisol may have a permissive role 
to play in glucose homeostasis in that their presence is necessary 
even though they do not have a direct effect (Cryer, 1984). 
Furthermore, the hyperglycaemic effects of glucagon, adrenaline and 
cortisol may be synergistic and thus have a role in glucose 
counter-regulation (Shamoon et al., 1981).
Neural and autoregulatory factors also have a role in glucose 
homeostasis. Vagal stimulation increases hepatic glycogen synthesis 
and direct hepatic sympathetic nerve stimulation decreases glycogen 
and increases blood glucose (Lautt, 1980). The concept of hepatic 
glucose autoregulation, that is, the role of hepatic glucose 
production is altered in inverse relation to the blood glucose 
concentration independent of the effects of circulating hormones, has 
been advocated (Sacca et al., 1979).
a) Glucose Counter-Regulation
Glucagon plays a primary role in promoting glucose recovery from 
hypoglycaemia. Glucose recovery from insulin induced hypoglycaemia is 
essentially normal when glucagon secretion is intact and partially 
impaired when glucagon secretion is inhibited. The latter is 
associated with an increased adrenomedullary adrenaline response 
(Rizza et al., 1979). Glucose recovery is impaired little, if at all, 
during adrenergic blockade. However, when glucagon secretion is 
inhibited glucose recovery from hypoglycaemia is markedly impaired by 
adrenergic blockade. Thus glucagon plays a primary role in recovery 
from insulin induced hypoglycaemia and glucagon deficiency is largely 
compensated by increased adrenomedullary adrenaline secretion.
Glucose recovery is severely impaired in the absence of both glucagon 
and adrenaline. The acute release of cortisol and growth hormone has 
little role in recovery from insulin induced hypoglycaemia, although 
chronic deficiency of both cortisol and growth hormone increase the 
sensitivity to insulin (Rizza et al., 1979).
b) Post-Absorptive State
Diminished insulin secretion is fundamental to the maintenance of
the post-absorptive blood glucose concentration in that it permits 
hepatic glucose production to proceed via hepatic glycogenolysis and 
gluconeogenesis and limits glucose utilization by the liver, muscle 
and adipose tissue. Thus obligatory glucose utilization (brain, renal 
medulla, red blood cells) does not result in hypoglycaemia. However, 
insulin is not the sole determinant of the post-absorptive blood 
glucose concentration. Glucagon and possibly adrenaline may also have 
a role in maintaining the fasting glucose concentration (Rosen et al., 
1984).
c) Post-Prandial State
After glucose ingestion blood glucose concentration rises as a 
result of glucose absorption and endogenous glucose production is 
markedly suppressed. The circulating concentration of glucose 
declines rapidly due to accelerated glucose utilization coupled with 
diminishing glucose absorption towards fasting levels. When glucose 
absorption is complete glucose production resumes. The transition 
from endogenous glucose declining to endogenous glucose production is 
regulated by the coordinated actions of insulin and glucagon. In the 
state of glucagon deficiency (induced experimentally by somatostatin 
and partial insulin replacement) adrenaline has a counter-regulatory 
effect but this is not observed in the presence of glucagon (Cryer, 
1984).
8. GLUCOSE METABOLISM IN DIABETES
A decrease in insulin production and release and/or decreased 
insulin activity in target tissue is fundamental to the development of 
diabetes. Consequent to insulin deficiency glucagon concentrations 
may rise and a fall in the insulin:glucagon ratio causes increased
production of glucose by the liver, while an absolute decrease in 
insulin concentration or insulin action reduces glucose utilization in 
peripheral tissues resulting in hyperglycaemia. A further decline in 
the insulin:glucagon ratio can lead to syndromes of decompensation 
such as diabetic ketoacidosis and hyperosmolar non-ketotic coma. The 
release of catecholamines and other stress hormones can act in many 
ways and affect both insulin and glucagon secretion from the islets. 
Catecholamines can reduce endogenous insulin and increase glucagon 
stimulated lipolysis, decrease muscle glucose utilization and increase 
hepatic glucose production. Growth hormone can increase insulin and 
glucagon secretion, stimulate lipolysis from adipocytes, promote 
hepatic glucose production and inhibit muscle glucose utilization. 
Cortisol can also have similar actions to growth hormone (Unger and 
Foster, 1985).
Insulin deficiency blocks glucose utilization by insulin requiring 
tissues, activates lipolysis in adipose tissue, increases proteolysis 
in muscle, causes hyperglucagonaemia and enhances glucagon effects on 
the liver. Glucagon when opposed by a normal insulin response is 
primarily responsible for the hepatic components of diabetic 
decompensation, i.e. increase glycogenolysis, gluconeogenesis and 
ketogenesis (Unger and Foster, 1985).
The metabolic pathways in liver, muscle and adipose tissue during 
insulin deficiency are depicted in Figure 1.8. In the liver (Figure 
1.8a) glucose release is mediated via glucagon although adrenaline, 
cortisol and growth hormone have a complementary role. Amino acid 
catabolism is stimulated by glucagon although cortisol does have an 
auxiliary role. Ketone body production is modulated by glucagon and 
adrenaline also has a 'permissive1 role. In muscle (Figure 1.8b), 
when the action of insulin is insufficient there is increased fatty
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Figure 1. 8 Major metabolic effects of insulin deficiency
acid and ketone body uptake. Adrenaline and growth hormone both 
contribute to fatty acid utilization in muscle. In the adipocyte 
(Figure 1.8c), triglycerides are broken down during insulin deficiency 
and the fatty acid release is modulated by adrenaline, cortisol and 
growth hormone.
This introductory chapter outlines glucose metabolism and its 
complex inter-relationships. The metabolic pathways and the role of 
the liver, muscle and adipose tissue were briefly discussed. Glucose 
and intermediary metabolism are regulated by hormonal and other 
factors to produce accurate control and reliable homeostasis. Aspects 
of glucose metabolism in diabetes were briefly summarized, including 
hormone physiology and intermediary metabolism. This chapter gives 
the biochemical and endocrine background to part of the research work 
of this thesis, in particular the study of glucoregulatory hormones 
and intermediary metabolites in uraemia and continuous ambulatory 
peritoneal dialysis (CAPD).
CHAPTER 2
GLUCOSE METABOLISM IN URAEMIA
1. INTRODUCTION
Abnormalities of carbohydrate metabolism in uraemia have been 
recognised for many years. Neubauer in 1910 first described 
hyperglycaemia in renal disease and this was soon confirmed by Hopkins 
in 1915. The prevalence of hyperglycaemia was probably overestimated 
prior to the mid 1960's as the methods for measuring glucose did not 
discriminate between glucose and non-glucose reducing substances 
(Reaven, 1974). However, these observations of 'uraemic 
pseudodiabetes' (Westervelt and Schriener, 1962) did not become 
clinically significant until the advent of dialysis. The development 
of dialysis and transplantation in the 1960's created a new 
significance for uraemic carbohydrate intolerance. The limited 
facilities for dialysis and restricted availability of donor kidneys 
resulted in exclusion of diabetics for renal replacement therapy. In 
many centres diabetics had a significantly higher morbidity and 
mortality than non-diabetics (Comty and Shapiro, 1975; Kjellstrand et 
al., 1972). Thus, it became important to distinguish between true 
diabetes and uraemia induced glucose intolerance.
In the past 20 years there has been a multitude of reports on 
carbohydrate metabolism which have widened our understanding of the 
complicated pathophysiology of renal failure.
2. THE ROLE OF THE KIDNEY IN PANCREATIC PEPTIDE METABOLISM
The kidney plays an important role in the metabolism of low 
molecular weight proteins including the alpha and beta cell peptides. 
This is characterised by a high extraction from the circulation and 
negligible urinary excretion of the intact molecule suggesting that 
hormone removed by the kidney is degraded locally (Katz and Emmanouel,
1978). Renal disposition involves both glomerular filtration and 
tubular uptake and degradation. The kidney plays an important 
function in the lowering and stabilizing of peptide hormone 
concentrations but does not regulate them, this being a function of 
the secreting endocrine gland. The increased circulating levels of 
certain peptide hormones in uraemia suggests that the secretory rate 
remains inappropriately high for the degree of reduction in their 
metabolic clearance. This reflects either impaired feedback control 
mechanisms, possibly in some instances due to end-organ resistance, or 
to the inability of the endocrine gland to reduce secretion rates 
appropriately (Emmanouel et al., 1981).
a) Insulin
Insulin is normally rapidly removed from the blood by the liver, 
which clears 40-60% in a single passage (Ferrannini et al., 1983).
This proportion of insulin removed is dependent, in part, on the 
plasma insulin concentration. The renal arterio-venous concentration 
difference is about 30-40% (Rabkin et al., 1970; Katz and Rubenstein, 
1973) and this is unaffected by changes in the plasma insulin 
concentration within the physiological range (Maude et al., 1981).
The renal clearance of insulin is about 200 ml/min in man and from 
this it is estimated that 6-8 units/day are degraded by the kidney 
(Rubenstein et al., 1975). This accounts for a quarter of the daily 
pancreatic secretion in man. However, only 0.1% of the endogenous 
pancreatic insulin is excreted in the urine (Rabkin et al., 1984). 
Since the normal glomerular filtration rate (GFR) (120 ml/min) is 
significantly less than the renal clearance of insulin (200 ml/min) 
peritubular uptake must be responsible for a significant portion of 
the renal removal. The physiology of the renal handling of insulin
has been recently reviewed (Rabkin et al., 1984).
The clinical importance of these observations is that there is 
little change in the metabolic clearance rate of insulin until the GFR 
is decreased to 40 ml/min. Marked prolongation of the half life does 
not occur until the GFR is below 20 ml/min (Rabkin et al., 1970; 
Rubenstein et al., 1975). However, with progressively declining GFR 
there is a compensatory increase in peritubular insulin uptake such 
that insulin clearance changes only minimally. However, when renal 
functional mass is reduced to a critical level and the GFR is less 
than 20 ml/min the metabolic clearance rate falls precipitously 
(Rubenstein et al., 1975).
Impaired hepatic degradation of insulin may contribute to the 
prolonged half life observed in uraemia (DeFronzo et al., 1978a). 
Improved insulin clearance was observed after haemodialysis and was 
attributed to increased degradation by non-renal tissues, liver and 
muscle (Mondon et al., 1978). The accumulation of uraemic toxins that 
might inhibit insulin degrading systems may be removed by 
haemodialysis and account for the improved clearance of insulin 
(DeFronzo et al., 1978a). Metabolic clearance rates and secretory 
rates of insulin have been reported to improve after haemodialysis 
(Navalesi et al., 1975; Ferrannini et al., 1979). However, several 
direct studies have not detected any hepatic abnormality of insulin 
clearance even in hepatic cirrhosis (Proietta et al., 1984; Taylor et_ 
al., 1985).
b) C-peptide
Insulin and c-peptide are secreted into the portal circulation in 
equimolar concentrations, but in the peripheral blood c-peptide is 5-7 
fold higher due to differences in the metabolic clearance rate (MCR).
The MCR for insulin (11 ml/min/kg) is higher than for c-peptide (4.4 
ml/min/kg). Unlike insulin, c-peptide passes through the liver 
without significant extraction and is almost exclusively metabolized 
and degraded by the kidney. The immunological half life for insulin 
(5 mins) is considerably shorter than c-peptide (11-33 mins depending 
on experimental conditions). Normally 5-20% of pancreatic secretion 
of c-peptide is excreted in the urine. Renal dysfunction causes an 
increase in serum c-peptide level and the relative concentrations may 
be dependent upon the quantitative role which the kidneys play in 
their removal (Jaspan et al., 1977).
c) Proinsulin
Small amounts of proinsulin are released into the circulation with 
insulin and c-peptide in normal subjects, but this accounts for less 
than 15% of the total circulating insulin immunoreactivity. There is 
no evidence to suggest that proinsulin is converted to insulin in the 
circulation (Rubenstein et al., 1977). The metabolic clearance 
independent of plasma levels, is slower for proinsulin (3.1 ml/min/kg) 
compared to insulin (11 ml/min/kg) and the half life for proinsulin is 
about 25 mins compared to 5 min for insulin. In contrast to the 
difference in their MCR, the renal disposition of both peptides is 
similar with high extraction and very low urinary clearance (Katz and 
Rubenstein, 1973). The extraction rate for proinsulin is 
approximately 36% while the fractional urinary clearance is about 
0.6% indicating more than 99% of the amount filtered is sequestered in 
the kidney. Thus the kidney is the major organ for proinsulin 
degradation and thus high concentrations of proinsulin may be expected 
in renal failure (Katz and Rubenstein, 1973; Mako et al., 1973).
d) Glucagon
Circulating glucagon is heterogeneous, consisting of proglucagon 
(molecular weight 9000) and the biologically active glucagon 
(molecular weight 3500). Glucagon is freely filtered by the 
glomerulus, reabsorbed and catabolized in the proximal tubule. There 
is active uptake and degradation by the peritubular membrane 
(Emmanouel et al., 1976). The metabolic clearance rate is
approximately 10 ml/min/kg and the half life is 5.5 mins (Alford e£
al., 1976). The fractional extraction by the kidney is about 40% and 
less than 5% is excreted in the urine. Compared to insulin the liver 
plays a less important role in glucagon degradation (Felig et al., 
1976) and renal excretion accounts for about half of glucagon 
degradation. In chronic renal failure the marked increase in
circulating glucagon levels is largely due to proglucagon, but there
is a significant rise in the biologically active glucagon (Emmanouel 
et al., 1976). The hyperglucagonaemia in uraemia is due to reduced 
renal clearance (Kuku et al., 1976) as the pancreatic secretion of 
glucagon is normal (Lefebvre and Luyckx, 1975).
3. GLUCOSE INTOLERANCE
Elevated fasting plasma insulin concentration with normal fasting 
glucose has been well documented in uraemia (Hutchings et al., 1966; 
Briggs et al., 1967; Horton et al., 1968). The fall in blood glucose 
following exogenous insulin administration is delayed and decreased 
(Westervelt and Schriener., 1962; Hampers et al., 1966; Horton et al., 
1968; Spitz et al., 1970). The fall in blood glucose following IV 
tolbutamide was also diminished and delayed (Cerletty and Engbring, 
1967; Spitz et al., 1970) and the concomitant insulin levels were 
elevated. All these studies suggest insulin antagonism. However,
there are conflicting reports on the plasma insulin response to both 
oral and IV glucose tolerance tests.
The early (2-10 mins) insulin response following IV glucose has 
been reported as normal (Horton et al., 1968), increased (Hutchings et_ 
al., 1966) or decreased (Hampers et al., 1966). Insulin levels during 
the latter part of the test (25-60 mins) have been uniformly increased 
(Horton et al., 1968; Hutchings et al., 1966; Hampers et al., 1966). 
Following an oral glucose stimulus the early release of insulin was 
found to be normal (Briggs et al., 1967; Cerletty and Engbring, 1967) 
or increased (Spitz et al., 1970) while late responses were elevated 
in all the studies.
These effects could be explained in part by prolongation of the 
half life of insulin, true hypersecretion of insulin, relative 
hypersecretion secondary to the higher glucose concentrations found 
later in the tests or a combination of these. Furthermore, the 
conflicting results could be explained by differences in the uraemic 
populations studied, such as the severity of renal failure (i.e. 
residual renal function) and the use and the 'adequacy1 of dialysis. 
The decreased insulin response to IV glucose, in contrast, to the 
increased response to oral glucose (Hampers et al., 1966; Hampers et 
al., 1968) has been suggested to be due to insulin-releasing gut 
hormones which may have a role for maintenance of insulin secretion in 
uraemia (Creutzfeldt et al., 1970).
4. TISSUE SENSITIVITY TO INSULIN AND BETA CELL SENSITIVITY TO GLUCOSE
DeFronzo (1978b) suggests that the seemingly conflicting results 
in the literature concerning the plasma insulin response in glucose 
tolerance tests may represent two distinct groups of uraemic patients. 
He postulates that one group have 'normal' glucose tolerance and
increased plasma insulin levels, while the other group have impaired 
glucose tolerance and diminished or normal plasma insulin responses to 
infused glucose.
DeFronzo proposed that since peripheral antagonism (tissue 
insensitivity) to insulin is uniform in uraemia, glucose tolerance 
would only remain normal if the pancreatic beta cells were able to 
increase their insulin secretion to overcome the insulin resistance. 
This would conform to the first group of patients with 'normal1 
glucose tolerance and increased plasma insulin responses. However, if 
significant inhibition of insulin secretion was superimposed on a 
state of insulin antagonism glucose intolerance would become overtly 
impaired. This would conform to the second group, with impaired 
glucose tolerance and normal or decreased insulin responses. Thus an 
interaction between tissue sensitivity to insulin and beta cell 
sensitivity to glucose might explain the seemingly discrepant results 
concerning the insulin response to glucose. DeFronzo (1978a) 
quantitated the relative contributions of impaired insulin secretion 
and insulin resistance using clamp techniques. Using the 
hyperglycaemic clamp technique the plasma insulin response was 
biphasic, the early (0-10 mins) response was normal but the later 
(10-120 mins) was higher in uraemics. After 10 weeks haemodialysis 
the late plasma insulin response decreased and was not significantly 
different from the controls. The decline in the insulin response was 
mainly due to an increase in the metabolic clearance rate of insulin. 
The change in insulin secretion was quite variable. In the majority 
of patients insulin secretion increased negligibly (suggesting that 
uraemia had an inhibitory effect on the beta cell). In some insulin 
secretion fell post-dialysis (suggesting that the primary disturbance 
was one of impaired insulin action). During the hyperglycaemic clamp
performed post dialysis the decreased insulin response resulted from a 
small increase in insulin secretion and a larger increase in the 
metabolic clearance rate of insulin. The amount of glucose 
metabolized during the clamp studies was significantly less in 
uraemics than controls. Although haemodialysis resulted in a marked 
improvement in glucose metabolism it did not restore it to normal. To 
provide an independent measure of tissue sensitivity to insulin, 
DeFronzofs group (1978a) employed the euglycaemic insulin clamp 
technique and found that tissue sensitivity to insulin was 
significantly reduced in uraemics and following haemodialysis insulin 
mediated glucose metabolism improved to a level only slightly less 
than controls. The observations for the above clamp techniques has 
promoted the concept than insulin resistance is present in most 
patients with chronic renal failure and plays a dominant role in 
glucose intolerance in uraemia. The normal beta cell response to this 
insulin antagonism would be to augment its insulin secretion in an 
attempt to override the insulin resistance. In some patients, 
however, uraemia also impairs insulin secretion. In those subjects in 
whom both tissue insensitivity to insulin and impaired beta cell 
response to glucose occur together, the greater decline in glucose 
tolerance is observed (DeFronzo, 1978a;1978b).
However, it should be noted that the increased circulating insulin 
in uraemia may not necessarily be due to resistance to the action of 
insulin, but delayed insulin degradation due to loss of renal 
parenchyma may also be important (Reaven and Olefsky, 1978). The 
insulin response to a constant glucose infusion was studied in an 
animal model of acute uraemia induced without loss of renal mass.
There was no difference between pre- and post-insulin responses 
(Swenson et al., 1973). The authors concluded that there was no
increase in insulin response when there was no loss of renal 
parenchymal tissue. These results suggest that the elevation of the 
insulin response in uraemia may be due to a defect in insulin removal 
rather than insulin hypersecretion. Thus the rise in insulin 
concentration does not necessarily mean an increased pancreatic 
insulin response.
5* THE SITE OF INSULIN RESISTANCE
Impairment of insulin-mediated glucose metabolism in uraemia could 
result from increased hepatic glucose production that does not 
suppress normally following insulin, diminished glucose uptake by the 
liver or impaired glucose uptake by peripheral (muscle and adipose) 
tissues. Using the euglycaemic insulin clamp technique in combination 
with radioisotope (H^-glucose) turnover methodology and 
hepatic/femoral vein catheterisation (DeFronzo et al. 1978a; 1980;
1981) showed that both suppression of hepatic glucose production and 
splanchnic (hepatic) glucose uptake are normal in uraemia. In 
contrast, the ability of insulin to increase glucose uptake in the leg 
was markedly impaired in uraemic subjects. These results suggest that 
the major site of insulin resistance resides in the periphery. This 
is consistent with the forearm perfusion studies with constant 
intra-arterial insulin infusion which showed reduced glucose uptake in 
uraemia (Westervelt, 1969). Following haemodialysis tissue 
insensitivity to insulin was found to return towards normal and 
overall glucose intolerance improved (DeFronzo et al., 1978a).
6. INSULIN RECEPTOR AND POST RECEPTOR DEFECTS
Insulin, like other peptide hormones, is known to initiate its 
effects on target tissues by binding to specific surface receptors
(Pastan et al., 1966). The resultant hormone receptor interaction 
triggers a sequence of membrane and intracellular events that produce 
the biological response. Thus insulin resistance could result from 
either a receptor or post receptor (intracellular) defect.
Decreased insulin binding to red cells has been reported in 
non-dialysed uraemics, however, after 1 year of haemodialysis 
erythrocyte binding decreased relative to controls (Gambhir et al.,
1981). In contrast, insulin binding to rat adipocytes was normal 
(Maloff and Lockwood, 1981) and insulin binding to circulating 
monocytes in uraemic subjects was also normal (Smith and DeFronzo,
1982). Thus, by inference if receptor binding is normal in uraemia 
then it may be predicted that intracellular defects are responsible 
for the insulin resistance.
The site of insulin resistance has been studied by constructing an 
in vivo dose-response curve using the euglycaemic clamp technique. 
Insulin resistance can be classified as being due to either a 
decreased sensitivity or a decreased responsiveness to insulin. These
two abnormalities are manifest by a shift to the right in the 
dose-response curve or a reduced maximum response respectively. The
spare receptor concept indicates that reduced insulin receptor binding 
usually results in a decreased sensitivity while a post-receptor 
defect results in insulin unresponsiveness. The maximal 
responsiveness to insulin was decreased in uraemics and partially 
corrected by dialysis (Schmitz et al., 1983). A similar study showed 
both a decreased sensitivity and reduced responsiveness but the 
monocyte insulin binding was normal in keeping with a post-binding 
defect (Smith and DeFronzo, 1982). Thus, there is evidence that the 
site of insulin resistance is due to impaired intracellular glucose 
metabolism or abnormal glucose transport within the cell.
7. THE ROLE OF THE LIVER
The role of the liver in the development of glucose intolerance 
has been examined by measuring the rate of glucose turnover and by 
quantifying the hepatic responses to glucose and insulin infusion.
Data on hepatic glucose production in uraemia are conflicting. 
Rubenfeld and Garber, 1978, observed a 50% increase in glucose 
turnover, a 2-fold rise in alanine and that gluconeogenesis (mainly 
from alanine) increased in non-dialysed uraemic patients. Following 
haemodialysis there was a reduction, but not a complete reversal of 
the accelerated gluconeogenesis (Rubenfeld and Garber, 1979). They 
postulated an increase in glucose utilization following dialysis 
treatment. The increased gluconeogenesis could also be due to 
increased hepatic sensitivity to glucagon (Sherwin et al., 1976).
The importance of gluconeogenesis for glucose homeostasis has been 
underlined by the observation of hypoalaninaemia and decreased rates 
of gluconeogenesis in debilitated uraemic patients presenting with 
hypoglycaemia (Garber et al., 1974). The kidney also has a role in 
gluconeogenesis. During prolonged starvation the normal kidney has 
been reported to contribute about half of the glucose production 
through recruitment of the gluconeogenic pathway (Owen et al., 1969).
However, in contrast, normal rates of glucose production have been 
reported (DeFronzo et al., 1981; Ricanati et al., 1983). Both 
suppression of hepatic glucose production and splanchnic (hepatic) 
glucose uptake were normal in uraemia. Kalhan et al. (1983) showed 
that in chronic renal failure glucose production did not change, but 
glucose carbon recycling increased and glucose oxidation decreased. 
Haemodialysis had no effect on any of these variables.
8. GLUCAGON AND GLUCOSE METABOLISM
Increased circulating levels of glucagon have been implicated in 
the development of carbohydrate intolerance and insulin resistance in 
uraemia. Although proglucagon is primarily responsible for the 
elevated levels of increased circulating glucagon, there is up to 
3-fold elevation of the biologically active glucagon (MW 3500) 
(Emmanouel et al., 1976). High circulating plasma glucagon 
concentrations result from decreased renal clearance (Kuku et al., 
1976). The increase in glucagon (MW 3500) is due to the decrease in
metabolic clearance rate as glucagon secretion is normal (Lefebvre and
Luyckx, 1975). Compared to insulin the liver plays a much less 
important role in glucagon degradation (Felig et al., 1974). The 
primary effect of glucagon is to stimulate hepatic glucose production. 
Basal hepatic glucose production is not increased and is normally
suppressed by insulin in uraemia and glucagon has no clear effect on
the peripheral utilization of glucose (DeFronzo et al., 1978a). Thus 
it is unlikely that hyperglucagonaemia per se plays a role in glucose 
intolerance under conditions where the plasma insulin is elevated.
However, the plasma glucose response to glucagon is enhanced in 
uraemia indicating increased hepatic sensitivity to glucagon.
Following glucagon infusion the increase in plasma glucose 
concentration in uraemia was 3-4 fold greater than controls. 
Haemodialysis corrected the excessive glycaemic response to glucagon 
(Sherwin et al., 1976). These findings suggest that hepatic 
sensitivity to glucagon is increased while tissue sensitivity to 
insulin is decreased in uraemia. In the situation, for example after 
a protein meal, when the plasma glucagon response is high and the 
insulin response is relatively low excessive stimulation of hepatic 
glucose output may ensue and result in glucose intolerance. Elevated
glucagon levels may also contribute to increased gluconeogenesis from 
alanine in skeletal muscle (Rubenfeld and Garber, 1978). Furthermore, 
DeFronzo and Smith (1985) have found increased alanine uptake by 
splanchnic tissue (liver) in uraemia suggesting gluconeogenesis is 
increased in chronic renal failure. This has important clinical 
implications and may explain the muscle wasting and negative nitrogen 
balance commonly observed in uraemia.
9. PARATHYROID HORMONE AND GLUCOSE METABOLISM
Abnormalities in the metabolism of parathyroid hormone (PTH) have 
also been implicated in the pathogenesis of carbohydrate intolerance 
associated with uraemia.
Increased insulin secretion was observed in uraemic patients with 
severe secondary hyperparathyroidism which improved following 
parathyroidectomy (Lindall et al., 1971). This observation was 
attributed to the parathyroid hormone effect on pancreatic islet 
function. However, others have failed to show any relationship 
between secondary hyperparathyroidism and glucose tolerance, insulin 
secretion and insulin sensitivity (Amend et al., 1975).
More recently studies in animals (Akmal et al., 1984) and humans 
(Mak et al., 1983) suggest that excess PTH inhibits the compensatory 
increase in insulin secretion in a insulin resistant state, thus 
contributing to the glucose intolerance of chronic renal failure.
Graf et al. (1985) using the hyperglycaemic clamp technique evaluated 
the role of PTH on glucose metabolism in chronic renal failure and 
dialysis. They found that patients on haemodialysis had normal 
peripheral glucose uptake. The beta cell response to hyperglycaemia 
(during the early phase as well as during the steady state) was the 
same in controls and non-parathyroidectomised uraemics, whereas, those
who had parathyroidectomy, i.e. previous severe and long standing 
secondary hyperparathyroidism, had markedly increased insulin 
secretion. Tissue sensitivity to insulin was normal in the 
non-parathyroidectomised haemodialysis group but was decreased in the 
parathyroidectomy group. Thus PTH may have a suppressive effect on 
insulin secretion.
10. GROWTH HORMONE AND GLUCOSE METABOLISM
Growth hormone (GH) concentrations are frequently elevated in 
renal failure but do not correlate with glucose intolerance in 
individual patients (Horton et al., 1968; Saaman and Freeman, 1970; 
Orskov and Christensen, 1971). Further, despite an apparent 
improvement in carbohydrate intolerance and insulin sensitivity with 
haemodialysis levels of growth hormone remain unaffected (Saaman and 
Freeman, 1970). Abnormal growth hormone concentration in chronic 
renal failure results from both impaired degradation and abnormalities 
in secretion. Peripheral disposal of this peptide depends largely on 
renal mechanisms (Cameron et al., 1972; Gottheiner et al., 1979). The 
normal response of reduction in growth hormone following glucose 
administration does not occur in renal failure suggesting that the 
secretory dynamics are altered. In fact, levels of growth hormone 
often show a paradoxical rise during glucose tolerance testing (Wright 
et al., 1968; Saaman and Freeman, 1970). The latter change has been 
attributed to protein and caloric malnutrition since this paradoxical 
response is observed in conditions such as kwashiorkor and marasmus 
(Pimstone et al., 1966).
DeFronzo (1978b) found no difference in fasting GH levels pre- and 
post-dialysis. The majority of patients showed no change in GH 
response with sustained hyperglycaemia. Thus the deranged growth
hormone physiology in uraemia is unlikely to be related to 
carbohydrate metabolism.
11. LIPID METABOLISM AND CARBOHYDRATE METABOLISM
There is an important inter-relationship between carbohydrate and 
lipid metabolism in uraemia. Type IV - (carbohydrate induced and 
accompanied by glucose intolerance) hyperlipidaemia is common in renal 
failure.
Hypertriglyceridaemia with normal or increased cholesterol is 
common in uraemia. The lipid abnormalities in chronic renal failure 
include an increase in very low density lipoproteins (VLDL), normal or 
increased low density lipoproteins (LDL) and decreased high density 
lipoproteins (HDL). There is also an increase in saturated fatty acid 
esters and a reduction in linoleic acid. Low concentrations of 
HDL-cholesterol, high total serum cholesterol (Kannel et al., 1979), 
high VLDL-triglyceride (Norbeck et al., 1980) and relatively low 
linoleic acid and high fatty esters (Norbeck et al., 1982) are thought 
to promote atherosclerosis.
The aetiology and pathogenesis of lipid abnormalities in uraemia 
are still unclear. Abnormalities from deranged carbohydrate 
metabolism have been long implicated (Bagdade et al., 1968; Olefsky et_ 
al., 1974). Increased hepatic synthesis of triglycerides or impaired 
removal of triglycerides from the circulation have been suggested as 
the cause of hypertriglyceridaemia.
Peripheral insulin resistance combined with hyperinsulinaemia, 
resulting from insulin antagonism and/or impaired degradation, have 
been reported to increase the hepatic synthesis of VLDL triglyceride 
(Bagdade et al., 1968). However, later studies have failed to show 
any relationship between hyperinsulinaemia and hypertriglyceridaemia
in chronic renal failure (Cattran et al., 1976). Indeed, reduced 
rates of triglyceride synthesis has been reported (Cattran et al., 
1976; Sanfelippo et al., 1977).
The main abnormality appears to be diminished catabolism of 
lipoproteins. Impaired removal of circulating triglycerides has been 
well documented (Cattran et al., 1976; Ibels et al., 1976). This may 
be due to low enzyme levels of both serum and hepatic lipoprotein 
lipase (Chan et al., 1982).
Serum lipoprotein abnormalities occur early in chronic renal 
failure and are only marginally, if at all, affected by haemodialysis 
(Hass et al., 1983) or low protein diets (Attman et al., 1984). In 
uraemia increased dietary intake of carbohydrate markedly increases 
triglyceride concentrations which may reverse with dietary restriction 
(Sanfelippo et al., 1978). In CAPD, patients are exposed to large 
quantities of glucose and subsequently develop an increase in both 
triglyceride and cholesterol (Gokal et al., 1981).
12. URAEMIA AND DIABETES
In type I (insulin dependent) diabetes mellitus, destruction of 
the beta cells leads to loss of insulin secretory capacity and the 
insensitivity to insulin appears to be secondary to the metabolic 
consequences of insulin deficiency (Nankervis etal., 1984).
In type II (non-insulin dependent) diabetes mellitus, the 
mechanism of the disorder is still not clear. Abnormalities of both 
insulin secretion and insulin action are found in patients with 
established type II diabetes (Weir, 1982) and in glucose intolerance 
(Reaven and Miller, 1979).
Insulin insensitivity was found to be a more constant feature of 
type II diabetes than defective insulin secretion which might result
from secondary decompensation of the beta cells in response to 
hyperglycaemia (Reaven, 1984). In contrast, others have found 
impaired beta cell secretory activity as the dominant feature 
(Kadowski et al., 1984). Recently, using the technique of continuous 
infusion of glucose with model assessment (CIGMA), O'Rahilly et al. 
(1986) found beta cell function the primary defect in type II 
diabetes.
In uraemia, insulin insensitivity appears to be the dominant 
feature whereas the beta cell response is variable and probably plays 
a minor role. Basal hepatic production of glucose is normal or only 
minimally elevated in both uraemia and type II diabetes (DeFronzo, 
1978b). Futhermore, glucose production decreases in both groups 
following physiological hyperinsulinaemia. Thus uraemia and type II 
diabetes share some similarities, with insulin resistance being more 
prominent in uraemia and beta cell dysfunction being more 
characteristic of type II diabetes (Figure 2.1). However, despite 
insulin insensitivity it is uncommon for uraemics to develop overt 
diabetes unless there is an underlying genetic diabetic 
predisposition. Both type I and II diabetes often have marked 
deterioration in their glucose control with progression of renal 
failure. Insulin requirements may need to be increased and type II 
diabetes may need insulin supplementation to control their glycaemia. 
However, when the GFR falls below 20 ml/min a paradoxical situation 
arises. The clearance of insulin becomes markedly reduced and less 
insulin is degraded resulting often in better control or reduced 
requirements and improved glucose tolerance. Following the 
institution of dialysis a complex situation situation develops. 
Dialysis may increase the tissue sensitivity to insulin thereby 
decreasing insulin requirements. However, dialysis may also improve
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Figure 2. 1 Comparison of mechanisms of glucose intolerance in 
uraemia and diabetes
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Figure 2. 2 Interrelationship between insulin antagonism and
disturbed carbohydrate, lipid and protein metabolism 
in uraemia
insulin degradation towards normal thereby increasing the need for 
insulin. In view of this paradox it is difficult to predict for any 
individual what will happen to their insulin requirements.
13. CLINICAL IMPLICATIONS OF GLUCOSE INTOLERANCE IN URAEMIA
As previously discussed, it is unusual for uraemic patients to 
develop overt diabetes despite their underlying glucose intolerance. 
However, impaired glucose metabolism in uraemia may have potential 
adverse effects.
Patients with chronic renal failure have a higher incidence of 
cardiovascular disease (Linder et al., 1974). Figure 2.2 shows the 
possible inter-relationship of disturbed carbohydrate, lipid and 
protein metabolism. However, there is no direct evidence that glucose 
intolerance per se contributes to atherosclerosis and its subsequent 
complications. Nevertheless, some insight can be gained from data 
available on patients with diabetes mellitus.
Accelerated atherosclerosis is common in diabetes. 
Hyperinsulinaemia in diabetes has been implicated as a causative 
factor in the pathogenesis of atherosclerosis (Stout, 1979). Insulin 
has been shown to increase the transport of cholesterol into 
arteriolar smooth muscle cells and to stimulate the proliferation of 
endothelial cells lining the arterial vascular wall. Thus the uraemic 
hyperinsulinaemic state may play a role in hyperlipidaemia.
Diabetes has been associated with an increase in cardiovascular 
mortality in clinical (Kessler, 1971), life insurance (Goodkin, 1975) 
and population studies (Garcia et al., 1974). Although other risk 
factors such as hypertension, obesity and hyperlipidaemia are well 
known, the presence of fasting hyperglycaemia and a diabetic glucose 
tolerance curve is an independent risk factor in cardiovascular
disease (National Diabetes Data Group, 1979).
However, most uraemic patients do not fulfil the criteria for the 
diagnosis of diabetes but do have impaired glucose tolerance. Some 
cross sectional population studies have shown that impaired glucose 
tolerance carries an increase in prevalence of coronary artery disease 
and is independent of hypertension and hyperlipidaemia (Keen et al., 
1965; Yano et al., 1982).
Although it is difficult to separate the other risk factors in 
uraemia, in particular hypertension and hyperlipidaemia, there is 
suggestive evidence that impaired glucose tolerance carries an 
increase risk of cardiovascular complications. Hyperglycaemia per se 
can result in production of abnormal circulating proteins such as 
glycosylated haemoglobin and albumin and this may contribute to 
abnormalities in structural proteins of the capillary basement 
membrane in muscle and kidney in diabetics (Skyler, 1979; Jovanovic 
and Petersen, 1981). Glycosylated haemoglobin has also been found to 
be elevated in uraemia in the absence of diabetes and is discussed in 
detail in Chapters 4 and 8. If uraemia per se increases glycosylated 
haemoglobin or some similar substance then possibly structural changes 
may ensue which might have a role in atherosclerosis (DeFronzo and 
Smith, 1985).
14. SUMMARY
In summary, abnormal glucose metabolism in uraemia is 
characterised by fasting normoglycaemia, abnormal glucose tolerance, 
hyperinsulinaemia and hyperglucagonaemia. Impaired renal degradation 
plays a significant role in the circulating concentrations of both 
insulin and glucagon. Glucose intolerance results from impaired 
glucose utilization manifested by reduced glucose uptake in peripheral
sites such as skeletal muscle due to the resistance to the action of 
insulin. In addition and possibly inter-related to tissue 
insensitivity to insulin impaired beta cell function to glucose may 
play a role. This concept could explain some of the conflicting 
evidence in the literature. Increased glucose production by the liver
is controversial. Recent studies have shown that hepatic glucose
production is normal but increased gluconeogenesis from amino acid 
pathways in skeletal muscle may be important. Hepatic sensitivity to
glucagon is increased while peripheral insulin sensitivity is reduced.
The site of peripheral antagonism appears to be post-receptor, that 
is, an intracellular rather than a receptor defect. The suppressive 
effect of parathyroid hormone on insulin secretion remains 
controversial but recent work suggests that it may have a role in 
carbohydrate metabolism in uraemia.
The pathophysiology of carbohydrate metabolism in uraemia remains 
complex and probably multifactorial. The abnormalities may partly be 
improved with dialysis treatment but complete reversal is uncommon.
The similarities between glucose intolerance in uraemia and diabetes 
mellitus, and the inter-relationship between disturbed carbohydrate 
and lipid metabolism and the resultant hyperlipidaemia, provide 
suggestive evidence that impaired glucose metabolism predisposes to 
cardiovascular disease.
CHAPTER 3
GLUCOSE METABOLISM AND CAPD
1. CONTINUOUS AMBULATORY PERITONEAL DIALYSIS
The term dialysis was introduced by the Scottish chemist Thomas 
Graham who demonstrated the process of separating substances using a 
semipermeable membrane made of parchment and albumin (Graham, 1854).
As well as designing a ’dialyser’ he suggested that tissue could be 
used as a functioning semipermeable membrane. However, it was not 
until the 1920's that both haemodialysis and peritoneal dialysis were 
used in man to treat acute renal failure. In the 1960's significant 
advances were made in the treatment of chronic renal failure. Vessel 
access in the form of arteriovenous shunts and the subcutaneous 
fistula were developed for haemodialysis, while Tenckhoff and 
Schechter (1968) designed a permanent peritoneal catheter for chronic 
intermittent peritoneal dialysis. Further development in machine and 
artificial dialyser technology made haemodialysis a more efficient and 
acceptable treatment for general use. However, intermittent 
peritoneal dialysis remained less popular because of inferior solute 
clearances, the high incidence of peritonitis and the relatively long 
periods patients were attached to fluid cycling machines. Continuous 
ambulatory peritoneal dialysis (CAPD) was developed in 1975 when 
Popovich and Moncrief described a 'portable equilibrium dialysis 
technique' (Popovich et al., 1976). Modifications (Oreopoulos et al., 
1978) and clinical experience have now made CAPD an acceptable mode of 
renal replacement therapy.
a) Principle
CAPD is jbased on solute diffusion across a semipermeable membrane 
and fluid movement by osmosis. The fluid compartments, blood and 
dialysis fluid in the peritoneal cavity are separated by a natural 
semipermeable membrane, the peritoneum. The process of
transperitoneal equilibration between dialysate and plasma is
determined by time of exposure of the dialysate to the peritoneum and
the molecular size of the solute.
Small molecules, such as urea (60 Daltons) achieve equilibration
within 2 hours of dialysate dwell whereas larger solutes (500-5000 
Daltons) take proportionately longer to approach equilibrium.
Although it may be expected that after small solutes achieve rapid 
equilibration clearances would be reduced with dwell times longer than 
3-4 hours the continuous nature of the system compensates such that 
weekly clearances are satisfactory to control uraemia. Small solute 
clearances in CAPD are superior to intermittent peritoneal dialysis 
though inferior to haemodialysis. The process of equilibration for 
large solutes continues for long periods and favours long dwell times. 
Clearance of large molecules falls less rapidly with long exchanges 
than small solutes. Large solutes are cleared more efficiently in 
CAPD than either intermittent peritoneal dialysis or haemodialysis. 
Thus CAPD has a low solute flow rate but this is compensated by the 
continuous process of the technique.
b) Technique
The procedure consists of instilling by gravity dialysis fluid, 
contained in plastic (PVC) bags, through a plastic tube (transfer set) 
which is connected to a permanent peritoneal catheter. The fluid 
equilibrates within the peritoneal cavity for 4 to 6 hours and is then 
drained out by gravity. Generally, three 2 litre exchanges are 
performed during the day and a longer (8 hours) exchange is done 
overnight. Following instillation of the fluid the empty plastic bag 
is rolled up and attached to the body, allowing the patient freedom to 
carry out normal daily activities, till the end of the cycle. At the
end of the exchange the bag is disconnected and replaced by fresh 
dialysis fluid. The instilling and drainage procedure takes about 25 
minutes. Several modifications of the system and innovations in 
’connector* technology have improved the technique and reduced the 
incidence of peritonitis.
Variations in the technique can be applied to meet the needs of 
the individual patient. Continuous cyclic peritoneal dialysis (CCPD) 
is a variation of CAPD which involves using a machine to instil and 
drain fluid automatically. Generally several cycles are performed 
during the night when the patient is asleep and one exchange (or none 
- empty peritoneum) is done during the day. Currently experience with 
this technique is limited.
2. THE ROLE OF GLUCOSE IN CAPD
a) Dialysis solutions
The chemical composition of peritoneal dialysis solutions is 
fundamental in the process of CAPD. Commercially available solutions 
are now relatively standardised and provide satisfactory electrolyte, 
mineral and acid-base balance. Ultrafiltration is achieved by an 
osmotic agent which to date has been glucose. Dialysis solutions and 
systems in CAPD have been recently reviewed by Winchester (1986).
There are minor differences in the non-osmotic composition of 
fluids which vary between manufacturers. In general, the constituents 
are sodium (130-134 mmol/1), chloride (100-103 mmol/1), calcium 
(1.35-1.75 mmol/1), magnesium (0.5-1.5 mmol/1) and lactate (35 
mmol/1). Fluids are usually potassium free. The osmotic component of 
the fluid is glucose (dextrose), which varies between 1.36 g/dl (%) 
and 4.25 g/dl. This allows manipulation of the osmotic strength of 
the fluid to achieve the desired degree of ultrafiltration.
A sodium content of about 132 mmol/1 is adequate in most clinical 
situations in CAPD and any extracellular fluid contraction and 
postural hypotension due to excessive ultrafiltration can be corrected 
by adjustment to the osmotic strength of the fluid or to the sodium 
and water oral intake. This is in contrast to intermittent peritoneal 
dialysis when a lower sodium concentration is often recommended, 
particularly when the dwell times are short and hypertonic solutions 
result in disproportionately greater removal of extracellular water 
than sodium. Potassium is generally not required to maintain normal 
serum concentrations and any change in serum potassium can be 
corrected by oral or dietary manipulation. A positive calcium balance 
is maintained in most patients, but underlying renal osteodystrophy 
may require alterations in either the calcium content of the fluid or 
more usually oral supplementation with calcium and vitamin D 
analogues. Magnesium concentrations are usually well maintained and 
rarely require alteration, but the increased use of magnesium 
containing phosphate binders may in the future warrant changes in the 
dialysate magnesium concentration.
Acid-base balance is achieved by lactate. Bicarbonate would be 
ideal but there are two drawbacks related to the manufacturing process 
that prevents its use. In the presence of bicarbonate insoluble 
calcium and magnesium salts precipitate on storage and the alkali pH 
of bicarbonate produces caramelisation of glucose during autoclaving. 
Acetate and lactate have been used as alternative buffers without the 
above problems. However, recently the use of acetate has been 
associated with loss of ultrafiltration (International Study Group,
1984) and a possible association with the rare,' but lethal, condition 
of sclerosing peritonitis (Slingeneyer et al., 1983). Thus lactate is 
now exclusively used as the buffer in CAPD fluids.
b) Osmotic agents
Fluid removal during peritoneal dialysis depends on osmotic 
forces. Glucose has been used as an osmotic agent since the early 
experimental days and has proven to be safe, effective and 
inexpensive. Indeed dextrose is the only commercially available 
osmotic agent at present. However, the high rate of peritoneal 
glucose absorption has lead to obesity, hypertriglyceridaemia and the 
potential hazardous effects on carbohydrate metabolism and accelerated 
atherosclerosis has generated interest in alternative osmotic agents.
Glucose in dialysis fluids can undergo spontaneous breakdown to 
aldehyde, 5-hydroxymethylfurfural, laevulinic and formic acids. This 
process may be accentuated by extreme heat during the sterilization of 
fluids during manufacture. The effect of storage and heating of the 
dialysis solution by the patient prior to instillation has been shown 
to increase glucose metabolites (Henderson et al., 1984). Henderson 
et al. (1984) propose that metabolites (5-hydroxymethylfurfural) may 
combine with lactate to form Schiff bases which can alter the 
properties of tissue components. Thus glucose metabolites may have an 
adverse effect on the peritoneal membrane. To prevent the 
caramelisation of glucose during autoclaving, hydrochloric acid is 
added to the dialysis solution to keep the pH below 5.5. This low pH 
may have disadvantages, as it has been attributed to the pain some 
patients have on initial instillation. It can also inhibit 
phagocytosis and affect intracellular killing of bacteria, but this is 
probably only transient as the dialysate pH rises to 7 within 1 hr 
after instillation (Vas et al., 1981).
Alternative agents have been investigated and reviewed by 
Winchester (1986). Currently, no agent has shown any definite
advantage over dextrose. Some agents have shown good ultrafiltration 
characteristics but adverse effects have prevented their use.
Sorbitol, fructose, xylitol and polyanions have revealed toxic 
effects. Amino acid solutions are potentially useful and have both 
good ultrafiltration properties and nutritional value but at present 
are too expensive for general use. Glucose polymers which are not 
significantly absorbed, with sustained ultrafiltration characteristics 
and reduced caloric load look promising but some have shown prolonged 
retention and impaired metabolism. Future research may soon find a 
suitable alternative to dextrose.
3. CLINICAL EXPERIENCE
Since its conception in 1975 there has been a vast global 
expansion in CAPD. The reasons are multiple and include medical, 
social and economic factors.
In recent years many reports on the clinical experience with CAPD 
have revealed variable results (Chan et al., 1981; Kurtz et al., 1983; 
Ramos et al., 1983; Heaton et al., 1986; Morgan et al., 1986, Tsakiris 
et al., 1986). Although patient selection can have a strong bias on 
clinical data (Coward et al., 1982), with experience clinical outcome 
has significantly improved. Peritonitis is undoubtedly the major 
complication (Williams et al., 1981; Gokal et al., 1982; Smith et al., 
1986), but catheter related problems are responsible for many hospital 
admissions and technical failures. CAPD is particularly suitable for 
diabetics (Flynn, 1983), the elderly (Nicholls et al., 1984) and young 
children (Balfe and Watson, 1986). These groups were often denied 
treatment in the recent past as they were considered ’poor candidates’ 
for haemodialysis or transplantation.
The merits of CAPD are generally compared to those of
haemodialysis as it is accepted that for most patients a successful 
transplant is the optimal treatment. In brief, CAPD provides adequate 
control of uraemic symptoms and signs. Salt and water removal is 
achieved by hypertonic glucose solutions and helps maintain fluid 
balance and controls hypertension. Electrolyte, mineral and acid-base 
balance are regulated by the chemical constituents of the dialysis 
fluid. The advantages of CAPD are; a feeling of well being (perhaps 
due to several factors including better clearance of ’uraemic 
toxins’), less restricted fluid and diet control, steady state 
biochemistry, improved control of anaemia and hypertension and is 
generally more appropriate for diabetics, young children and the 
elderly. Social factors such as relative independence, freedom to 
travel and lower financial cost are also important. The disadvantages 
include peritonitis and catheter-related problems, particularly if 
they require regular hospital admissions, obesity and other forms of 
malnutrition, hyperlipidaemia and the uncertainty of long term 
viability of the peritoneum.
It is estimated that about 30,000 patients are on CAPD worldwide 
(Gokal, 1986). In the UK the ’CAPD explosion’ has resulted in more 
patients being treated with CAPD than home haemodialysis (EDTA report,
1985). Patient and technique survival have improved and are now 
similar to haemodialysis. Patient survival is about 80% at 2 years 
and 50% at 4 years, and the main reason for ’drop out' from CAPD is 
now transplantation (Gokal, 1986).
a) Diabetes and CAPD
Prior to 1970 most diabetics with end stage renal disease were 
denied treatment largely due to the high morbidity and mortality 
(Drukker et al., 1971; White et al., 1973). Progress on the
understanding of the pathophysiology of diabetes, improved control of 
glycaemia and management of complications as well as advances and 
improved facilities in dialysis and transplantation have dramatically 
changed the outlook. It is now estimated that 25% of new dialysis 
patients and 20% of transplant recipients in the USA are diabetic 
(Friedman, 1985). In the UK the proportion of diabetics on renal 
replacement therapy has increased from 1.4% in 1975 to 11.1% in 1984 
(Cameron and Challah, 1986).
The advantages of CAPD over haemodialysis for diabetics is partly 
factual, partly anecdotal and still debatable (Legrain and Keen, 1983; 
Whitley and Kjellstrand, 1984; Friedman and Peterson, 1986). In 
brief, the advantages of CAPD include steady state control of uraemia, 
good control of hypertension and a stable cardiovascular state without 
rapid fluid shifts and tighter blood glucose control by the use of 
intraperitoneal insulin. Heparinisation and vessel access are 
avoided. However, the peritoneal glucose load may promote obesity, 
hyperglycaemia, hyperlipidaemia and aggravate accelerated 
atherosclerosis. Despite the theoretical advantage of removal of 
middle molecules and uraemic toxins in CAPD peripheral neuropathy is 
generally unchanged.
b) Blood glucose control and intraperitoneal insulin
Improved blood glucose control is seen in most diabetics on CAPD 
and is largely due to the use of intraperitoneal insulin 
administration (Flynn et al., 1979; Khanna et al., 1983; Rottembourg 
et al., 1983). Normally insulin is secreted into the portal vein in 
response to various stimuli and about 50% is removed by passage 
through the liver. Intraperitoneal insulin acts like an ’artificial 
pancreas’ and mimics this physiological route. Clinical experience in
CAPD suggests that intraperitoneal insulin is superior to the 
subcutaneous route. However, the dose of insulin requires to be 
increased (often 3-4 fold) to achieve adequate glycaemic control. In 
addition to the peritoneal glucose load, insulin binding and retention 
to the dialysate bags, slow transperitoneal absorption because of its 
large molecular size, losses to the dialysate and possibly other 
metabolic and kinetic factors contribute to the higher insulin 
requirements (Khanna et al., 1986).
The use of intraperitoneal insulin to reduce hypertriglyceridaemia 
is unclear. A fall in triglyceride concentrations has been reported 
by some (Moncrief et al., 1981) but not by others (Beardsworth et al., 
1983). Despite the use of intraperitoneal insulin, which usually 
involves injecting directly into the dialysate bags, the incidence of 
peritonitis in diabetics is no different from non-diabetics on CAPD 
(Rottembourg et al., 1983).
The use of glycosylated haemoglobin in monitoring glycaemic 
control in diabetics is well established but the value of this 
indicator in uraemic diabetics is controversial and is discussed and 
investigated in Chapters 4 and 8.
The survival of diabetics on dialysis and transplantation has 
significantly improved in recent years (Friedman and Peterson, 1986). 
Recent data from two large centres show that CAPD (Toronto) and 
haemodialysis (Minnesota) have similar morbidity and mortality and 
this was largely due to accelerated atherosclerosis (Khanna and 
Oreopoulos, 1986).
4. GLUCOSE ABSORPTION AND CAPD
CAPD provides the patient with a continuous glucose infusion and 
quantification of this carbohydrate load is important due to its 
nutritional consequences.
The average daily absorption of glucose from dialysis solutions 
varies between 100 to 200g (Grodstein et al., 1981; Von Baeyer et al., 
1981). On a typical regimen of 3 isotonic (1.36%) and 1 hypertonic 
(3.86%) 2 litres exchanges about 120g of glucose will be absorbed per 
day (Nolph et al., 1979). During a 6 hour cycle 60-80% of glucose 
instilled into the peritoneal cavity is absorbed. This amounts to 
45-60g from a 3.86% solution and 15-22g from a 1.36% solution 
(Grodstein et al., 1981). These workers calculated that on average 
182g of glucose was absorbed per day, which represented 8.4 
Kcal/Kg/day or between 12% and 34% of the total energy intake.
Similar studies have reported that glucose absorption from peritoneal 
dialysis fluid accounts for about 20% of the total energy intake 
(Lindholm and Bergstrom, 1986).
The rate of glucose absorption varies between patients, indicating 
individual differences in peritoneal permeability. However, within an 
individual patient the glucose absorption is fairly constant for a 
given fluid regimen (Grodstein et al., 1981; Lindholm and Bergstrom, 
1986).
The rate of glucose absorption may increase during episodes of 
peritonitis due to increased peritoneal permeability and increased 
diffusive transperitoneal transport of glucose (Rubin et al., 1981a; 
Verger et al., 1984). The accelerated glucose absorption results in a 
rapid decrease in dialysate glucose concentration and a reduction in 
the osmotic driving force for water removal (Henderson, 1985). This 
may result in the need for more hypertonic and/or more frequent
exchanges to maintain adequate ultrafiltration.
The long term effect of glucose absorption through the peritoneum 
is unknown. Loss of ultrafiltration has been reported with time on 
CAPD and several aetiological factors have been proposed, including 
the use of hypertonic dextrose, acetate, impurities such as 
particulate matter, endotoxins and glucose metabolites. Morphological 
and functional changes in the peritoneum have also been observed and 
associated with some of these factors. This subject has been reviewd 
by Diaz Buxo (1984) and more recently by Henderson and Gokal (1986).
5. METABOLIC AND NUTRITIONAL ASPECTS OF CAPD
The continuous absorption of glucose in CAPD may contribute to: 
hyperglycaemia, hyperinsulinaemia, excess weight gain, aggravation of 
lipid and lipoprotein abnormalities, alteration in protein and amino 
acid metabolism which may induce malnutrition, and possibly promote 
premature atherosclerosis.
a) Glucose intolerance in CAPD
Glucose intolerance is common in uraemia and is largely due to 
impaired peripheral insensitivity to the action of insulin (DeFronzo 
et al., 1978a). The effect of CAPD on glucose intolerance is unclear. 
Further deterioration in glucose tolerance and a decreased rate of 
insulin secretion was found with oral glucose testing (Armstrong e_t 
al., 1980) and a suggestion of beta cell depletion after intravenous 
glucose loading has also been reported (Panzetta et al., 1982). In 
contrast, others have found no change in the degree of glucose 
intolerance up to 1 year after commencing CAPD (Lindholm et al., 1981; 
Von Baeyer et al., 1983). The continuous glucose administration could 
potentially alter pancreatic beta cell function possibly by depleting
the beta cells. This is discussed in Chapters 2 and 6.
During CAPD a hypertonic exchange induces hyperglycaemia and 
hyperinsulinaemia in a similar manner to an oral or intravenous 
glucose load. Isotonic solutions, however, appear to have only a 
marginal effect on blood glucose and insulin (Heaton et al., 1983; 
Armstrong et al., 1985). Although the occasional patient on CAPD may 
develop diabetes mellitus de novo, there is no convincing data 
currently to suggest that CAPD induces diabetes. However, it is not 
uncommon to find type II diabetics on CAPD to require insulin 
supplementation to control their blood glucose (DeFremont et al., 
1981). It is possible, therefore, that patients with a genetic 
predisposition to diabetes may have precipitation of type II disease 
induced by the continuous hyperglycaemic stress of CAPD.
b) Nutritional state
Weight gain, particularly during the first year on CAPD, is well 
documented (Kutz et al., 1983; Young et al., 1983; Tsakiris et al.,
1986). This may be due to increased body fat (Young et al., 1983; 
Bouma et al., 1984) and has been attributed to excessive glucose 
absorption and hyperinsulinaemia. However, most patients return to 
their premorbid non-uraemic weight after 1 year on CAPD (Rubin et al., 
1983). Weight gain has also been attributed to an increase in lean 
body mass indicating an improved nutritional state (Rubin et al.,
1983; Lindholm et al., 1981). Accumulation of body water is usually 
easily recognisable and readily correctable provided there is no loss 
of ultrafiltration. In the early years of CAPD a liberal oral intake 
of fluid was prescribed which often resulted in the frequent use of 
hypertonic solutions to control fluid balance and lead to excessive 
caloric intake.
On the contrary, malnutrition and loss of appetite may also be 
related to glucose absorption. The abdominal distension due to the 
volume of fluid in the peritoneal cavity may suppress satiety and the 
continuous peritoneal absorption of glucose has been reported to 
contribute to anorexia (Von Baeyer et al., 1983; Young et al., 1983).
c) Lipid metabolism
Lipid metabolism is deranged in uraemia and further changes occur 
in CAPD. Excessive carbohydrate and abnormalities in glucose 
metabolism (hyperinsulinaemia and insulin insensitivity) may lead to 
hyperlipidaemia (Olefsky et al., 1974; Coulston et al., 1983). Serum 
VLDL and total triglyceride concentrations in renal failure strongly 
correlate with the quantity of carbohydrate consumed (Cattran et al., 
1976; Sanfelippo et al., 1977). Thus in CAPD with continuous glucose 
absorption one might anticipate deterioration in lipid status.
Indeed, within the first year of CAPD hyperlipidaemia is very common
(Gokal et al., 1981; Nolph et al., 1984) and about one third of
patients may develop hypertriglyceridaemia. The latter change has 
been associated with protein loss in the dialysate (Gokal et al.,
1981) similar to that seen in the nephrotic syndrome. However, many 
studies have shown that after about 1 year on CAPD there is a tendency 
for both cholesterol and triglycerides to fall (Khanna et al., 1983; 
Lindholm et al., 1983). This may indicate a metabolic adaption to the 
glucose load and also correlates with weight reduction in many 
patients. This may be due to changes in energy intake over time. It
has been shown that the total carbohydrate intake in some CAPD
patients is regulated by a spontaneous reduction of the oral 
carbohydrate intake (Von Baeyer et al., 1981).
d) Protein and amino acid metabolism
Protein and amino acid abnormalities are well recognised in 
uraemia and CAPD. In CAPD protein is lost (5-15 g/day) in the 
dialysate and this is membrane permeability dependent (Rubin et al., 
1981b; Blumenkrantz et al., 1981). This explains the large 
interindividual difference in dialysate loss. Variations in 
ultrafiltration volume and the use of hypertonic exchanges appear to 
have little effect on protein losses (Rubin et al., 1981b;
Blumenkrantz et al., 1981). Small proteins may be depleted rapidly, 
particularly after peritonitis, that synthesis or oral replacement is 
insufficient. Thus protein depletion can contribute to malnutrition 
in CAPD. A high protein diet is generally recommended but compliance 
can be a problem. Patients may have a reduced appetite for reasons 
previously discussed or may genuinely have difficulty consuming 
protein, especially if they have been accustomed to a low protein diet
for many years as part of their chronic renal failure management.
CAPD patients often require to be re-educated to reduce their 
carbohydrate and fat intake and increase the protein content of their 
diet.
Deranged amino acid metabolism is observed in chronic renal
failure, haemodialysis and CAPD (Bergstom et al., 1978). In CAPD the
loss of amino acids depends largely on the plasma concentration and 
ultrafiltration volume (Dombros et al., 1982). The decreased 
essential amino acids and reduced valine-glycine ratio seen in CAPD is 
also observed in non-dialysed uraemics. This tends to suggest that 
the amino acid abnormalities may largely reflect the underlying 
uraemia. Sustained hyperinsulinaemia in CAPD has been reported to 
contribute to reduced amino acid concentrations (Dombros et al., 1982; 
Martin et al., 1982). Glucose administration to non-uraemic patients
has been shown to lower plasma amino acid concentrations (Martin et 
al., 1982). Thus peritoneal glucose may affect amino acid metabolism. 
Dialysate solutions containing amino acid have been studied and may 
have a further role in selected patients (Winchester, 1986).
6. SUMMARY
CAPD, at least in the short term, has proven to be an effective 
and acceptable treatment for end stage renal failure. Glucose plays a 
major role in this therapy being responsible for the osmotic and 
ultrafiltration effect. However, the long term effect of glucose on 
the integrity of the peritoneum is unknown. Glucose exerts metabolic 
and nutritional changes during CAPD. The hyperglycaemia and 
hyperinsulinaemia can, at times, be an advantage in promoting 
anabolism and improving the nutritional state. However, CAPD may also 
be detrimental by promoting nutritional imbalances in the form of 
protein deficiency and net catabolism. Furthermore, the increased 
body fat in some patients, in addition to hyperlipidaemia may 
aggravate atherosclerosis. The continuous effect of peritoneal 
glucose absorption on pancreatic beta cell function is still not 
known. Nevertheless, despite these possible adverse effects of 
glucose, the use of CAPD has resulted in good control of uraemia, 
hypertension and blood glucose.
The future of CAPD ultimately depends on the preservation of the 
peritoneum to retain its solute clearances and ultrafiltration. New 
dialysis solutions, substituting non-glucose osmotic agents, may prove 
advantageous in reducing the metabolic and nutritional consequences of 
glucose.
CHAPTER 4
GLYCOSYLATED HAEMOGLOBIN
Glycosylated haemoglobin has become universally accepted in the 
past 10 years as an independent and objective indicator of glycaemic 
control in diabetes. Its clinical value is clear, but it also 
provides an important tool for research as a model of non-enzymatic 
glycosylation and has opened up new avenues into the pathogenesis of 
the complications of diabetes as well as advancing the concept of 
non-enzymatic carbamylation.
1. INTRODUCTION
The non-enzymatic 'browning1 reaction was recognised in 1916 by 
Maillard who pioneered work on sugar and amino acid condensation in 
food. In the past 20 years there has been a great surge of interest 
in non-enzymatic glycosylation, that is, the attachment of glucose to 
certain amino acid residues of proteins, particularly in the field of 
diabetes. Current interest in glycosylated haemoglobin began with the 
potential clinical application of the measurement of modified 
haemoglobins. Blood from diabetic patients was observed to contain 
increased amounts of unusual haemoglobin fractions that migrated 
faster on electrophoresis or chromatography (Rahbar et al., 1968; 
Trivelli et al., 1971). In addition to identifying the haemoglobin 
species it was also demonstrated that non-enzymatic glycosylation 
occurred slowly and cumulatively, and the measured percentage of 
glycosylated haemoglobin in an individual could reflect ambient 
glucose concentrations over an integrated period of time (Bunn et al., 
1976; Koenig et al., 1976).
In the past 10 years, there has been an explosion of data, on 
glycosylated haemoglobin as a tool in assessing diabetic status, on 
the development of new and improved methodology, on the understanding 
of the nature and use of haemoglobin glycosylation and the widespread
use of glycosylated haemoglobin as an indicator of blood glucose 
control in diabetics.
Non-enzymatic glycosylation of haemoglobin has stimulated research 
into the pathogenesis of the complications of diabetes. Increased 
glycosylation of other proteins, in particular proteins derived from 
specific tissues typically involved in diabetic complications suggest 
that the glycosylated proteins may have altered structure and function 
(Cohen, 1986).
It has been suggested that non-enzymatic carbamylation of 
haemoglobin, that is, the attachment of urea-derived cyanate to 
haemoglobin, occurs in uraemia (Fluckiger et al., 1981) and this is 
analogous to non-enzymatic glycosylation in diabetes. However, little 
is known about carbamylated haemoglobin and the possible clinical 
relevance and pathophysiological significance in uraemia remains to be 
seen.
2. CHEMISTRY
a) Structure and Biosynthesis of Glycosylated Haemoglobin
Enzymatic glycosylation is a normal post-translational process 
which greatly expands the structure and function of proteins that are 
synthesized from the 20 amino acids. Collagen, basement membrane 
protein, HLA antigens, some cell surface receptors and certain 
hormones are but a few glycoproteins synthesized enzymatically. When 
a protein is exposed to a high glucose concentration for a relatively 
long duration non-enzymatic incorporation of glucose can occur.
Structural heterogeneity of a protein is generally due to either 
multiple gene coding for that protein or to post-translational 
modifications. Normal human red cells contain one major haemoglobin 
component, HbA [ot^, $2] anc* two minor components, HbA2 [c^ j anc*
HbF [(*2, Y2^  eac^ with 4 polypeptide chains. These proteins are coded 
by 4 different globin genes. Haemoglobin consists of HbA which 
accounts for 97% of the total and HbA2 and HbF, 2.5% and 0.5% 
respectively. Additional minor components arise because of 
non-enzymatic glycosylation. Chromatographic analysis of HbA has 
identified HbA^a, HbAj^, HbA^> ^^lc' ^^ld» ^^le* a^tter two
are not clearly elucidated and will not be discussed further.
The components of HbA^ result from post-translational 
non-enzymatic modification of HbA-^  by a variety of small molecular 
weight substances, such as glucose, phosphorylated sugars, cyanate and 
aspirin, and comprise about 7% of the total haemoglobin in normal 
subjects. Each of the chromatographically determined components is
not homogenous and may be composed of many different entities. The
major component of the HbA-^ c peak is glycosylated haemoglobin (about 
70% in normal subjects).
Glycosylated haemoglobin is formed when a glucose molecule 
attaches to the N-terminal amino group (valine) of the 3 chain of 
haemoglobin to form a Schiff base (Bunn et al., 1975). The labile 
Schiff base, often called ’pre HbA^c' or the ’labile fraction', is an 
intermediate which is reversible and increases rapidly in amount 
within a few hours after incubation of HbA with glucose (Higgins e£ 
al., 1981). The Schiff base subsequently undergoes an Amadori 
rearrangement to a stable ketoamine linkage (Bunn et al., 1975). This 
is present in increased amounts in diabetics as a consequence of 
increased blood glucose concentrations. The post-translational 
non-enzymatic glycosylation of HbA occurs slowly but continuously 
within the red cell throughout its 120 day life span in the 
circulation.
The attachment of glucose to haemoglobin occurs non-enzymatically
via a 2 step mechanism (Figure 4.1). In the initial rapid and 
reversible condensation the Schiff base aldimine is formed and slowly 
undergoes the Amadori rearrangement to the more stable ketoamine form. 
The Schiff base formation is dependent on the glucose concentration 
and is readily reversible with dialysis of the reaction mixture or 
lowering of the blood glucose concentration. The Schiff base accounts 
for the labile fraction as it elutes from the cation exchange resin 
with the same mobility as the more stable ketoamine form. Although 
there is equilibrium between the 2 configurations the balance is in 
favour of the ketoamine.
The formation of 5-hydroxymethylfurfural (5HMF) by mild acid 
hydrolysis of the Amadori rearrangement of HbA^c is shown in Figure 
4.2. The characteristic spectrum of the adduct formed with 
thiobarbituric acid is specific for ketoamine linked hexoses and forms 
the basis of the specific chemical method to detect total ketoamine 
glycosylation of proteins (Gabbay et al., 1979).
HbAiai and HbA a^2 (Table 4.1) are predominantly the 3 chain 
N-terminal adducts of fructose-1,6,-diphosphate and
glucose-6-phosphate respectively (McDonald et al., 1978), while HbA^ 
is not yet fully clarified but may be a deamidisation product of HbA 
(Krisnamoorthy et al., 1977). In addition to the termini of the 8 
chain, glucose adducts can form with the amino terminal of the a chain 
as well as free amino groups in the haemoglobin molecule. Various 
lysine residues (Table 4.II) in the a and 3 chains become glycosylated 
on exposure to glucose (Bunn et al., 1979) and glucose can also 
condense with e-amino groups of lysine residues along the polypeptide 
chains of many proteins. Thus haemoglobin glycosylation is a general 
and non-specific process. The amount of HbA in red cells, like HbA^c, 
is increased in diabetics, but unlike HbA^c, the modification of
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Table 4. I Minor Components of Haemoglobin A
Haemoglobin Modification
Abundance
(%)
A  (a2&2) • • • 95*
Aia i a^p-iV-fructose-1,6-diphosphate)2(?) 0.2
A l»2 a2(P-jV-gliicose-6-phosphate)2 0.2
Ajb CL^  p-JV-ca rbo hyd ra te)^ ?) 0.5
Aic a2(P-Ar-glucose)2 4
•An estimated 8% to 10% is glycosylated at sites other than //term ini.
Table 4. II Sites on Human Haemoglobin which 
Undergo Nonenzymatic Glycosylation
In V itro In V ivo
/3 V a l 1 p  V a l 1
a  L y s 16 p  Lys 66
13 Lys 66 a  Lys 61
P  Lys 17 P  Lys 17
or Va l  1 a Va l  1
or Lys 7 a  Lys 40
P  Lys 8
glucose at these other sites do not result in changes in the 
electrophoretic or ion exchange chromatographic properties (Gabbay et^  
al., 1979).
b) Modifying Factors
Non-enzymatic glycosylation takes place under physiological 
conditions in normal individuals. The reaction follows second order 
kinetics (McDonald et al., 1979) and the amount of glycosylated 
product is proportional to the concentration of reactants. The major 
determinant is the glucose concentration which according to the law of 
mass action will cause a proportionate increase in the amount of 
Amadori product formed. The second main determinant is the time of 
exposure of the protein to the increased glucose concentration. Thus, 
in vivo, the degree and duration of hyperglycaemia are the prime 
factors in determining the amount of glycosylated haemoglobin.
Temperature and pH are important in vitro factors and are 
critical, particularly in column chromatography (see later). The 
half-life of the protein in the circulation or tissue is also 
significant. Reduced half-life of the protein such as in haemolytic 
anaemia and shortened red cell survival can cause a decrease in HbA^c 
even in diabetics (Bunn et al., 1976) and old erythrocytes contain 
more HbA^c than young ones (Fitzgibbons et al., 1976).
The permeability and availability of glucose in different tissues 
will influence the extent of glycosylation. The erythrocyte is freely 
permeable to glucose and hence the ease of haemoglobin glycosylation. 
It is interesting that several characteristic complications of 
diabetes occur in tissue that do not require insulin for glucose 
transport and can dispose of glucose via insulin-independent pathways. 
This adds to the concept that non-enzymatic glycosylation contributes
to the pathogenesis of diabetic complications in these tissues.
Biochemical factors such as the number of free amino groups, 
accessibility and pK of the amino group within the structure of the 
protein also influence the formation of glycosylated proteins (Cohen, 
1986).
c) The Mai Hard Reaction
The ketoamine adduct formed from the reaction between glucose and 
protein amino groups can undergo a series of dehydration, 
rearrangement and cleavage reactions collectively known as the 
Maillard or browning reaction (Figure 4.3). The products of such 
reactions are highly cross-linked, insoluble pigmented and fluorescent 
polymers. The formation of these substances has been studied 
extensively in vitro, particularly in the food industry but recent 
evidence indicates that these products can form in vivo, particularly 
in long-lived proteins and when non-enzymatic glycosylation is 
increased. These advanced glycosylation products have recently been 
implicated in the pathogenesis of diabetic complications (recently 
reviewed by Cohen, 1986) as well as in the aging process. Thus the 
Maillard browning reaction involves three stages, first the formation 
of a ketoamine (as seen in Figure 4.1), i.e. non-enzymatic 
glycosylation, then deamination followed by dehydration, cyclization 
and fusion to generate secondary products such as 
hydroxymethylfurfural (Figure 4.2) and the final stage involves 
polymerization (Figure 4.3). The biological significance of advanced 
glycosylation end-product formation is at present unclear but has 
stimulated a new area of research in the field of glucose metabolism.
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3. MEASUREMENT OF GLYCOSYLATED HAEMOGLOBIN
a) Nomenclature
There has been some confusion about the nomenclature of 
glycosylated haemoglobin and this is mainly due to the fact that our 
knowledge of the subject has been changing rapidly. Glycosylated 
haemoglobin (is synonomous with glycohaemoglobin and glycated 
haemoglobin) refers to a series of stable adducts that are formed 
between haemoglobin and sugars and whose concentrations are increased 
within the red cell of patients with diabetes. Some assay methods 
quantify all glycosylated haemoglobin species regardless of the 
haemoglobin tetramer and this is called total glycosylated 
haemoglobin. Other assays measure the products formed by 
glycosylation of the amino termini of HbA (c^ , l^ )* Some are specific 
for one product, e.g. HbA^c, while others measure the sum of HbA^a, 
HbA-j^  and HbA-^ c, which is called HbA-^  or ’fast1 haemoglobin (Figure 
4.4). It is generally accepted that regardless of the particular 
glycosylated haemoglobin, values obtained from the same blood sample, 
but assayed by different methods are clinically comparable. However, 
there are exceptions such as in renal failure which will be discussed 
later.
b) Methods
Glycosylated haemoglobin is currently estimated by 2 basic methods 
which operate on different principles and yield independent results 
which are nonetheless related. The chromatographic methods depend on 
a net change in the charge of the haemoglobin molecule when the 
N-terminal position of the 3 chain is modified. Thus the components 
of HbA^ are eluted readily from a cation exchange resin and can be 
quantified and expressed as a percentage of total haemoglobin.
Haemoglobin molecules glycosylated at sites other than the 3 
N-terminal do not have sufficiently altered net charge to increase 
their mobilities and are thus not measured by these techniques. These 
chromatographic operations are very sensitive to minor changes in 
buffer pH and temperature which can significantly affect the values 
obtained.
Separation based on a charge difference is the principle for the 
macro-column (Biorex-70 column chromatography - Trivelli et al.,
1971), isoelectric focus ing (Spicer et al., 1978), agar gel 
electrophoresis (Nathan, 1981), high performance liquid chromatography 
(HPLC) (Dunn et al., 1979a) and the convenient commercial mini-column 
kits (Bio-Rad, Richmond, Calif.). The latter columns can measure the 
sum of HbA^a_c (HbA^ ) or specific fractions (HbA^c and HbA^a+^).
These are detailed in Chapter 5.
The other general type of method involves direct chemical 
measurement of total glycosylation in the red cell. In the 
thiobarbituruic acid (TBA)-colorimetric method (Fluckiger and 
Winterhalter, 1978), furfural compounds are generated from the 
ketoamine-linked carbohydrate moieties upon heating under acidic 
conditions and are quantified colorimetrically with TBA (Figure 4.2). 
This method is detailed in Chapter 5.
Several new methods have been developed in recent years and one of 
the most promising is affinity chromatography (Klenk et al., 1982), 
which uses affinity gel columns to separate glycosylated haemoglobin 
from the non-glycosylated fraction. Results from this method suggest 
that glycosylation accounts for only about 70% of the HbAjLQ peak 
isolated by cation-exchange chromatography. This is consistent with 
the finding that a variety of non-glucose substances can modify the 
N-terminal amino acid of the 8 chain such as carbamylation and
acetylation (see later).
c) Limitations of Assay Methods
Despite the variety of methods all have some limitations although 
all are adequate for assessing clinical status and glycaemic control. 
Ion exchange chromatography is greatly influenced by buffer pH, the 
temperature of reagents, interference by non-glucose adducts, aldimine 
intermediates (pre-HbA^c) and haemoglobinopathies. It also requires a 
high degree of operator skill for precision, but has the advantage of 
being rapid to perform, relatively inexpensive to run and suitable for 
the small laboratory. HPLC has similar limitations and is expensive 
to install but is useful particularly for research purposes. 
Electrophoresis is subject to interference by several reactants 
including non-glucose adducts, can be time consuming and relatively 
expensive. The TBA-colorimetry method is unaffected by non-glucose 
adducts, aldimine intermediates and haemoglobinopathies and is 
relatively inexpensive to run. However, standardization can be a 
problem (with no universally accepted standard) and hydrolysis 
conditions must be carefully controlled for precision. Generally it 
is a time consuming manual process but can be semiautomated for use in 
large laboratories.
d) Interference
The chromatographic-type procedures can under certain conditions 
produce falsely abnormal results due to interference. These are 
listed in Table 4.Ill (adapted from Gabbay, 1983). Conditions such as 
uraemia, chronic aspirin intake, antibiotic therapy and recent alcohol 
intake can lead to false elevation of glycosylated haemoglobin. These 
effects are due to changes in charge of the haemoglobin molecule
I  - Conditions leading to false elevation of HbA-^
A. Chromatographic abnormalities:
1. Hyperlipidaemia - due to lactescence
2. Elevated temperature and/or buffer pH
3. Negatively charged Hb variants - e.g. HbF
4. Acute hyperglycaemia - ’fast glycosylation’
B. Other post-translational Hb modifications:
1. Aspirin - acetylation
2. Antibiotics - penicilloylation
3. Alcohol - 5-deoxy-xylulose-l-phosphate
4. Uraemia - carbamylation
II - Conditions leading to falsely low Hb A^ values
A. Chromatographic abnormalities:
1. Low temperature and/or buffer pH
2. Positively charged Hb variants - e.g. HbS,C
B. Altered red blood cell dynamics:
1. Increased destruction - e.g. haemolytic anaemia
2. Active erythropoeisis - e.g. pregnancy
3. Recent transfusions
Table 4. Ill Factors interfering with HbA^
H
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Figure 4. 5 Formation of isocyanate from urea and its reaction 
with an amino group
brought about by post-translational modification occurring via 
mechanisms other than glycosylation. Elevation of HbA^ in uraemia has 
been reported to be due to a carbamylation species (Fluckiger et al., 
1981) which is detected by the chromatographic technique but not by 
the TBA-colorimetric method. Glycosylated haemoglobin measured by any 
method will be significantly reduced in patients with decreased red 
cell life span (Elseweidy etal., 1983) such as in haemolytic anaemia, 
uraemia or in patients with active erythropoiesis such as pregnancy. 
The use of whole blood haemolysates in chromatography may give rise to 
artefacts which can falsely elevate HbA-^  or HbA^c- The presence of 
the labile fraction or pre-HbA^c is influenced by the ambient blood 
glucose concentration and in a poorly controlled diabetic acute 
hyperglycaemia can cause false elevation of HbA^c unless the labile 
fraction is removed (Nathan et al., 1981). Hyperlipaemic blood, 
common in both diabetes and uraemia, can also increase the 'fast' 
(HbA^a__c) fraction due to interference from lactescence, which elutes 
with the HbA-^  fraction and is absorbed at the same wavelength (Dix et 
al., 1979a). However, these complications are circumvented by the 
TBA-colorimetric method with the exception of shortened red cell 
survival.
4. CLINICAL SIGNIFICANCE
The clinical usefulness of glycosylated haemoglobin in diabetes 
has been firmly established.
a) Blood Glucose Control
Periodic monitoring of glycosylated haemoglobin is useful in 
documenting the degree of glucose control that has prevailed during an 
interval of weeks to months before the sample is taken since
glycosylated haemoglobin concentration reflects the time averaged 
concentration of glucose within the erythrocyte during that period.
The evidence supporting the correlation between glycosylated 
haemoglobin and glucose control is well established (Gabbay et al., 
1977; Gonnen et al., 1977; Koenig et al., 1976; Jovanic et al; 1981). 
Periodic measurement of glycosylated haemoglobin concentrations 
provides an objective assessment of glycaemic control that complements 
and extends information obtained from traditional methods (such as 
regular home urine and blood glucose testing). This assessment is 
independent of the daily variations due to meals, insulin dosage and 
physical activity and improves the clinical management of diabetes.
The technique employed to measure glycosylated haemoglobin is less 
critical than the consistent use of the same technique with reliable 
performance, since normal ranges will differ according to what is 
being measured by different methods.
b) Diagnosis
Attempts to use glycosylated haemoglobin as a more sensitive or 
specific test and to replace the oral glucose tolerance test have not 
been corroborated in clinical studies (Santiago et al., 1978; Dunn et_ 
al., 1979b; Flock et al., 1979). The combination of an elevated 
fasting blood glucose and elevated glycosylated haemoglobin usually 
obviates the need for further testing and indicates clinically 
significant hyperglycaemia. However, the value of glycosylated 
haemoglobin in detecting degrees of glucose intolerance is limited. 
Screening studies have shown that there is considerable overlap in 
glycosylated haemoglobin values in patients with normal and abnormal 
glucose tolerance (Dix et al., 1979b; Cederholm et al., 1984; Hall et 
al., 1984).
c) Complications of Diabetes
The complications of diabetes include microvascular and 
macrovascular disease, retinopathy, neuropathy and nephropathy, but 
the biochemical basis for the development of such sequelae is not 
known. Moreover, considerable controversy exists about the 
relationship between the degree of control of blood glucose and the 
eventual development of such sequelae. Strict control of carbohydrate 
metabolism should reduce the risk of secondary complications, but it 
has been difficult to document this because of the lack of means of 
measuring both the degree of control and the pathological changes that 
occur with chronic disease. Long term prospective clinical studies 
are necessary to assess the contribution of the severity and duration 
of hyperglycaemia to the development and progression of diabetic 
complications.
Several short term studies show a correlation between HbA^c and 
cholesterol possibly indicative of hyperglycaemia as a causative 
factor in macroangiopathy (Gabbay et al., 1977; Sosenko et al., 1980). 
Muscle basement capillary membrane thickness has been reported to 
decrease after optimal glucose control assessed by glycosylated 
haemoglobin (Petersen, 1980; Raskin, 1983). Increased glomerular 
filtration rate (GFR), an early marker of diabetic nephropathy, has 
been shown to fall in conjunction with normalisation of HbA^ (Wiseman 
et al., 1985). Thus microangiopathy may be influenced by persistent 
hyperglycaemia. However, although glycosylated haemoglobin can be 
used as an index of metabolic control much more investigation is 
needed before a definite link can be established between 
hyperglycaemia and the complications of diabetes.
5. PATHOPHYSIOLOGICAL SIGNIFICANCE
a) Haemoglobin
The amino terminal of the B chain of haemoglobin, to which glucose 
attaches, is also a site where 2,3-diphosphoglycerate (2,3-DPG) binds.
2.3-DPG is an important red cell glycolytic intermediate which 
influences the affinity of haemoglobin for oxygen through its binding 
to B chain residues of deoxyhaemoglobin. Addition of organic 
phosphate decreases the oxygen affinity of haemoglobin, whereas 
removal increases the oxygen affinity of HbA and HbA-^. The 
availability of this site for interaction with 2,3-DPG is compromised 
when it is covalently linked to glucose (Bunn et al., 1970). Hence 
HbA^c exhibits greater oxygen affinity than HbA in the presence of
2.3-DPG (McDonald et al., 1979). The increase in HbA^c in red cells 
of diabetics shows a slight increase in oxygen affinity of these cells 
in the presence of 2,3-DPG compared to non-diabetics (Arturson et al., 
1974). This difference could be due to interference by the
NH2-terminal glucose of HbA^c to the binding of 2,3-DPG.
The impact of the minor shift in the haemoglobin-oxygen 
dissociation curve arising from increased HbA^c in diabetics is 
unclear. It has been suggested increased HbA^c coupled with low red 
cell 2,3-DPG could compromise oxygen delivery to the tissues and 
promote hypoxia and diabetic complications (Ditzel et al., 1979). 
However, this has been challenged by the fact that certain 
haemoglobinopathies produce greater shifts in the oxygen dissociation 
curve without significant effects on tissue oxygen (Bunn et al.,
1981).
b) Other Proteins
Glycosylation of other proteins may also have pathological 
significance. Like HbA-p measurement of glycosylated albumin provides 
an index of blood glucose control during the preceding 1-2 weeks 
(Dulhofer et al., 1981). Furthermore, glycosylated albumin has been 
implicated in the pathophysiology of diabetic microangiopathy as it is 
filtered through the glomerulus faster than normal albumin (Ghiggeri 
et al., 1984) and may contribute to the increased capillary membrane 
permeability and proteinuria seen in diabetic nephropathy.
Glycosylated lipoproteins are increased in poorly controlled diabetics 
(Curtiss et al., 1985) suggesting a possible role in atherosclerosis. 
Glycosylation of lens protein has also been implicated in the 
pathogenesis of cataract formation (Kasai et al., 1983) and 
glycosylation of myelin has been observed in the central nervous 
system and peripheral nerves in diabetics (Vogt et al., 1982; Vlassara 
et al., 1983).
Increased glycosylation of collagen is found in many tissues of 
diabetics including aorta, skin, tendon, glomerular and lens capsular 
basement membrane collagen (Vogt et al., 1982). Non-enzymatic 
glycosylation may induce resistance to collagenase digestion and cause 
a premature aging process which correlates clinically with 
complications, such as the premature atherosclerosis seen in Type I 
diabetes.
Covalent interactions or cross-linking between glycosylated 
proteins and other soluble proteins such as albumin and IgG have been 
reported (Brownlee et al., 1983). This may explain the increased 
concentration of albumin in glomerular basement membrane of patients 
with diabetic nephropathy (Michael et al., 1981). Glycosylation can 
also alter the immunogenic properties of proteins (Bassiouny et al.,
1983) which may initiate an immune response against tissue components 
and could also explain the deposition of albumin and IgG in the 
microvascular matrix of diabetic patients.
c) Advanced Glycosylation
Glucoadducts produced as a result of non-enzymatic glycosylation 
can give rise to advanced glycosylation end-products, which can induce 
molecular modifications and subsequent trapping or binding of 
unrelated proteins. Thus advanced glycosylation has the potential for 
disturbing structural and biological characteristics of proteins or 
for exerting toxic effects on cell processes. It has been postulated 
that a period of hyperglycaemia could initiate excess non-enzymatic 
glycosylation, but deleterious effects could ensue as a result of 
protein interactions and abnormalities brought about by the subsequent 
formation of advanced end-products even after hyperglycaemia is 
corrected (Cohen, 1986). However, further studies are needed to 
confirm this possible link between diabetic control and the chronic 
complications of diabetes.
6. GLYCOSYLATED HAEMOGLOBIN AND HAEMOGLOBIN CARBAMYLATION IN URAEMIA 
Uraemia influences the chromatographic measurement of HbA^ (DeBoer 
et al., 1980; Lunetta et al., 1981; Fluckiger et_al., 1981). Elevated 
concentrations of both HbA^ and HbA^-like haemoglobins have been 
reported in renal failure. Glucose intolerance is common in uraemia 
and some dialysis patients are dialysed against fluid with a high 
glucose content. This has lead to the assumption that the increase, 
at least in part, may be due to increased formation of glycosylated 
haemoglobin resulting from abnormalities in carbohydrate metabolism. 
However, the colorimetric estimate of glycosylated haemoglobin
does not show an increase in uraemia (Fluckiger et al., 1981). The 
increase in fast (HbA-^ a_c) haemoglobin has been suggested to result 
from haemoglobin carbamylation occurring via the condensation of 
urea-derived cyanate with the N-terminal amino groups of the 
haemoglobin chains (Figure 4.5). This form of non-glycosylated 
haemoglobin is detected by column chromatography, but not by the 
TBA-colorimetric method which is specific for the detection of 
glycosylation. Fluckiger et al. (1981) identified valine hydantoin, 
which is released from the carbamylated N-termini of the haemoglobin 
chains upon acid hydrolysis and showed that valine hydantoin 
correlated with time averaged blood urea of the previous 2-3 months in 
uraemic patients. These authors also suggest that the increase in 
HbA^ in uraemia was entirely due to an increase in the HbA-^ a+  ^
component.
Thus carbamylated haemoglobin may reflect the urea concentration 
over a period of time, a situation analogous to that of glycosylated 
haemoglobin in diabetes. It should also be noted that the 
interpretation of glycosylated haemoglobin in uraemia is complicated 
by the presence of shortened red cell survival which would tend to 
reduce glycosylated haemoglobin independently of the method of 
measurement. Glycosylated haemoglobin status in uraemia is complex 
and caution is required in interpreting results in both diabetic and 
non-diabetic uraemic patients. The relevance of carbamylated 
haemoglobin is unclear, but the implication that it may be analogous 
to glycosylated haemoglobin suggests that future research is needed to 
explore possible clinical applications and pathophysiological 
consequences.
7. GLYCOSYLATED AND CARBAMYLATED HAEMOGLOBIN IN URAEMIA -
REVIEW OF THE LITERATURE
The use of glycosylated haemoglobin as an indicator of long-term 
blood glucose control in diabetics with normal renal function is well 
established (Koenig et al., 1976; Gabbay et al., 1977). However, the 
role of glycosylated haemoglobin in uraemia and diabetics with renal 
failure is unclear. Confusion is partly related to methodology and 
nomenclature and partly to conflicting data in clinical studies.
Generally chromatographic techniques measuring HbA^ or HbA-^ c have 
shown elevated concentrations of glycosylated haemoglobin in 
non-diabetic uraemia patients (Casparie et al., 1977; DeBoer et al., 
1980; Kovarik et al., 1981), but other have found low concentrations 
(Dandona et al., 1979; Freedman et al., 1982). Chemical methods such 
as the thiobarbituric acid-colorimetric technique, which measures the 
total glycosylation of the red cell have revealed normal values of 
glycosylated haemoglobin (Fluckiger et al., 1981; Oimomi et al., 1981; 
Nath et al., 1982) in non-diabetic uraemic patients. Thus differences 
in methodology reveal different results in the presence of uraemia.
Clinical studies showing increased HbA^ or HbA^c in non-diabetic 
uraemic patients initially suggested that the elevation was due to 
glucose intolerance which is common in uraemia (DeFronzo and 
Alvestrand, 1980) or coexisting hyperglycaemia in renal patients 
(Casparie et al., 1977; Stanton et al., 1978). However, later studies 
did not find any correlation between glucose intolerance, fasting 
blood glucose or 24 hour glycosuria and HbA^ (Kovarik et al., 1981; 
Panzetta et al., 1983). The association between uraemia and elevated 
HbA-^  was strengthened by the common finding of a linear relationship 
between urea or creatinine and HbA^ (Graf et al., 1980; Fluckiger et 
al., 1981; Kovarik et al., 1981). However, others did not find a
correlation between HbA^ and urea in haemodialysis patients (De Marchi 
et al., 1983a). The latter group found HbA^ strongly correlated with 
arterial pH and plasma bicarbonate. De Marchi et al. (1983b) 
reported, in a larger study in non-dialysis chronic renal failure 
patients, a weak correlation between HbA-^  and urea, but again 
emphasised the role of acidosis. The effect of acidosis, however, was 
not confirmed by others (Panzetta et al., 1983).
The increase in HbA-^  and sub-fractions has also been related to 
the presence of a non-glucose adduct of haemoglobin that is 
chromatographically indistinguishable from glycosylated haemoglobin. 
Fluckiger et al. (1981) demonstrated that HbA-^  was elevated largely 
due to haemoglobin carbamylation resulting from a condensation of 
urea-derived cyanate with the N-terminal amino groups of haemoglobin. 
These authors showed that this non-glycosylated haemoglobin was 
detected by column chromatography but not by a chemical method 
specific for the detection of glycosylation. In addition to elevation 
of HbA^ they found an increase in HbA^a+  ^fraction. Carbamylation of 
haemoglobin was detected in vitro from the components of the 
chromatographic peaks. Although frequently suggested as a possible 
cause for the elevation of glycosylated haemoglobin in uraemia no 
other studies have directly measured carbamylated haemoglobin in 
uraemia. Oimomi et al. (1984) studied the in vitro addition of urea 
to erythrocytes and found the amount of cyanate produced was
proportional to the amount of HbA^.
Reduced concentrations of HbA^ have been reported by one group
(Dandona et al., 1979; Freedman et al., 1982) in a wide range of
uraemic patients. They suggested that low concentrations were due to 
shortened red cell life span although no measurement of erythrocyte 
survival was done. It is well documented that red cell survival is
reduced in uraemia (Shaw, 1967; Hocken, 1982; Hefti et al., 1983). 
Furthermore, glycosylated haemoglobin is reduced in conditions with 
shortened red cell life span but not in non-haemolytic anaemias 
(Fitzgibbons et al., 1976).
The effect of uraemia on diabetes is clinically important if 
glycosylated haemoglobin is to be used as an integrated index of 
glycaemic control. The data on glycosylated haemoglobin in diabetics 
with uraemia measured by direct chemical means is apparently unaltered 
by uraemia and should therefore reflect glycaemic control in diabetics 
with renal failure. This would then appear to be the method of choice 
but the effect of shortened red cell life span must also be 
considered. To date this has not been directly studied.
HbA-^  has been reported to be higher in uraemic diabetics than 
non-diabetic uraemics (Kumar et al., 1983), while others found little 
difference between similar groups of patients (Panzetta et al., 1983). 
Saloranta et al. (1986) assessed HbAp HbAj,c, HbA^a+  ^by column 
chromatography in diabetics and non-diabetic uraemic patients. They 
found the expected increase in HbA-^  which weakly correlated with urea 
and creatinine in non-diabetics, while diabetics had even higher HbA^ 
which was less influenced by urea and creatinine concentrations. 
Saloranta and colleagues also found that the HbA^c/HbA^a+k ratio was 
higher in diabetics than non-diabetics confirming the findings of 
others (Lantz et al., 1981; Oimomi et al., 1981). This suggests that 
the diabetics state influences HbA^c more than HbA^a+ .^ However, 
Saloranta et al. (1986) did not find any change in the H^ ^ c/HbA^a+  ^
ratio in non-diabetic uraemic patients. This is contrary to the 
results of others (Fluckiger et al., 1981; Lantz et al., 1981) who 
found that uraemia influenced the HbA^a+  ^components more than the 
HbA-^ c fraction. In a small number of diabetics with renal failure
repeated measurements of HbA^ and blood glucose showed correlation and 
the authors (Saloranta et al., 1986) concluded that HbA^ or HbA^c 
measured chromatographically was still a useful index of glycaemic 
control.
In summary, current data suggests that HbA-^  is elevated in uraemia 
when measured chromatographically. The cause of this elevation could 
be due to glucose intolerance, acidosis or carbamylation of 
haemoglobin. The latter is an attractive possibility, bearing in mind 
the similarities with non-enzymatic glycosylation. Shortened red cell 
survival in uraemia would be expected to reduce or have an inhibitory 
effect on glycosylated haemoglobin independent of the assay method 
used and theoretically, could also influence the concentration of 
carbamylated haemoglobin. Assessment of diabetics with uraemia 
requires further clarification and although the direct chemical 
colorimetric methods appear to be unaffected by uraemia the usefulness 
of the common chromatographic procedures are still unclear.
8. THE ROLE OF NON-ENZYMATIC CARBAMYLATION IN URAEMIA
Non-enzymatic carbamylation of haemoglobin in uraemia has been 
suggested as being analogous to non-enzymatic glycosylation in 
diabetics (Fluckiger et al., 1981). To date, no studies have been 
published to implicate a clinical or pathophysiological role for 
non-enzymatic protein carbamylation in uraemia. However, recently an 
in vitro study demonstrated reduced biological activity of insulin 
after incubation with cyanic acid (Oimomi et al., 1987).
Carbamylated adducts of haemoglobin have been known for many years 
and were used experimentally both in vitro and in vivo in the 
treatment of sickle cell disease. Sodium cyanate was used as a 
covalent agent to inhibit sickling of red cells. Cyanate binds firmly
to both alpha and beta chains of haemoglobin and increases the oxygen 
affinity and reduces the capability of the red cell to sickle (Nigen 
et al., 1974). Red cell survival was increased and the increase in 
red cell life span reflected the degree of carbamylation (Cerami et_ 
al., 1971; Gillette et al., 1974). Unfortunately, carbamylation in 
vivo was not confined to the NH2 groups of haemoglobin, but affected 
the other enzyme systems (De Furia et al., 1972). Numerous symptoms 
including weight loss, nausea, vomiting, epigastric pain and 
drowsiness were reported (Gillette et al., 1974; Petersen et al., 
1974). Peripheral nerve conduction was also abnormal but resolved on 
cessation of cyanate therapy (Petersen et al., 1974). Thus toxicity 
limited the potential clinical benefit of prolonging red cell survival 
and inhibition of sickling.
Theoretically, many of the characteristics of non-enzymatic 
glycosylation may also be applicable to non-enzymatic carbamylation. 
Fluckiger and coworkers suggested that carbamylated haemoglobin may 
reflect time averaged blood urea. Thus carbamylated haemoglobin may 
be used as an integrated index of uraemic control. This could 
conceivably have a clinical value in several situations. Carbamylated 
haemoglobin may have a role in distinguishing acute from chronic renal 
failure, detecting the timing of deterioration in chronic renal 
failure, assessing compliance in protein diet restriction therapy and 
evaluating the efficiency of dialysis therapy. Carbamylated 
haemoglobin may give a mean estimate of the uraemic state prevailing 
during the previous 4-8 weeks.
Non-enzymatic carbamylation may also have a wider application if 
it can modify other proteins analogous to non-enzymatic glycosylation. 
Carbamylated plasma proteins and carbamylated insulin have recently 
been demonstrated in vitro (Oimomi et al., 1985; Oimomi et al., 1987).
It is interesting that vascular disease, lipoprotein abnormalities and 
neuropathy are common to both diabetes and uraemia and it is tempting 
to speculate that non-enzymatic modification of proteins are 
implicated. The effects of cyanate used in sickle cell disease are 
similar to common uraemic symptoms such as the nausea, vomiting and 
tiredness and peripheral neuropathy with prolonged nerve conduction 
time*
Thus non-enzymatic carbamylation of proteins would appear to 
warrant further investigation in uraemia to assess its potential 
clinical usefulness and pathophysiological relevance.
9. SUMMARY
The structure, biosynthesis and measurement of glycosylated 
haemoglobin has been outlined, with particular emphasis on the 
difference between methods, modifying and interfering factors. The 
clinical usefulness of glycosylated haemoglobin as a measure of 
integrated long-term glucose control is well established in diabetics 
without uraemia. The effect of interference due to uraemia is 
unclear, but may be circumvented by using colorimetry as opposed to 
ion-exchange chromatography. The process of non-enzymatic 
glycosylation has wide implications from the evidence that it can 
alter the structure and function of proteins. The association between 
non-enzymatic glycosylation and the complications of diabetes provides 
a possible link between glucose control and the sequelae of diabetes. 
This has long been suspected but has generally lacked direct evidence. 
Thus, glycosylation of proteins has an important pathophysiological 
significance.
The controversial data on the role of glycosylated haemoglobin in 
non-diabetic patients with renal failure is reviewed. The concept of
a non-glucose adduct of haemoglobin interfering with the 
chromatographic, but not the colorimetric measurement of glycosylated 
haemoglobin is presented. The formation of carbamylated haemoglobin 
from urea-derived cyanate is discussed and the analogy between 
glycosylated haemoglobin and diabetes, and carbamylated haemoglobin 
and uraemia is developed. The potential role of carbamylated 
haemoglobin in uraemia including the possible clinical usefulness and 
pathophysiological significance is postulated. This Chapter provides 
the background to the project "Glycosylated and Carbamylated 
Haemoglobin in Uraemia" (Chapter 8).
CHAPTER 5
METHODS
This Chapter describes the biochemical procedures performed during 
the work of this thesis. Brief details are given of the methods used 
to assay hormones which were undertaken by others. A more in depth 
description of the methods carried out by myself include the 
measurement of intermediary metabolites, glycosylated haemoglobin and 
carbamylated haemoglobin.
PREPARATION OF SAMPLES
1. Containers
a) Plain tubes without anticoagulant were used for serum separation 
and lithium heparin tubes were used for plasma separation.
b) Standard tubes coated with potassium oxalate and sodium fluoride 
were used for blood glucose estimation by the colorimetric 
oxidase method.
c) Aprotinin and EDTA were added to plain tubes for pancreatic 
glucagon analysis.
d) Whole blood was added to perchloric acid for the assay of 
intermediary metabolites.
e) Lithium-heparin tubes were used for analyses of glycosylated 
haemoglobin, haemoglobin A^ and carbamylated haemoglobin.
f) Full blood count and platelets were measured in EDTA-K^ 
vacutainers.
2. Separation, Storage and Transportation
All hormone and metabolite specimens were kept on ice until 
centrifuged at 0°C (3000 rpm for 5 minutes) and the separated serum or 
plasma was stored at -20°C until assayed. Specific sample preparation 
is detailed where appropriate later in the Chapter. Frozen specimens 
were transported between laboratories in card ice (-80°C).
BIOCHEMICAL ASSAYS
1. GENERAL
a) Biochemical profile: Urea, creatinine, electrolytes, liver
function tests and proteins were analysed by the SMAC (Sequential 
Multiple Analyser plus Computer), a Technicon instrument. 
Haematological profile: Full blood count was analysed by the
Technicon H6000 autoanalyser.
b) Blood glucose was measured by two methods: a) Automated
colorimetry using the oxidase method with 4-aminophenazine in the
colour reagent (Barham and Trinder, 1972) and b) Enzymic 
fluorometric continuous flow analysis (Lloyd et al., 1978) which 
is detailed in below.
c) Serum lipoproteins were measured by Cobas biocentrifugal analysis 
using standard Boehringer reagents. Cholesterol was assayed by 
automated enzymatic determination (Deeg and Ziegenhorn, 1982) and 
total triglycerides by enzymic hydrolysis (Wahlefeld, 1974).
2. HORMONES
a) INSULIN: Serum insulin was measured by double antibody
radioimmunoassay (Soeldner and Slone, 1965) [Courtesy of the 
Department of Clinical Biochemistry, University of Newcastle].
The standard was human insulin (RD13, Wellcome Diagnostics,
Dartford), the first antibody was antisera to insulin raised in 
guinea pig (RD10, Wellcome) and the second antibody was rabbit 
anti-guinea pig serum (RD18, Wellcome). In diabetics, free 
insulin was measured by the removal of endogenous insulin 
antibodies with polyethylene glycol (PEG) precipitation 
(Desbuquois and Auerbach, 1971). This was done immediately after 
serum separation and prior to storage. Details of the PEG
solution are given in Appendix 2. All insulin samples were 
assayed in duplicate. The intra- and inter-assay coefficients of 
variation were between 5% and 8%.
C-PEPTIDE: Plasma c-peptide was measured by the Department of
Clinical Biochemistry, University of Newcastle. The modified 
method (Heding, 1975), used the Novo radioimmunoassay kit for 
human c-peptide (Novo Biolab, Denmark). The standard was 
synthetic human c-peptide and the antibody antisynthetic human 
c-peptide guinea pig serum (M1230). This antiserum had about 10% 
cross reactivity with proinsulin and no prior separation of 
c-peptide was needed with non-diabetics subjects. In insulin 
treated diabetics with insulin antibodies a significant amount of 
proinsulin might be bound to the antibodies, and to prevent 
co-determination of the proinsulin, c-peptide was determined by 
PEG precipitation to remove antibody bound proinsulin. The 
sensitivity of the assay showed a lower limit of detection of 
0.02 nmol/1. Precision over the linear range of the standard 
curve had a within-assay C.V. of 3% and between-assay C.V. of 5%. 
Uraemic patients with high serum c-peptide concentrations had 
dilution of serum samples so that the working samples were within 
the linear part of the standard curve.
GLUCAGON: Glucagon was measured by c-terminal specific
radioimmunoassay using wick chromatography (Orskov et al., 1968) 
[Specimens were sent to Professor Hans Orskov, Aarhus, Denmark 
for assay]. Due to the instability of pancreatic glucagon, blood 
was added immediately after venesection to a mixture of EDTA and 
the proteinase inhibitor aprotinin (Trasylol, Bayer). Details of 
this solution are in Appendix 2.
GROWTH HORMONE: Serum growth hormone (GH) was measured by the
Supraregional Assay Service (SAS), Royal Victoria Hospital, 
Newcastle upon Tyne. The method was a double antibody 
radioimmunoassay using human GH, UK6 standard (EQAS, Edinburgh), 
the first antibody was anti-human GH raised in rabbit (RD16, 
Wellcome) and the second antibody was goat anti-rabbit gamma 
globulin (Calbiochem-Behring, Cambridge). The assay precision 
was;
GH level Between Batch Within Batch 
mu/1 C.V.% C.V.%
1.7 11.1 7.1
4.2 8.6 7.2
1.8 6.0 5.0
e) CORTISOL: Plasma cortisol was measured by the SAS laboratory in
Newcastle using a double antibody radioimmunoassay technique. A 
commercial cortisol standard was supplied by Seron o Biodata, the 
first antibody was antisera to cortisol raised in rabbits (NZ06, 
Cambridge Medical Diagnostics) and the second antibody was goat 
anti-rabbit gamma globulin. The precision of the assay was;
Cortisol level Within Batch Between Batch 
nmol/1 C.V.% C.V.%
130 8.9 10.7
435 7.3 10.5
996 8.8 11.5
3. INTERMEDIARY METABOLITES
Blood glucose, lactate, alanine, 3-hydroxybutyrate and glycerol 
were measured by enzyme fluorometric continuous flow assays by the 
method of Lloyd et al., 1978. Dialysate glucose and lactate were also 
measured by the same technique. Blood acetoacetate and pyruvate were 
measured by manual spectrofluorometry. A detailed description of both 
techniques are described.
Preparation of samples
Two ml of whole blood was deproteinised in 5 ml of 5% ice cold 
perchloric acid (0.8 mol/1). The sample was mixed and the bottle 
reweighed, centrifuged (3000 rpm for 5 minutes at 0°C) and the acid 
supernatant was removed for analysis. The dilution factor was 
calculated from the weight change observed. Glass bottles were 
weighed before and after the addition of perchloric acid (PCA) and 
then again after the addition of blood.
Dilution factor (DF) = Wt. of PCA + Wt. of blood
Wt. of blood
The supernatant was stored at -20°C until specimens were assayed 
in batches. All metabolites were analysed within 2 weeks of 
collection except for acetoacetate and pyruvate which were measured 
within 24-48 hours.
a) AUTOMATED ENZYME FLUOROMETRIC ANALYSIS
The method used was adapted from that of Lloyd et al., 1978. 
Principle: The principle of the assay is the detection of changes
in fluorescence due to altered concentrations of NADH. Reduced NAD 
has a characteristic fluorescence, whereas the corresponding oxidised 
form does not exhibit the same property. Thus with the use of a 
fluorometer and specific hydrogenase enzymes one can measure
metabolites that require NAD in the reduced or oxidised form as 
coenzymes.
Reagents: En zymes and coenzymes were from Boehringer Corporation
Ltd., Sussex. The following enzymes were used; glucose-6-phosphate 
dehydrogenase (G-6-P-DH) 700 kU/1, hexokinase 1400 kU/1, lactate 
dehydrogenase (LDH) 4000 kU/1, L-alanine dehydrogenase (ADH) 150 kU/1, 
glycerokinase 600 kU/1, glycerol-3-phosphate dehydrogenase (G-3-P-DH) 
1700 kU/1, 3-hydroxybutyrate dehydrogenase (3-0HB-DH) 15 kU/1, NAD, 
NADH (Grade II Analar).
Standards: Glycerol, L-alanine, glucose (50 mol/1): Analar grade
(British Drug Houses, Dorset). Lithium lactate (Grade L, Sigma 
Chemical Co. Ltd., Surrey). DL-3-hydroxybutyrate (Boehringer Corp. 
Ltd.). All other reagents were Analar grade.
Method:
GLUCOSE
hexokinase
GLUCOSE + ATP ------------ * GLUCOSE-6-PHOSPHATE + ATP
G-6-P-DH
GLUC0SE-6-PH0SPHATE + NADP------- > 6-PH0SPH0GLUC0NATE + NADPH + H
Buffer: prepare 0.1 mol/1 triethanolamine buffer, pH 8.0 
containing 2 mmol of magnesium chloride per litre. Enzyme-coenzyme 
reagent : Dissolve 37 mg ATP, 32 mg NADP, 140 U of glucose-6-phosphate 
dehydrogenase and 160 U hexokinase in 10 ml of 0.4 mol/1 
triethanolamine buffer, pH 7.4.
LACTATE
LDH
LACTATE + NAD r ■ PYRDVATE + NADH + H
Buffer: prepare 0.5 mol/1 glycine buffer, pH 9.6, containing 0.2 
mol of hydrazine and 2 g of disodium ethylene-diaminetetracetate per 
litre. Enzyme-coenzyme reagent : Dissolve 20 mg NADH and 60 U of 
lactate dehydrogenase in 10 ml of 0.1 mol/1 phosphate buffer, pH 7.4.
ALANINE
ADH
L-ALANINE + NAD + H20 V —  NPYRUVATE + NADH + NH^
Buffer: Prepare 40 mol/1 tris (hydroxymethyl) methylamine buffer, 
pH 10.0, containing 1 mol of hydrazine and 500 mg of disodium 
ethylenediaminetetracetate per litre. Enzyme-coenzyme reagent : 
Dissolve 20 mg of NAD and 15 U of L-alanine dehydrogenase in 10 ml 0.1 
mol/1 phosphate buffer, pH 7.4.
GLYCEROL
Glycerokinase
GLYCEROL + ATP -------------- * L-GLYCER0L-1-PH0SPHATE + ATP
G-3-P-DH
L-GLYCEROL-1-PHOSPHATE + NAD ^ = = = ±  DIHYDROXYACETONE PHOSPHATE
+ NADH + H
Buffer: Prepare 0.2 mol/1 glycine buffer containing 1 mol of 
hydrazine and 0.01 mol of magnesium chloride per litre.
Enzyme-coenzyme reagent : Dissolve 20 mg NAD, 20 mg of ATP, 20 U of 
glycerokinase and 30 U of glycerol-3-phosphate dehydrogenase in 10 ml 
of 0.4 mol/1 triethanolamine buffer, pH 7.4.
3-HYDROXYBUTYRATE
, 3-OHB-DH
D(-) 3-HYDROXYBUTYRATE + NAD *.-— . A^CETOACETATE + NADH + H
Buffer: Prepare 0.1 mol/1 of tris (hydroxymethyl) methylamine 
buffer, pH 9.0, containing 500 mg/1 disodium
ethylenediaminetetracetate. Enzyme-coenzyme reagent : Dissolve 20 mg 
NAD and 1.5 U of 3-hydroxybutyrate dehydrogenase in 10 ml of 0.1 mol/1 
phosphate buffer, pH 7.4.
Dialysate glucose and lactate were analysed in an similar manner. 
The dialysate solutions were diluted 1 in a 100 with 0.5 mol/1 
perchloric acid.
Standard solutions:
Stock solutions were prepared in deionised water and all dilutions 
of stock were made with perchloric acid 0.5 mol/1. The range of 
working standards were (mmol/1)
Glucose 1.0 - 5.0
Lactate 0.5 - 2.0
Alanine 0.04 - 0.30
3-Hydroxybutyrate 0.01 - 0.10
Glycerol 0.02 - 0.12
Instrumentation:
Modules consisted of an Autoanalyser II sampler and peristaltic 
pump (Technicon, Hants), fluorescent spectrophotometer (Model 1000 
with a 355 nm excitation filter and a 485 nm emission filter) and a 
twin channel recorder (Perkin-Elmer, Bucks).
Procedure:
Details of the manifold are shown in Figure 5.1. Perchloric acid 
(0.5 mol/1) was pumped through the sample line from the wash reservoir 
and the appropriate buffer through the other line until a steady 
baseline was reached on the recorder. Enzyme-coenzyme reagent was 
then pumped into the system and the baseline readjusted to give a 5% 
deflection for NADH. Standards were run at the beginning of each 
batch and at intervals of 5 samples to compensate for drift changes 
during analysis. The native fluorescence of each sample was measured 
by omitting the enzyme-coenzyme reagent on a blank run for all 
samples. All assays were done at room temperature (20-25°C).
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Native fluorescence:
This assay system depends on changes in fluorescence resulting 
from alterations in NADH concentrations produced by enzyme action.
Any fluorescence that is non-enzymatic in origin must be taken into 
account to increase the accuracy of the analysis. Serum from uraemic 
patients has a native fluorescence, the intensity correlating with the 
level of serum creatinine and the presence of drugs can also affect 
the fluorometric analysis (Hadjivassiliou et al., 1984). Thus all 
samples were run with blanks (i.e. omitting the enzyme-coenzyme stage 
in the assay) to exclude all non-enzyme (native) fluorescence.
Precision:
Analytical recovery was not performed during the assays but 
previous estimates from the laboratory by adding a known quantity of 
stock solution showed a recovery range of between 90-95%.
Within-batch and between-batch precision was under 5% for each 
metabolite, except 3-hydroxybutyrate which had a within assay C.V. of 
8% and between assay C.V. of 12%.
Calculation of metabolites:
The metabolite concentration was determined by subtracting the 
blank from the standard activity and calculating the concentration 
relative to the appropriate working standard. Metabolite 
concentrations were expressed in mmol/1 by multiplying the whole blood 
dilution factor for each sample.
b) MANUAL SPECTROPHOTOMETRIC ANALYSIS OF ACETOACETATE AND PYRUVATE
Acetoacetate (AcAc) and pyruvate (Pyr) are unstable relative to 
the other metabolites even at -20°C storage. Thus a manual 
spectophotometric method was used for the analysis, which was 
performed usually within 24 hours, but always within 48 hours of
collection. Samples were stored at -20°C during this short storage 
period. This method is based on the following reactions:
LDH
PYRUVATE + NADH + H ~ " - LACTATE + NAD
3-OHB-DH
ACETOACETATE + NADH + H s  - D(-) 3-HYDROXYBUTYRATE + NAD
Reagents:
Enzymes: lactate dehydrogenase (LDH) 4000 kU/1, 3-hydroxybutyrate 
dehydrogenase (3-OHB-DH) 15 kU/1.
NADH 0.3%: NADH (13.33 mg) was dissolved in 4 ml of deionised water. 
Acetoacetate standard: 10.8 mg was dissolved in 10 ml water.
Pyruvate standard: 11.0 mg was dissolved in 10 ml water.
Standards were frozen in aliquots and working standards were prepared 
on the day of assay by dilution (1:100) to give a final concentration 
of 0.1 mmol/1. Phosphate buffer, pH 7.4, contained 61 ml Na2HP04, 0.1 
M (1.42 g/100 ml) and 39 ml NaH2P04, 0.1 M (1.56 g/100 ml).
Procedure:
All manipulations were carried out at room temperature although 
all reagents xrere kept on ice during procedure.
Sample neutralization:
To 1.4 ml of sample (volume 1) was added 4 drops of universal
indicator solution (BDH) and a few drops of 20% potassium hydroxide
•ne
until the solution was alkali^(pH 10). This was back titrated with 5% 
perchloric acid till neutral (pH 7.0). The total volume of solution 
was noted (volume 2). The sample dilution factor was volume 2/volume
Cuvettes: (volumes-ml)
Spec Reag AcAc
STD
Pyr
STD
Samp]
Phosphate buffer - 1.0 1.0 1.0 1.0
Distill H2O 3.0 2.0 1.0 1.0 1.0
NADH 0.04 0.1 0.1 0.1 0.1
STD - - 1.0 1.0 -
Sample - - - - 1.0
STD = standard : Spec = Spectrometer blank : Reag = Reagent blank.
Cuvette solutions were mixed well and the optical densities read 
on a SPS 400 UV/VIS spectrophotometer (Pye, Unicam, Cambridge) at 340 
nm wavelength using a tungsten lamp.
Then, 10 |ul of diluted lactate dehydrogenase (5 mg/1) [1:1 in 3.2 
M (NH^^SO^] was added, mixed and read after 10 minutes. The change 
in optical density estimates the pyruvate concentration. Then, 10 pi 
3-hydroxybutyrate dehydrogenase was added, mixed and read after 20 
minutes. The change in optical density estimates the acetoacetate 
concentration.
Calculation of metabolite j concentration
The concentration of metabolite (mmol/1) was determined from:-
I  I
A0D = E X TVc X V^ V-j^  X B.D.F.
A0D = change in optical density
E =| Extinction coefficient of NADH at 340 nm = 6.22 
TVc = total volume in cuvette = 3.10 ml
V2/V^  = sample dilution factor 
B.D.F. = whole blood dilution factor
Precision: The within-assay C.V. was 5% and 8% for pyruvate and
acetoacetate respectively (n=10), and between-assay C.V. was 8% and 
12% for pyruvate and acetoacetate respectively (n=6).
4. GLYCOSYLATED HAEMOGLOBIN
a) SEMIAUTOMATED COLORIMETRIC METHOD
This method of determining the total glycosylation in the red cell 
was based on the colorimetric assay described by Fluckiger and 
Winterhalter, 1976. The automated aspect being loosely based on the 
methods of Ross and Gibson (1979) and of Burrin et al., 1980. The 
modifications were made by M. Benton (unpublished) and now form the 
routine method of determining glycosylated haemoglobin in the 
Department of Clinical Chemistry, Royal Hallamshire Hospital, 
Sheffield.
Principle: Blood was collected in lithium heparin tubes to prevent 
coagulation, the red cells were spun, separated and then washed with 
saline. The cells were then lysed, diluted and heated with oxalic 
acid to hydrolyse off the glycosyl (frucrosyl) moiety which converts 
to 5-hydroxymethylfurfural (HMF). The HMF was then measured 
colorimetrically by forming an adduct with thiobarbituric acid (TBA). 
The reaction is shown in Figure 5.2.
Sample preparation: Blood (5-10 ml) was collected in tubes
containing an anticoagulant (lithium heparin), centrifuged at 3000 rpm 
for 5 minutes, the plasma was removed and the red cells washed twice 
with isotonic saline to eliminate interference from glucose and 
glycosylated plasma proteins. The red cells were then hydrolysed by 
the addition of an equal volume of 0.1% Brij. The haemolysate was 
stored at 4°C prior to analysis. All assays were determined within 5 
days of haemolysate storage.
Preparation of working haemolysate:
The original haemolysate was diluted 1:30 in 0.1% Brij. A small 
amount of haemolysate (0.25-0.5 ml) was left undiluted and stored in 
case adjustment of the total haemoglobin content was required (see
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Figure 5. 2a Non-enzymatic interaction of glucose with amino groups. The labile and easily 
reversible aldimine (Schiff base) is readily formed. The aldimine slowly enolizes to form the 
more stable ketoamine configuration via an Amadori rearrangement
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Figure 5. 2b Chemistry of the TBA colorimetric test for detection of glycosylation. Only the 
ketoamine rearranged form reacts to yield 5-hydroxymethylfurfural (5 -H M F). The latter is 
detected by forming an adduct with thiobarbituric acid
below).
Determination of Total Haemoglobin
Haemoglobin reagent: (Van Kampen and Zijlstra, 1961)
Potassium Ferricyanide 400 mg (Sigma Ltd.)
Potassium Cyanide 100 mg (Sigma Ltd.)
Potassium Dihydrogen Phosphate 280 mg (Sigma Ltd.)
Sterox SE 1 ml (Monsanto Chemical Co.)
These were dissolved in 2 litres of water. This reagent was 
stable for at least 2 weeks at room temperature. Working haemolysate 
(1 ml) was added to 5 ml of haemoglobin reagent and the optical 
density (OD) was determined at 540 nm using a digital 
spectrophotometer (Cecil Instruments). The haemoglobin concentration 
of the working reagent was calculated from the formula 
Dilution factor X OD = 6 X OD
There was an inverse and non-linear relationship between the 
concentration of haemoglobin in the reaction mixture and the final 
yield of 5 HMF per mol of haemoglobin. Concentrations of haemoglobin 
were expressed in terms of the monomer (M Wt = 16,520). The 
haemoglobin concentration was kept within 10% of 0.275 mmol/1 (range
0.250 - 0.300). This range adjustment of the total haemoglobin of the 
haemolysate was made by further dilution with 0.1% Brij, if greater 
than 0.300 or by taking the remainder of the original haemolysate and 
making a weaker dilution if the concentration was less than 0.250.
mmol/1
m molar Extinction coefficient 11
Determination of Hydroxymethylfurfural (HMF)
Reagents:
Brij 0.1% solution in water.
Oxalic acid (BDH, Dorset) 0.5 M : Oxalic acid (126 g) was 
dissolved in water and made up to 2 litres.
Thiobarbituric acid (BDH, Dorset).
TBA reagent 0.2% in 0.25 M oxalic acid : TBA reagent (1 g) was 
dissolved in 0.25 M oxalic acid and made to 500 ml with 0.25 oxalic 
acid, 0.5 ml of Brij was also added. This solution was stable for at 
least 1 week at 4°C.
Standard Hydroxymethylfurfural (HMF)
Stock HMF (Sigma Chemical Co., Dorset) 10 mmol/1 : HMF (126 g) was 
dissolved and made to 100 ml with water. A 1:100 dilution was made 
with water and the optical density was determined at 283 nm on a Cecil 
spectrophotometer. This was normally between 1.68 and 1.72. The 
volume of stock was adjusted if necessary and then stored in 10 ml 
aliquots at -20°C. Substock solutions were prepared in 0.1% Brij at 
150, 300, 450, 600 and 750 umol/1. This method was used to prepare 
standard HMF because solid HMF is deliquescent and accurate weighing 
of the pure substance is difficult.
Working standards
Since HMF standards degrade on heating, a set of standards were 
diluted 1:30 as in the tests, then diluted 1:1 oxalic acid and 
hydrolysed before being assayed colorimetrically.
Hydrolysis
Hydrolysis liberates fructose and converts it to 5 HMF.
Haemolysate (4 ml) was placed in a 10 ml vial and 4 ml of 0.5 M oxalic 
acid containing 0.1% Brij was added. This mixture was capped and 
placed on a heating block at 100°C for 6 hours and then cooled in
water immediately.
Colorimetry
The flow diagram shows the manifold for the glycosylated 
haemoglobin method (Figure 5.3). The sampler, peristalic pump, 
dialyser, colorimeter and dual channel recorder were all standard 
autoanalyser II equipment (Technicon, Hants.).
Samples of hydrolysate were aspirated, air segmented and dialysed
with a 'C* type membrane into the TBA reagent. The sample stream was
dialysed either directly into the TBA reagent (to increase
0.25M
sensitivity) or into ^ oxalic acid for the blank measuremnt. The 
recipient stream was passed through a double length mixing coil (DMC) 
to develop the colour, this reaction as well as the dialysis, being 
carried out at 47°C to increase the.sensitivity.
Calculation
The values are read from a conventional chart reader, the 
difference between test and blank being the concentration of HMF in 
the working haemolysate in pmol/1. The final result is obtained by 
dividing the level of glycosylated haemoglobin (i.e. HMF) in pmol, by 
the concentration of haemoglobin in the sample in mmol. This is 
expressed as mmol HMF/mol Hb (i.e. multiplying each by 1000).
Reference range for normal adults in the laboratory was 29-39 mmol
HMF/mol Hb, established by testing 80 healthy subjects.
Precision
Within batch and between-batch coefficients of variation were 3.5% 
and 6.0% respectively at a mean glycosylated haemoglobin level of 35 
mmol HMF/mol Hb. A very strong correlation was found between this 
method and the micro-column method of determining HbA^ (Bio-Rad Lab. 
Ltd., Herts.) [r=0.92, n=130].
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b) HAEMOGLOBIN Al, Ale, Ala+b BY MINICOLUMN CHROMATOGRAPHY
Haemoglobin Ap ^la+b were measured using commercial kits.
Haemoglobin A^ and haemoglobin A^c column tests (Bio-Rad, Herts.).
Principle
In the Bio-Rad haemoglobin A^ column test whole blood was mixed in 
a haemolysis reagent which lysed the red cells and liberated 
haemoglobin. An aliquot of haemolysate was then applied to a weak 
acidic cation exchange resin in a disposable column. An 
elution/developing reagent was then added to the column, which 
separated the ’fast* moving glycosylated haemoglobin component 
(HbA^a,b,c) from the remaining 'slow' haemoglobin fraction.
The total haemoglobin was measured by mixing an aliquot of 
haemolysate with the elution/developing reagent. After the column 
eluate containing HbA-^  (A^a+b+c) had been collected the relative 
concentrations of the glycosylated and the total haemoglobin were 
determined spectrophotometrically (415 nm) and the percentage 
glycosylated haemoglobin (HbA^ ) was calculated.
In the Bio-Rad HbA^c column assay separate determination of HbA^c
and HbA^a+k was achieved by using 2 elution/developing reagents.
Haemolysate was prepared as in the HbA^ method which lysed the cells
and initiated removal of the Schiff base (aldimine). A low ionic
strength borate/phosphate buffer was added to the column after
application of the haemolysate. This first buffer eluted the HbA^a
and HbA^ and further dissociated the labile Schiff base fraction.
The HbA. and HbA fractions remain on the column. HbA. was then lc o lc
eluted from the remaining haemoglobin fraction by the addition of the 
second elution/developing reagent.
The total haemoglobin was prepared as in the HbA-^  method and the 
relative percentage concentrations of HbA-^ a+  ^and HbA^c were
determined by spectrophotometric analysis of the first and second 
elutes respectively.
The assays were performed according to the manufacturers 
instructions, but several modifications were made to improve the 
sensitivity and precision. The exact method for each assay is 
detailed below. All assays were carried out at a constant 26°C in a 
water bath. Positive displacement micropipettes (50 pi and 500 pi) 
were used to obtain adequate reproducibility and accuracy. Assays 
were performed in batches of 10 samples and analysed within 24-48 
hours after collection.
Haemoglobin A1 Assay
Reagents
Haemolysis reagent : polyoxyethylene ether (0.33% v/v). 
Elution/developing reagent : phosphate buffer pH 6.7. Resin columns : 
disposable columns containing a measured amount of weakly acidic 
cation exchange resin. All stored at room temperature.
Procedure
1. Whole blood in a lithium heparin tube was mixed well and 100 pi
(2x50 pi) was added to 500 pi of haemolysis reagent, vortexed and
allowed to stand for a least 5 minutes.
2. Resin columns were shaken, resuspended and the waste fluid
allowed to drain. The columns were placed in a bath at 26°C
(controlled by a Grants Thermostatic heater) throughout the 
assay.
3. Within 15 minutes of preparing the columns 100 pi (2x50 pi) of 
haemolysate or control was carefully pipetted dropwise onto the 
centre of the resin bed.
4. After 5 to 7 minutes 10 ml of elution/developing reagent was
added to the column without disturbing the resin bed. The column
eluate was collected within 45 minutes (Solution A).
5. Total haemoglobin of the sample was determined by adding 50 pi of 
haemolysate or control to 10 ml of elution/developing reagent 
(solution B).
6. Samples were then read on a spectrophotometer (Digital 
spectrophotometer CE 393, Cecil Instruments, Cambridge) at 415 nm
after ’zeroing* with a elution/developing reagent blank.
Calculation of HbAl
The purpose of the test was to determine what percentage of total 
haemoglobin was the A-^ fraction. This was calculated from the 
formula
Absorbance of Solution A 1 *
%HbA1 =  X ~ X 100
Absorbance of Solution B
^correction factor for differences in sample concentration 
Precision
Within-batch precision, in the normal range (10 replicate samples) 
gave a mean and standard deviation of 7.73+0.26%, i.e. coefficient of 
variation of 3.36%. In the upper or ’diabetic1 range (10 samples) 
mean and SD was 14.42+0.62%, C.V. was 4.3%.
Between-batch precision (5 replicate samples), in the ’normal* 
range was 7.60+0.47% with a C.V. of 6.2%. In the ’diabetic' range 
mean and SD was 13.63+0.95, C.V. was 7.0%.
Haemoglobin Ale and Ala+b assay
Reagents
Haemolysis reagent : polyethylene ether (0.33% v/v). 
Elution/developing reagent. First elution buffer : borate/phosphate
buffer, pH 6.7. Second elution buffer : phosphate buffer, pH 6.7. 
Resin columns : disposable columns with weakly acidic cation exchange 
resin. All stored at room temperature.
Procedure
1. Whole blood in a lithium heparin tube was mixed well and 100 pi 
(2x50) was added to 500pl of haemolysis reagent, vortexed and 
allowed to stand for 5 minutes.
2. Resin columns are shaken, resuspended and waste fluid allowed to 
drain. The columns were placed in a constant temperature bath 
(26°C) throughout the assay.
3. Within 20 minutes of preparing the columns 100 pi (2x50) of the 
haemolysate or control was carefully pipetted on to the column 
resin bed.
4. After 5 minutes 4.0 ml of the first elution/developing reagent 
was added to the column without disturbing the resin bed. Within 
30 minutes the first elution buffer was drained and collected for 
HbA^a+  ^estimation (Solution A).
5. Then 10 ml of the second elution/developing reagent was added and
after 45 minutes the second eluant was collected for HbA,lc
determination (Solution AA).
6. The total haemoglobin of the sample was prepared by adding 50 pi 
of haemolysed sample or control to 10 ml of the second elution 
buffer (Solution B).
7. Samples were then read on a spectrophotometer at 415 nm.
Calculation of HbAla+b and HbAlc
la+b was calculated using the formula
Absorbance of Solution A fl]* 10l+
X —  X —  X 100
Absorbance of Solution B 2 4
HbA^c was calculated using the formula:-
Absorbance of Solution AA 1 *
HbAlc%
Absorbance of Solution B
X
2
X 100
Correction factors:
* to correct for difference in sample concentration 
+ to correct for difference in sample volume 
Precision
HbA-^ a+k within-batch precision was (on 10 replicate samples)
a) in the normal range : C.V. 4.1% (mean 1.46%, SD 0.06)
b) in the diabetic range : C.V. 4.4% (mean 2.04%, SD 0.09)
Between-batch precision was (on 5 replicate samples);
a) in the normal range : C.V. 4.8% (mean 1.65%, SD 0.08)
b) in the diabetic range : C.V. 6.6% (mean 2.12%, SD 0.14)
HbA^c within-batch precision was (on 10 replicate samples);
a) in the normal range : C.V. 2.8% (mean 5.96%, SD 0.17)
b) in the diabetic range : C.V. 2.4% (mean 9.71%, SD 0.23)
Between-batch precision was (on 5 replicate samples);
a) in the normal range : C.V. 3.4% (mean 6.21%, SD 0.21)
b) in the diabetic range : C.V. 4.9% (mean 9.2%, SD 0.45)
Quality control
Periodicaly during the HbA-^  and HbA^c assays precision and 
accuracy was checked using lyphochek controls (Bio-Rad, Hants). 
Lyphochek was prepared from human whole blood and exhibits column 
elution profile and temperature restrictions comparable to those of 
patient whole blood haemolysate.
HbA-^  lyphochek for normal levels gave a mean value of 7.4% 
(manufacturer's mean value 7.1%, range 6.4-7.7) and for the higher 
(diabetic) levels a mean value of 13.8%, (manufacturer's assayed 
value, mean 13.3%, range 12.2-14.3).
HbA^c lyphochek for normal levels gave a mean value of 6.1%, 
(manufacturers assayed value, mean 5.8%, range 5.3-6.3) and for the 
higher (diabetic) levels a mean of 9.8%, (manufacturer's assayed 
value, mean 9.4%, range 8.6-10.1).
5. CARBAMYLATED HAEMOGLOBIN
Carbamylated haemoglobin was measured by the methods of Fluckiger 
et al. (1981) and Manning et al. (1973) with several modifications 
which are detailed.
Principle
Red blood cells were washed in normal saline and the haem was 
removed by washing in acid-acetone. The globin was then hydrolysed 
with acetic acid and hydrochloric acid to split off isopropyl 
hydantoin (IPH). IPH was extracted into ethyl acetate and estimated 
by gas liquid chromatography (GLC). The reaction is showi in Figure 
5.4.
Reagents
Sodium hydroxide 10 M 
Concentrated hydrochloric acid 
Sodium chloride; saturated solution 
Sodium bicarbonate; 5% solution 
Acid-acetone; 2% HC1 in acetone 
Acetic acid 
Diethyl ether
Analar grade reagents used when available 
Standards
Isopropyl Hydantoin (MW 142) (Aldrich Chemical Co., Dorset)
Stock solution; 172.5 mg in 25 ml methanol
Working solution; Dilute 2 ml to 100 ml with de-ionised water; 100 
pi of this solution was used for the standard, i.e. working 
standard contained 13.8 jig of isopropyl hydantoin.
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Internal Standard
Hexobarbitone (MW 236) (May and Baker, Dagenham).
Stock solution; 70.8 mg in 25 ml methanol.
Working solution; dilute 2 ml to 100 ml with de-ionised water; 100 
pi of this solution was used for the working internal standard, i.e. 
working internal standard contained 5.7 pg of hexobarbitone.
Preparation of sample
Blood was taken into lithium heparin tubes and the red cells 
separated within 24 hours. The red cells were washed in normal 
saline. The red cells were then resuspended in an equal volume of 
physiological saline. To 1 ml of this suspension, 10 ml of ice cold 
acid-acetone was slowly added on a vortex mixer. The globin was 
washed several times (on average 5) in 10 ml volumes of ice cold 
acetone to removed the haem and finally washed with diethyl ether and 
dried overnight at room temperature. The globin (white powder) was 
then stored at 4°C until hydrolysis was carried out (usually within 
1-2 weeks).
Hydrolysis of Globin
Globin (50 mg) was resuspended in 0.5 ml of 50% acetic acid in a B 
14 tube and 0.5 ml of concentrated hydrochloric acid was added. The 
tube was then capped with a glass marble and heated for 1 hour at 
100°C and then cooled on ice.
Extraction
Sodium hydroxide 10 M (0.65 ml) was added to the hydrolysate. The 
pH should be between 3.0 and 5.0. Saturated sodium chloride (0.5 ml)
was added, then 100 pi of the internal standard, hexobarbitone, 100 pi 
of de-ionised water and finally 5 ml of ethyl acetate. The tube was 
stoppered and mixed gently for 3 minutes. The ethyl acetate was 
transferred to another B14 tube and washed with 1 ml of 5% sodium 
bicarbonate. After centrifuging 4 ml of ethyl acetate was taken off 
into a conical glass centrifuge tube and evaporated to dryness at 60°C 
under a stream of air. The residue was redissolved in 100 pi of ethyl 
acetate and 5 pi prepared for injection on to the GLC column.
Standard
forking1 internal standard, hexobarbitone (100 pi) and isopropyl 
hydantoin (100 pi) fworkingf standard were added to a mixture of 0.5 
ml of 50% acetic acid and 0.5 ml hydrochloric acid and then treated as 
in the sample extraction.
Gas liquid chromatography
GLC analysis was performed using a Sigma I gas chromatograph 
(Perkin Elmer, Bucks). Aliquots (5 pi) were chromatographed on a 
glass column, 2 mm x 1 m, packed with GP 2% SP 2110/1% SP-2510 DA on 
100/200 supelcoport (Supelco Inc., Bellfonte, PA, USA). The carrier 
gas was Argon, flow rate 40 ml/min, using a nitrogen detector and an 
oven temperature of 170°C.
The retention times (Figure 5.5) were 2 minutes for isopropyl 
hydantoin and approximately 5 minutes for hexobarbitone. Periodically 
the column was repacked when accumulation of 'contaminants1 produced 
extra or erratic peaks.
IN J1 INJ2
IPH
STD
I NT 
STD
I NT 
STD
TEST
T T TTr T T
Time (m ins)
GLC peaks and retention times
Carbamylated Haemoglobin is determined by the release 
of isopropyl hydantion, calculated from:
Ht. of Test/Ht. of INT STD X 13.8* .
Ht. of IPH STD/Ht. of INT STD 50 " nSIPH/mg globin
INT STD - internal standard (hexobarbitone)
IPH STD - Isopropyl hydantoin standard 
HT - peak height
* 13.8 ng is weight of IPH injected onto column 
50 mg is weight of globin hydrolysed
Figure 5. 5 GLC peaks and retention times
Calculation of carbamylated haemoglobin
Calculation
Carbamylated haemoglobin was calculated using the formula
Ht. of Test sample/Ht. of Internal Std. 13.8
— ------------------------------   X  = ng IPH/mg
Ht. of Std. IPH/Ht of Internal Std. 50
where 13.8 ng is the weight of IPH injected into the column and 50 mg 
is the weight of globin hydrolysed.
Precision
A reference range has not been previously recorded, but in 40 
subjects (20 healthy controls and 20 patients with normal renal 
function) concentrations were less than 40 ng IPH/mg globin. A mean 
value with 95% C.I. was 27 (22-32) ng IPH/mg globin.
All samples were assayed in duplicate and a coefficient of 
variation of 12% was found between test samples.
STATISTICS
Multics is the operating system on the Joint Cardiff Computing 
Service mainframe computer (Honeywell DPS - 8/70 M). This facility 
was used at the University of Wales College of Medicine.
Much of the data in this thesis were analysed using the MLnitab 
Statistical Package on the Multics system. Some data were also 
analysed using the HP 67/97 and 41Cx Hewlett Packard statistical 
package on a micro computer.
Specific statistical methods are described in the appropriate 
chapters under the method section.
CHAPTER 6
PANCREATIC BETA CELL FUNCTION IN URAEMIA
INTRODUCTION
The abnormalities of carbohydrate metabolism in uraemia have been 
discussed in Chapter 2 and include the effect of tissue sensitivity to 
insulin and the beta cell response. It has been suggested that the 
beta cell response may be altered in uraemia. To compensate for the 
increased peripheral antagonism to the action of insulin the beta cell 
may hypersecrete in an attempt to overcome the insulin resistance. 
However, despite the tissue insensitivity to insulin a normal or 
decreased insulin response to oral glucose has also been observed.
Thus beta cell function may be normal, hyperactive or relatively 
inhibited in uraemia.
1. HAEMODIALYSIS
The glucose intolerance of uraemia has been reported to improve 
markedly with haemodialysis (Hampers et al., 1966; Alfrey et al., 
1967). In contrast, more recent studies, using glucose specific 
methods, have shown that haemodialysis produces only marginal 
improvement or no significant improvement in glucose tolerance 
(Swenson et al., 1974; Ferannini et al., 1979; Marumo et al., 1979). 
However, studies on the metabolic clearance rates have shown that 
haemodialysis significantly improves but does not fully correct the 
abnormalities of carbohydrate metabolism in uraemia (DeFronzo et al., 
1978a; Graf et al., 1985).
2. INTERMITTENT PERITONEAL DIALYSIS
During intermittent peritoneal dialysis large quantities of 
glucose are absorbed from the dialysis fluid and can induce 
hyperglycaemia (Nolph et al., 1970). The serum insulin response to an 
oral glucose load has been shown to decrease within a few days after
intermittent peritoneal dialysis suggesting possible exhaustion of the 
pancreatic beta cells (Spitz et al., 1970).
3. CONTINUOUS AMBULATORY PERITONEAL DIALYSIS (CAPD)
CAPD is a unique clinical situation that involves constant glucose 
administration. The effect of this persistent glycaemic stress is a 
potential hazard and its effect on beta cell function is of paramount 
importance. The continuous glucose absorption from the dialysate 
could affect insulin release with profound effects on carbohydrate, 
lipid and amino acid metabolism (see Chapter 3).
There are several similarities between uraemia and diabetes, 
particularly type II (maturity onset) as discussed in Chapter 2. The 
tissue insensitivity to insulin and impaired beta cell reponse to 
glucose are seen in both conditions although to different degrees. 
Continuous glucose administration in maturity onset diabetes has been 
shown to exhaust insulinogenic reserves (Seltzer and Harris, 1964). 
Thus CAPD with its continuous peritoneal glucose administration may 
possibly exhaust beta cell function. Alternatively, continuous 
stimulation of the beta cell may further augment serum insulin 
concentrations that are already increased in response to the insulin 
resistance in uraemia. Thus CAPD may adversely affect beta cell 
secretory function, either by depletion of the beta cell or even to 
stimulate further secretion, both of which would affect glucose 
homeostasis. The inability to adapt to the extra glycaemic stress in 
CAPD might even lead to overt diabetes mellitus.
Present data on glucose metabolism in CAPD is limited because the 
duration of experience of this mode of dialysis is short. Few centres 
have more than 7 years experience and relatively few patients have 
been on CAPD for longer than 3 years due to the initial high failure
rate of this technique (see Chapter 3).
Deterioration in the insulin response to oral glucose has been 
reported (Armstrong et al., 1980). In contrast, others have shown 
that although glucose intolerance was present prior to CAPD, no 
further deterioration was observed in the short term (Lindholm et al., 
1981; Von Baeyer et al., 1983). A similar study in children showed no 
change in glucose intolerance after 1 year on CAPD (Broyer et al., 
1983).
4. DIABETES AND DIALYSIS
CAPD is not only a viable alternative to haemodialysis for the 
diabetic with end stage renal disease but is, in the United Kingdom, 
the preferred mode of dialysis treatment (Cameron and Challah, 1986). 
In other parts of Europe haemodialysis is the main modality of 
treatment (Jacobs et al., 1983) for diabetics. At present most 
diabetics on CAPD are type I but increasing numbers of older type II 
diabetics are being treated (Cameron and Challah, 1986). It initially 
may seem paradoxical that a treatment consisting of continuous glucose 
administration is actually beneficial. The advantages of this 
treatment are discussed in Chaper 3. Although insulin requirements 
increase in type I and many type II diabetics require supplemental 
insulin blood glucose control with intraperitoneal insulin is much 
improved (Flynn, 1979; Khanna et al., 1983; Rottembourg et al., 1983).
Type I diabetics have negligible beta cell function, especially 
after 20 to 30 years, when they reach end stage renal disease, but 
type II diabetics often have some residual beta cell function which 
could be depleted by continuous glucose administration.
5. BETA CELL SECRETORY FUNCTION
Stimulation of the beta cell normally results in extrusion of the 
beta cell granule where proteolytic cleavage of proinsulin to insulin 
and c-peptide takes place. The secretory products of the beta cell 
consists of equimolar amounts of insulin and c-peptide, which account 
for 94% of the secreted products. The remaining 6% is due to 
proinsulin intermediates (Rubenstein etal., 1977). In the peripheral 
blood the circulating c-peptide concentration is approximately 5-fold 
greater than insulin in healthy fasting subjects and this falls to 
about 2-3 fold after pancreatic stimulation (Faber et al., 1978).
This reflects the slower metabolic clearance of c-peptide compared to 
insulin (see Chapter 2).
Beta cell secretory activity has been assessed using intravenous 
glucagon stimulation and measuring the c-peptide response in 
peripheral blood (Faber and Binder, 1977; Binder and Faber, 1978).
This dynamic test is simple, specific, sensitive, rapid to perform, 
causes no discomfort to the patient and applicable to both diabetic 
and non-diabetic subjects. Diabetic patients with insulin antibodies 
and those taking exogenous insulin present a problem when measuring 
plasma insulin concentrations. The plasma of these patients contain 
both free (unbound) and antibody bound insulin which makes 
interpretation of plasma insulin difficult unless specific extraction 
procedures are carried out (Heding, 1969; Desbuquois and Auerbach, 
1971; Hanning et al., 1985). Hence the value of c-peptide 
measurement. In non-diabetics both insulin and c-peptide measurements 
are complementary.
6. OBJECTIVES
The primary objective of this study was to evaluate beta cell 
function in a mixed uraemic population and to determine if CAPD 
treatment per se affects the beta cell secretory capacity. However, 
as beta cell peptides can be elevated in uraemia it was necessary to 
compare non-dialysed uraemic and haemodialysis patients with those on 
CAPD to distinguish the effects of uraemia from dialysis therapy.
The secondary aim of this study was to determine beta cell 
integrity in diabetics with renal failure including those on 
haemodialysis and CAPD.
METHODS
1. PATIENTS
Beta cell function was investigated in 67 subjects. Forty 
non-diabetic uraemic patients on different modes of dialysis were 
studied. They were classified into four groups (with 10 patients in 
each): chronic renal failure (CRF) on conservative treatment, i.e. 
non-dialysis; haemodialysis (HD); NEW CAPD (on CAPD for less than 6 
months); and CHRONIC CAPD (established on CAPD for more than 1 year). 
Eight healthy subjects were used as controls.
In the diabetic groups all 19 patients had proven diabetes of 
varying duration and most, but not all, had diabetic nephropathy as 
the cause of their renal failure. The selection of diabetic subjects 
with renal failure was limited due to the relatively small number 
available for study. Diabetic patients were classified in two ways i) 
by mode of renal therapy, i.e. CRF, HD or CAPD and ii) by type of 
diabetes, i.e. type I insulin dependent or type II non-insulin 
dependent. Diabetics with normal renal function (NRF) were used as 
controls. Normal renal function was judged by normal serum creatinine 
concentrations, but lesser degrees of diabetic nephropathy such as 
impaired glomerular filtration rate and microalbuminuria were not 
excluded.
All subjects had normal liver function assessed by history and 
absence of clinical manifestations of hepatic disease and normal 
biochemical indices of liver function. The non-diabetic subjects had 
no clinical or biochemical features of diabetes. No subjects were 
taking steroids, beta blockers or thiazide diuretics at the time of 
the study. All subjects continued with their usual diet prior to the 
study. Haemodialysis patients were studied on their interdialysis day 
(i.e. 24 hours after their last dialysis) and all CAPD patients
omitted their overnight dialysis exchange prior to the study.
Diabetics on insulin omitted their morning dose and oral hypoglycaemic 
drugs were delayed until after the study.
2. PROTOCOL
All subjects had a 12 hour oral fast and CAPD patients also had an 
overnight ’peritoneal1 fast by omitting their overnight exchange. The 
study was done between 9.00 and 11.00 a.m. All subjects remained 
semi-supine throughout the 1 hour test. An intravenous cannula was 
inserted into a forearm vein for serial blood sampling and kept patent 
by heparinised saline flushes after each blood sample was taken. 
Patients were constantly under medical supervision throught the study. 
The Sheffield hospitals medical ethics committee approved the study.
3. PILOT STUDY
Prior to the main study 5 patients were given 0.5 mg or 1.0 mg of 
glucagon intravenously and samples were taken at frequent intervals to 
determine the optimal dose and timing of samples. From this study, 1 
mg of glucagon and eight time intervals were chosen for the glucagon 
stimulation test.
4. MAIN STUDY
After a fasting blood sample (time zero), 1 mg glucagon (Novo 
Labs) was given by I.V. bolus and blood specimens were taken at 5, 10, 
15, 20, 30, 45 and 60 minutes post injection for glucose, insulin and 
c-peptide determination. Fasting serum lipoproteins, glycosylated 
haemoglobin, full blood count and a ’routine1 biochemical screen 
including liver function tests were measured. Specimens were kept on 
ice until transported to the laboratory. Blood for peptide
estimations were separated within 3 hours of collection and stored at 
-20°C until assayed.
5. ASSAYS
Blood glucose was measured by the glucose oxidase method (Barham 
and Trinder, 1972). Serum insulin was determined by modification of 
the double antibody radioimmunoassay technique of Soeldner and Slone 
(1965). Serum free or unbound insulin was measured in diabetic 
subjects by using PEG precipitation after serum separation but prior 
to storage. Plasma c-peptide was determined by a modification of the 
Heding (1975) technique using a radioimmunoassay kit (Novo Biolab). 
Serum insulin had a 5% and 8% intra- and inter-assay precision 
respectively. The intra- and inter-assay coefficients of variation 
for c-peptide were 3% and 5% respectively. C-peptide antibody had 
less than 10% cross-reactivity with proinsulin. Glycosylated 
haemoglobin was measured by colorimetry (a modification of the 
Fluckiger and Winterhalter (1976) technique) and serum lipoproteins by 
Cobas biocentrifugal analysis (Deeg and Ziegenhorn, 1982; Wahlefeld, 
1974). A more detailed description of each assay is given in Chapter
5.
6. STATISTICS
Data within each group was analysed by the paired ft! test and 
data between groups by analysis of variance. Analyses of the glucagon 
response with time curves was done by the analysis of variance 
technique using repeated measures analysis to investigate differences 
between the groups and their response patterns with time.
RESULTS
Intravenous glucagon was given without any adverse effects 
although approximately 30% of subjects experienced transient nausea 
lasting about 1 minute which occurred usually between 3 and 4 minutes 
post-injection. Results of the study are divided into two sections:-
1. Non-diabetics, 2. Diabetics.
1. NON-DIABETICS
Clinical data (values are mean and S.D.) are given in Table 6.1. 
The mean age and weight of each group were comparable. The difference 
in duration of dialysis was clearly seen particularly distinguishing 
NEW CAPD from CHRONIC CAPD. Serum creatinine although higher in the 
CHRONIC CAPD group was not statistically different from the other 
uraemic groups. Fasting total serum triglycerides were increased in 
all uraemic groups but this was only statistically significant in the 
HD group (p<0.05). Glycosylated haemoglobin was normal in all groups.
Fasting lipoprotein profiles are shown in Figure 6.1 (values are 
mean and SEM). Total triglycerides and cholesterol were increased in 
all uraemic groups and HDL-cholesterol was decreased in all uraemics 
except the CRF group. However, there was marked variation within each 
group and the only statistically significant change was the increase 
in total triglycerides in HD group compared to controls.
a) Basal and peak responses to glucagon
Fasting and maximum responses (values are mean and SEM) of 
glucose, insulin and c-peptide to I.V. glucagon are shown in Table 
6.II and Figure 6.2. Basal glucose concentrations (3.6 to 4.4 mmol/1) 
were similar in all groups and there was also no difference between 
peak concentrations (6.4 to 7.4 mmol/1). The increment (59-80%)
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Values are mean and SEM
(n = 10 in each group, except controls n=8)
o
Cl. CM O 0
< C\J in —^ •a- • CO T—
O • • o • O r~ • • 0o . o. O r— T— .O O 0
O +  + • +  1 + 1 • + 1 + •t—t C\J T— o r>. o O 00 CM 0
21 • « V • • V CO cn V
O I'"'. in • •
DC in CM CO
3=
C_J
o O *3-
Q . CM *3" r— o CO T— CM 00 —^
< ♦ • O • • O • • 0c_> O 1 ° . o r - O O 0+ + • + + * + + •3 r— «5J- o in cn O «3" *3- 0
LU • • V • • V cn O V
21 cn • •
in r— 3^"
cn in
cn CO in r— CO in r—• ♦ o • * O • • O
Q o o O 0 O3= + + • + 1 + 1 • + + •CM CO o r>. CM O in 0 O• • V • • V CM CO V«d- T— cn • •
T_ in CM •3-
00 in
cn r— CO T~ CO r~
• • o • • O • • O
Ll_ o o *— . ir> . O 0 OQC + + • + 1 + • + + •O «3* o o in cn O *3- 0 O• • V • • V 00 0 V
»d* r— cn • •
r— T— CO
CO CO
_J CM in T— CO cn T--- 0 r—o • • o • • O • • O
oc O i ° , o T— . ° \ O 0 O . O(— + 1 +  1 • + 1 +  1 • + + 1 •21 CO o in O CO O
O • • V • • V «d- in V
C_J CO in i— cn • •in 0 T—
CO s: a. CQ 21 Q. CO 2: Q.
LU
O
LU i— z *—• r—
in  — •—i -— h- \o  <— _j <— CU r—o  o ZD ^ LU O
=3 E in  zj a. E
_J E 2= E 1 tz
CO •—1'— » 0
GO
00
CO
o3
T—1 S
00
TO
0 3
0 : 0
0 PQ
CQ
£ 3
O 0
cl 0
CO
0 •U
0
S 0'—✓ s 0
W a
E CO 3
3 0
E n0 u
•H a 0
X CO
CO M-l
E a •H
cO TD
nD 0
g E 0
co U
0 0
u
PQ 0 0
v_/ 0
0 3
rH 0 r—1
CO 3 0
CQ rH >
CO 0
PQ > CL
MM
cO
CL)i—I X 
CO H
Figure 6 .
o
E
E
CD
CO
OO
13
O
**
70 
60
9  50 
1  40 
=  30 -
I 20 
10 
0
* * * * ** * *
D
FI
/
/
/
/
/
/
/
z.
T / FI
/ / /
/ / /
/ / /
/ / /
/ / /
/ / /-X./ J./ /
/ / s
/
/
/
/
/
/
■/
LA
** * * *  *
0  
E 
c=
CD
*T=J
• H
■4— 'o_
CD
Q.
1
O
5 i 
4 - 
3 - 
2 -
1 - 
0
** **
A
J3
f]
/
z
J L /
/  
/
FI _L i
/ / PI
/ / /
/ / T,/
/ / /
/ / /
/ / /
B P  B P  B P
HD New Chronic
CAPD CAPD
B P  B P  
Controls CRF
* p < 0 .0 1  
* *  p <  0.001
Basal (B) and Peak (P) responses to glucagon 
Values are mean and SEM 
p values are differences between B and P
between basal and peak was significant (p<0.001) in all groups.
Fasting serum insulin was higher (9.5 to 11.7 mu/1) in the uraemic 
groups but this was not statistically significant. There was also no 
difference between the uraemic groups maximum response (49.9 to 59.2 
mu/1) and the controls (53.4 mu/1). The increment between fasting and 
maximum responses was highly significant in all groups. Fasting 
plasma c-peptide concentrations were significantly increased in all 
the uraemic groups (1.84 to 2.38 nmol/1) compared to controls (0.48 
nmol/1) (p<0.001). There was a 4-5 fold rise in the uraemic groups. 
Similarly peak c-peptide concentrations were significantly increased 
(p<0.001). Peak c-peptide concentrations in the uraemic groups were 
2-3 times higher than controls. There was no difference between any 
of the uraemic groups in either basal or peak concentrations. The 
increment from basal to peak stimulation by glucagon was highly 
significant in all groups (p<0.001). This increment was between 163% 
and 208% in the uraemic groups compared to 314% in the controls.
b) Glucagon-response curves
The glucose response to glucagon over 60 minutes, Figure 6.3 
(values are mean and SEM), showed that the four uraemic groups were 
different from the controls (Fy gQ^=14.74, p<0.001). The rate of rise 
in the early phase (0-15 minutes) was similar in all groups, but the 
uraemic groups continued to rise for 30 minutes and had a prolonged 
elevation and delayed fall in glucose concentration. Repeated 
measures analysis of variance showed no difference between any of the 
uraemic groups.
The insulin response to glucagon, Figure 6.4, revealed significant 
differences between the 5 groups (^ 28 301=^*^* p<0.001). However, 
this was due to the difference between controls and the 4 uraemic
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groups (Fy pcO.OOl). There was no difference between the
uraemic groups, all of whom showed a similar rise and delayed fall in 
serum insulin concentration.
The c-peptide response to glucagon, Figure 6.5, showed significant 
differences between the groups (F2g gQ^=4.90, pcO.OOl). This was 
mainly due to differences between the controls and the four uraemic 
groups (Fy gQ^=13.6, P<0»001)> but there was a small difference 
between the CRF group and the 3 dialysis groups ( F y  gQ^=2.04, pc0.05). 
The control group had a prompt rise reaching a peak at 5 minutes 
followed by a progressive fall over the remaining hour. The uraemic 
groups had a supranormal basal concentration, which increased within 
20 minutes of stimulation and then had a plateau effect over the 
remainder of the test period.
c) Time to maximum response
The time course of glucose, insulin and c-peptide from basal to 
maximum response was prolonged in all uraemic groups. The mean time 
in minutes, for individuals to reach their maximum response is shoitfn 
in Table 6.Ill (values are mean and SD). Glucose peaked significantly 
earlier in controls (pcO.OOl). The uraemic groups had similar time 
courses. The insulin response peaked at 6 minutes in controls which 
was significantly shorter (pcO.OOl) than the uraemic groups. There 
was no difference between any of the uraemic groups. C-peptide also 
peaked at 6 minutes in controls which was markedly shorter than the 
uraemic groups (pcO.OOl). Thus, all uraemic groups had a protracted 
time course in response to glucagon. It should be noted that there 
was marked variation in the time to reach maximum response within each 
uraemic group. The timing of the absolute maximum response in 
individual patients was occasionally difficult to assess as many had
small increments over a period of time before their absolute maximum. 
This is clearly seen in Figures 6.3, 6.4 and 6.5. This probably 
accounts for the small difference (p<0.05) in time course between the 
HD group and the other uraemic groups with respect to the glucose and 
c-peptide responses.
d) Molar ratio of c-peptide/insulin
The molar ratios of c-peptide to insulin, calculated from 1 mu/1 
insulin equals 0.00689 nmol/1, are shown in Table 6.IV (values are 
mean and SD). The elevated basal ratios in the uraemic groups 
reflected the high c-peptide concentration. The maximum response 
after glucagon stimulation resulted in a decrease in the ratio due to 
a relatively greater increase in insulin. All uraemic groups had 
higher basal (pcO.OOl) and maximum response (0.1cpc0.05) ratios 
compared to controls. The fasting molar ratio was increased 2-3 fold 
in uraemics and the stimulated ratio was increased by about 2-fold 
compared to controls. However, all groups showed a significant fall 
in the c-peptide to insulin ratio with beta cell stimulation. There 
was no difference between any of the uraemic groups.
Fasting serum triglycerides showed a strong positive correlation 
with fasting serum insulin in controls (r=0.923, pcO.Ol) but no 
significant correlation was found in uraemic subjects. Fasting plasma 
c-peptide showed a positive correlation with serum creatinine in the 
CRF group (r=0.800, pcO.Ol) but no correlation was found in the 
control or any of the dialysis groups. Fasting c-peptide showed a 
positive correlation with fasting serum insulin in the control 
(r=0.795, p<0.01), CRF (r=0.861, p<0.01) and HD (r=0.710, p<0.05) 
groups but no significant association was found in either of the CAPD 
groups.
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2. DIABETICS
r
Diabetics were classified by renal status and diabetic type. When 
classified by renal status the diabetic patients were grouped as 
normal renal function (NRF), CRF, HD and CAPD (Table 6.V). When 
classified by diabetic type the diabetic groups consisted of NRF type 
I (insulin dependent), uraemic type I and uraemic type II (non-insulin 
dependent) (Table 6.VI).
a) Clinical data
When patients were classified by renal status (Table 6.V, values 
are mean and SD), subjects were of comparable age and weight. Serum 
creatinine in the three uraemic groups was also similar although there 
was more variation in the CRF group. The mean time on dialysis was 
2.5 times longer in the haemodialysis group than the CAPD group but 
there was marked variation between patients in both groups. Fasting 
triglycerides were increased in all diabetic subjects compared to 
healthy controls. There was no difference in triglyceride 
concentrations between the diabetic groups. Glycosylated haemoglobin 
was raised in all groups compared to healthy controls (37.1 +2.7 mmol 
HMF/molHb), but there was no difference between diabetic groups.
When the same patients were reclassified by diabetic type (Table
6.VI, values are mean and SD) it was seen that there were more type I 
uraemic diabetics than type II. It was also observed that all CRF 
diabetics were type I as were most of the CAPD group. Type II 
diabetics were older but there was marked variation in age in type I 
diabetics. Serum creatinine did not differ between the uraemic 
groups. Serum triglycerides were higher and glycosylated haemoglobin 
(although increased compared to controls) lower in the type II group.
DIABETICS: RENAL STATUS
NRF CRF HD CAPD
Subjects 4 5 5 5
Age 49 ± 17 44 ± 11 49 ± 13 46 ± 11
Weight (Kg) 75.5 ± 17..5 65.8 ± 6.0 70.6 ± 8.5 66.6 ± 12.1
Duration of Dialysis 
(months)
- - 53 ±40 21 ± 20
Creatinine
(jimol/1)
116 ± 12 618 ± 216 846 ± 168 728 ± 143
Triglycerides . 
(mmol/1)
2.0 ± 0.7 2.5 ± 1.1 3.0 ± 0.8 2.3 ±0.7
Glycosylated 
Haemoglobin 
(mmol HMF/mol Hb)
56 ± 8 55.0 ± 7 46 ± 7 51 ± 10
Table 6. V
Clinical Data: Diabetics classified by renal status 
Values are mean and SD
DIABETICS: DIABETIC TYPE
NRF Type I Uraemic Type I Uraemic Type II
Subjects 4 11 4
CRF
HD
CAPD
-
5
2
4
3
1
Age 49 ± 17 43 ± 1 55 ± 6
Weight (Kg) 75.5 ± 17.5 64.8 + 8.3 74.0 ± 7.5
Creatinine
(pmol/l)
116 ± 12 712 ± 210 782 ± 134
Triglycerides
(mmol/1)
2.0 ± 0.7 2.41 ± 1.0 3.1 + .3
Glycosylated 
Haemoglobin 
(mmol HMF/mol Hb)
56 ±8 54 ± 7.0 41 ± 3
Table 6. VI 
Clinical Data: Diabetics classified by diabetic type 
Values are mean and SD
b) Basal and peak responses to glucagon
Basal and peak responses to glucagon are shown in Figures 6.6 and
6.7 (values are mean and SEM).
When diabetics were classified by renal status (Figure 6.6) the 
glucose response to glucagon showed a significant increase in hepatic 
released glucose in all diabetics (p<0.05). There was no difference 
between the groups both in basal or peak concentrations but the
increment (40-61%) from basal to peak (mean 4.0 mmol/1) was
statistically significant. Basal serum free insulin (unbound) was 
lower in the CAPD diabetics than the other groups but this is not 
statistically significant. Peak free insulin also showed much 
variability between the groups, but again no significant difference 
was found. The increment from basal to peak was not significant in 
any of the groups (p>0.05), although the HD group had a greater rise 
in free insulin. Plasma c-peptide concentrations were almost 
undetectable in the NRF and CRF groups and did not change with 
glucagon stimulation. The HD group had a relatively high basal 
c-peptide concentration and the CAPD group had basal levels within the 
normal range (0.18-0.52 nmol/1). After glucagon stimulation neither 
the HD nor CAPD groups showed a change in c-peptide concentration.
When diabetics were reclassified by diabetic type (Figure 6.7) 
basal glucose was similar in all groups. Peak response was also 
similar in the three groups but the increment (about 50%) from basal 
to peak (mean 4.2 mmol/1) was significant. Basal free insulin was 
similar in all groups but peak free insulin in the type II uraemic 
group was higher than in both type I groups, although the difference 
was not significant. The change from basal to peak was not 
significant in any of the groups. Basal and peak c-peptide were 
negligible in both type I groups. Type II uraemic diabetics had both
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increased basal and peak concentrations (p<0.05) compared to the other 
diabetic groups, but this did not change with glucagon stimulation.
Thus all diabetics independent of diabetic type and renal status 
had a positive glucose response to glucagon. None of the diabetic 
groups showed a beta cell response as neither free insulin nor 
c-peptide concentrations changed with glucagon stimulation. The high 
c-peptide concentrations in the HD group corresponded to the type II 
diabetics in this group.
c) Glucagon response curves
Diabetics classified by renal status (Figure 6.8, values are mean 
and SEM), showed a small but steady rise in glucose in the first 20 
minutes following glucagon and thereafter glucose levels remained 
relatively stable. There was much variability within each group (for 
clarity some of the error bars have been omitted) and overall there 
was no difference between any of the groups.
The free insulin time response showed that the HD group had a 
slight but not significant rise in response to glucagon and 
concentrations throughout remained higher than in the CAPD group. 
Diabetics with NRF, CRF and CAPD showed no response to glucagon and 
free insulin levels remained unchanged. Absolute concentrations of 
free insulin in the NRF and CRF groups were intermediate between the 
HD and CAPD groups. Statistically there was a small difference 
between the HD and CAPD groups (p<0.05).
Plasma c-peptide concentrations were low to negligible in the NRF, 
CRF and CAPD groups, but were elevated in the HD group (p<0.05). No 
change occurred in the curve patterns with time in any group, i.e. 
there was no positive beta cell response.
When the same patients were reclassified by diabetic type (Figure
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6.9, values are mean and SEM), the glucose response showed a slow 
steady rise with time but there was no difference between any of the 
groups.
The free insulin time response was similar in both uraemic and non 
uraemic type I diabetic groups, neither or which responded to glucagon 
stimulation. Type II uraemic diabetics had a small but not 
statistically significant rise in free insulin after glucagon.
Although the type II group had a higher free insulin level in the 
first 20 minutes following beta cell stimulation this was not 
significantly different from the other groups.
G-peptide was negligible in both type I groups and no change 
occurred with glucagon. C-peptide concentrations were elevated in 
type II diabetics (p<0.05) but no change occurred with glucagon.
Thus all diabetics independent of renal status or diabetic type 
had a slow but steady increase in glucose especially within 20 minutes 
of glucagon administration. Although there was variability in the 
free insulin concentrations the small rise following glucagon in the 
HD group could be accounted for by the presence of type II diabetics 
in that group. Likewise, the elevated c-peptide concentrations found 
in the HD group largely corresponded with the type II diabetics. 
However, neither free insulin nor c-peptide increased in any group 
following glucagon, thus there was no positive beta cell response.
DISCUSSION
1. NON-DIABETICS
In this study CAPD was temporarily discontinued 12 hours before 
the glucagon challenge to achieve a fperitoneal* as well as on oral 
fast, for comparison with the other groups. Haemodialysis patients 
were studied on their interdialysis day, that is 24 hours after their 
last dialysis, which represented a state midway between the two 
extremes of pre and post dialysis. These conditions were applied in 
an attempt to achieve comparable basal states. Steroids, which can 
decrease hepatic and peripheral tissue sensitivity to insulin and 
induce hyperglycaemia (Pagano et al., 1983; Rizza et al., 1982), and 
beta blockers, which can impair the insulin response in uraemia (Pun 
et al., 1985), were part of the exclusion criteria of the study. A 
minority of patients (4 out of 10) in the chronic renal failure group 
had been taking frusemide, but there is no direct evidence that loop 
diuretics unlike thiazides can cause deterioration in glucose 
tolerance (Taylor, 1986).
The glucose, insulin and c-peptide responses to glucagon were 
abnormal in uraemics compared to controls. These were manifested by a 
prolonged elevation and a delayed fall in glucose and insulin, as well 
as an increased fasting and persistent elevation of c-peptide. These 
features reflect glucose intolerance induced by uraemia.
Normal fasting blood glucose was found in all subjects. This is a 
common finding in uraemia despite the presence of glucose intolerance 
(DeFronzo et al., 1973), in contrast, to maturity onset diabetes where 
fasting hyperglycaemia and often a normal fasting insulin are found 
(Turner and Holman, 1978).
Although fasting serum insulin was slightly increased in the 
uraemic groups this was not statistically significant. JData on the
fasting insulin state in uraemia are conflicting. Normal fasting 
insulin concentrations have also been reported by many (Spitz et al., 
1970; Roth et al., 1973; DeFronzo, 1978b). Spitz et al. (1970) have 
also reported a group of uraemics with increased basal levels.
Several reports, particularly in the late 1960’s (Hutchings et al., 
1966; Briggs et al., 1967; Horton et al., 1968) found basal 
hyperinsulinaemia in patients with chronic renal failure some of whom 
were on haemodialysis. More recently, decreased fasting insulin 
concentrations were found in CAPD patients (Von Baeyer et al., 1983). 
The reason for the discrepancies is not clear and is probably 
multifactorial.
Studies in the late 1960’s used assay techniques which by today's 
standards were crude and less specific. Both insulin standards and 
antibody preparation were less pure and specific and probably much 
cross-reactivity with proinsulin occurred. This may have resulted in 
over-estimation of serum insulin. The relatively more sensitive and 
specific assay used in this study (detailed in Chapter 5) was a double 
antibody radioimmunoassay with minimal cross-reactivity with 
proinsulin. It has been suggested (DeFronzo, 1978b) that two 
categories of uraemic patients may exist, some having normal basal 
insulin (possibly reflecting impaired beta cell function) and others 
having increased basal insulin (in an attempt to overcome peripheral 
insulin resistance). In this study 8 or the 40 uraemic patients had 
basal levels above the laboratory normal reference range (2.5-13.5 
mu/ml). However, the majority of these had only marginally elevated 
concentrations. Even allowing for the heterogeneity of the uraemic 
population there was no difference between any of the groups.
Fasting plasma c-peptide concentrations were increased in all 
uraemic patients. This confirms the findings of others (Jaspan et
al., 1977) that renal failure impairs the catabolism of c-peptide.
The elevated c-peptide basal concentrations reflect impaired renal 
metabolism rather than basal hypersecretion of the beta cell and this 
in keeping with the essentially normal basal insulin concentrations in 
all the uraemic groups. This has important clinical implications as 
elevated c-peptide in uraemia may mistakenly be interpreted as 
increased beta cell secretory activity. Similarly, the occurrence of 
hypoglycaemia in renal failure in association with elevated c-peptide 
might erroneously suggest the presence of endogenous hyperinsulinaemia 
due to an insulinoma. Increased c-peptide concentration may also be 
due to the presence of proinsulin. The antibody to c-peptide used in 
the radioimmunoassay (Novo Biolab M1230) had a 10% cross-reactivity, 
on a molar basis, with proinsulin. Proinsulin is increased in 
uraemia, largely due to impaired renal degradation (Katz et al., 1973) 
and, therefore, may have contributed in a small way to the increase in 
c-peptide.
The time dependent glucose response to glucagon showed prolonged 
elevation with a delayed rate of decline in all uraemic patients 
although the absolute maximum responses were similar to healthy 
subjects. This is typical of the glucose intolerance induced by 
uraemia and was seen in both non-dialysis and dialysis patients. The 
abnormal time dependent changes may be explained by several 
mechanisms. Increased hepatic sensitivity to glucagon, which is 
documented in uraemia (Sherwin et al., 1976), could account for the 
prolonged hepatic glucose production and the impaired degradation of 
glucagon in uraemia (Lefebvre et al., 1975) could also explain the 
prolonged glucose response. However, peripheral resistance to the 
action of insulin causing impaired peripheral glucose utilization 
(DeFronzo, 1973; 1978b) may also induce the prolonged hyperglycaemia.
The insulin response to glucagon was similar in all uraemic groups 
but differed from the controls. Although the absolute maximum 
response was similar in all subjects a slower rate of rise, prolonged 
elevation and delayed fall in insulin was found in uraemic patients. 
Several mechanisms could be responsible for this type of response. 
Impaired beta cell secretion might account for the slower rate of
rise, but the similar maximum responses in all groups suggests that
beta cell secretion was adequate. The prolonged hyperinsulinaemia 
could be due to tissue insensitivity to insulin (peripheral insulin 
resistance) with relative secondary hypersecretion of the beta cell 
(DeFronzo, 1978b). The prolonged elevation and delayed decline could 
also be explained by delayed renal degradation of insulin (Rubenstein
et al., 1975; Rabkin et al., 1984).
The c-peptide response to glucagon differed markedly in uraemic 
patients compared to normal subjects. The increased basal 
concentrations most likely due to impaired renal catabolism have been 
discussed. However, all uraemic groups despite their elevated basal 
concentrations showed a significant increase in response to glucagon. 
The metabolic clearance rate of c-peptide is much slower than that of 
insulin, thus differences in hepatic extraction and peripheral 
kinetics (Faber et al., 1978) explain the difference in rate of 
decline between insulin and c-peptide in all groups. The slower rate 
of rise followed by persistent elevation (plateau effect) can be 
explained by the impaired renal clearance of c-peptide (Jaspan et al., 
1977; Faber et al., 1978). The small difference between the 
non-dialysis (some residual renal function) and the 3 dialysis groups 
reflects the quantitative role the kidney has in c-peptide removal.
The mean time to reach the maximum response was 6 minutes for both 
insulin and c-peptide in normal subjects and confirms the findings of
others (Faber and Binder, 1977). The time course for all uraemic 
subjects was prolonged in keeping with glucose intolerance.
The molar ratio of c-peptide to insulin is an index of beta cell 
function. The basal ratio in normals was similar to that found by 
Jaspan et al. (1977) and Heding (1975). Following stimulation the 
ratio fell, due to a relatively greater increase in insulin because of 
its lower basal concentration, and was comparable with data of Heding 
(1975). In uraemia the increased basal ratio was due to the high 
basal c-peptide concentration. The basal ratios in this study were 
comparable to that found by Jaspan et al. (1977), who studied a group 
of haemodialysis patients. Following stimulation, although both 
insulin and c-peptide increased there was a fall in the ratio as there 
was a relatively greater increase in insulin. The CRF non-dialysis 
group had marginally lower basal and maximum molar ratios than the 
dialysis groups due to lower c-peptide concentrations which reflected 
a degree of residual renal function.
Fasting plasma c-peptide strongly correlated with fasting serum 
insulin in controls, CRF and haemodialysis subjects but the two 
variables did not correlate in either CAPD group. The reason for this 
is not clear but possibly peritoneal clearance of c-peptide (Wideroe 
et al., 1984) may play a role, although absolute concentrations of 
c-peptide and insulin in both CAPD groups were similar to the other 
uraemic groups. Plasma c-peptide showed a strong positive correlation 
with serum creatinine in the non-dialysis chronic renal failure group, 
but no linear relationship was found in the dialysis groups. This may 
be explained by the differential clearances of both molecules by 
dialysis.
Serum lipoproteins were abnormal in all uraemic groups. The 
characteristic pattern of hypertriglyceridaemia, increased total
cholesterol and low HDL-cholesterol was found in agreement with 
numerous previous studies (Kannel et al., 1979; Norbeck et_al., 1980). 
However, as previously documented, there was much interpatient 
variability in lipoprotein concentrations.
This study confirms that glucose, insulin and c-peptide responses 
to glucagon stimulation in renal failure are different from controls 
and that the abnormalities are due to uraemia. The significant rise 
in beta cell peptides to glucagon confirms adequate pancreatic 
reserve. There were no differences between the non-dialysis, 
haemodialysis or CAPD patients. Thus, there is no evidence that CAPD 
therapy per se has any adverse effect on beta cell function.
2. DIABETICS
The limited number of diabetics on dialysis restricted the study 
and this has to be taken into account when interpreting the results. 
Diabetics were classified by renal status to determine if mode of 
treatment affected beta cell function and by diabetic type which 
clearly has a profound effect on the beta cell integrity.
The majority of diabetics studied were type I. All of the CRF 
group and most of the CAPD group were insulin dependent, of variable 
duration, but generally had diabetes for at least 15 years. Type II 
diabetics were in the minority but accounted for three-fifths of the 
HD group. The duration of type II diabetes was difficult to assess 
with any accuracy but was at least 10 years in all patients.
Hypertriglyceridaemia was found in all diabetic patients and this 
was most marked in the older type II patients. This association 
between hyperlipidaemia and diabetes is well established (Steiner, 
1981; Gibbons, 1986).
All diabetic patients independent of diabetic type or renal status
had an increase in blood glucose in response to glucagon. This is in 
agreement with others (Faber and Binder, 1977), who found an increase 
in hepatic glucose release to glucagon in diabetics. Diabetics had 
persistent hyperglycaemia throughout the 1 hour test suggesting no 
effective counterregulatory insulin response.
Serum free (unbound) insulin was measured by PEG precipitation 
after separation of serum and prior to storage which improves the 
accuracy of the assay (see Chapter 5). However, immediate 
precipitation after venesection has been shown to further improve the 
sensitivity and precision of the method (Hanning et al., 1985). There 
was considerable variation in free insulin concentrations, 
particularly between type I and II diabetics, the latter having much 
less or negligible antibody bound insulin. However, there appears to 
be no definite correlation between total insulin and free insulin 
concentrations in diabetics (Nakagawa et al., 1973). Thus a direct 
comparison between total insulin concentrations in non-diabetics and 
free insulin concentrations in diabetics is not possible. All 
diabetics had similar basal free insulin concentrations which did not 
significantly change after glucagon stimulation, indicating no 
significant beta cell reserve. The time dependent changes essentially 
showed no response, but in the type II group (predominantly HD 
patients) there was a suggestion of an increase in free insulin 
although this was not significant. This has to be interpreted with 
caution in view of the small numbers studied. The absolute 
concentrations of free insulin were higher than found by Nakagawa and 
colleagues (1973). The reason for this is not entirely clear.
Several explanations may account for the differences. The 
radioimmunoassay may have been more sensitive, the presence of uraemia 
in the majority of patients may have contributed to elevated insulin
by inducing peripheral insensitivity to insulin as well as impaired 
renal degradation. Furthermore, type II diabetics may have relatively 
1normal* or even 'high' circulating insulin concentrations due to 
defects in insulin receptor binding. This has been reviewed by Bailey 
et al. (1984).
Fasting plasma c-peptide was just detectable in the type I 
diabetics confirming negligible beta cell function which did not 
change with glucagon stimulation. However, in the type II diabetics 
elevated basal c-peptide was observed but again there was little 
change following glucagon. Thus, it is evident that the circulating 
c-peptide levels were high largely due to the presence of uraemia 
rather than significant residual beta cell function. The time 
dependent changes confirm no effective residual beta cell function.
The high c-peptide concentrations in the type II diabetics obviously 
reflect some degree of beta cell secretion, perhaps even relative 
hypersecretion as a secondary compensatory mechanism, but as no change 
occurred with glucagon stimulation the main mechanism behind the 
elevated levels must be the presence of uraemia. Elevated proinsulin 
in uraemia, which has some cross-reactivity with c-peptide 
estimations, may also have contributed to the increase.
Type I, insulin dependent diabetics generally have negligible beta 
cell function, particularly after 10-20 years, when end stage renal 
disease is reached and therefore it is not unexpected that no response 
to glucagon occurred. Type II, non-insulin dependent diabetics 
present a more complex problem. Defects in both insulin secretion and 
insulin action have been demonstrated (Reaven, 1984; Truglia et al., 
1985; O’Rahilly et al., 1986). This is further complicated by the 
effect of uraemia (discussed in detail in Chapter 2). From this study 
the effects of diabetes predominate over the uraemic effects and it is
not possible to conclude what effect if any, dialysis per se has on 
beta cell function in diabetics. The small though insignificant rise 
in insulin in the HD group reflects the presence of type II diabetics 
rather than any specific effect of haemodialysis.
The important points derived from this study are that c-peptide 
and possibly free insulin concentrations may be altered by the 
presence of uraemia. The interpretation of beta cell function by 
random c-peptide measurements may falsely imply adequate reserve. The 
use of c-peptide determination as a means of assessing deficiency of 
endogenous insulin secretory capacity and to categorise type II 
diabetics into those requiring diet, oral drugs or even insulin 
therapy has been widely studied (Madsbad et al., 1981; Rendell, 1983). 
However, the presence of renal failure will increase the c-peptide 
concentration and thus limit the potential of this test.
The use of recent techniques such as the hyperglycaemic and 
euglycaemic clamp (DeFronzo et al., 1978a) and continuous infusion of 
glucose with mathematical model assessment (O'Rahilly et al., 1986) 
may in the future elucidate residual beta cell function in diabetics 
with uraemia.
SUMMARY
Pancreatic beta cell function was evaluated in uraemic patients by 
measuring the beta cell peptides in the peripheral blood after glucagon 
stimulation. Non-diabetic subjects in chronic renal failure, on 
haemodialysis, new to and established on CAPD were studied. Fasting 
glucose and insulin concentrations were normal and did not differ between 
the uraemic groups, but c-peptide concentrations were markedly increased. 
Following glucagon stimulation an exaggerated blood glucose response with 
delayed glucose peak was observed, while the peak insulin response was 
normal but the return to basal concentrations was delayed in uraemia. The 
c-peptide response was also exaggerated and peak concentrations in uraemic 
subjects were greatly increased. The possible underlying mechanisms are 
discussed. Glucose intolerance persisted despite dialysis therapy 
confirming the abnormalities were due to the underlying uraemia. However, 
the glucagon test showed significant increments in beta cell peptides 
reflecting adequate residual beta cell function. The response was similar 
in both new and established CAPD patients to those on haemodialysis and 
non-dialysed chronic renal failure patients. Thus, it can be concluded 
that despite continuous intraperitoneal glucose CAPD per se does not 
adversely affect beta cell function.
Glucagon stimulation in diabetics was assessed by classifying patients 
by diabetic type and mode of renal therapy. As expected, type I diabetics 
had no beta cell response, although glucagon caused a rise in glucose.
Type II diabetics showed hepatic glucose release and a very small beta cell 
response. However, the absolute concentrations of c-peptide in uraemic 
diabetics can be misleading as concentrations are elevated due to impaired 
renal degradation. This dynamic test of residual beta cell function 
confirmed no significant reserve in any of the diabetic subjects. The 
effect of diabetes predominated over any possible uraemic effect and 
dialysis per se had no detectable effect on beta cell function.
CHAPTER 7
GLUCOREGULATORY HORMONES AND INTERMEDIARY METABOLITES IN CAPD
INTRODUCTION
The continuous peritoneal glucose absorption that occurs in CAPD 
could conceivably affect glucoregulatory hormone homeostasis and 
intermediary metabolism, but to date this has not been adequately 
investigated. The normal physiological and biochemical changes in the 
post-absorptive state (after an overnight fast) induce a tendency to 
stimulate gluconeogenesis, lipolysis and ketogenesis. After a meal or 
oral glucose load increased glycolysis and inhibition of 
gluconeogenesis, lipolysis and ketogenesis occurs. This has been 
discussed in Chapter 1.
The hyperglycaemia and hyperinsulinaemia in CAPD have been 
documented (Heaton et al., 1983; Armstrong et al., 1985), but only one 
group has studied the changes in intermediary metabolism (Heaton et 
al., 1983). In a small group of patients Heaton et al. showed 
elevation of gluconeogenic precursors and decreased ketone bodies 
during CAPD. No other reports have been published.
Furthermore, although high and low dextrose dialysis solutions may 
affect hormone and metabolite homeostasis, other factors such as age, 
diabetes mellitus and peritonitis may also have additional 
consequences. CAPD patients are frequently elderly or diabetic and 
peritonitis is the commonest complication of this mode of treatment.
1- Age
Disposal of an oral or intravenous glucose load is impaired with 
aging. This is probably multifactorial and factors such as reduced 
diet, physical inactivity and decreased lean body mass may all play a 
role. Pancreatic beta cell function appears to be normal but evidence 
of insulin antagonism is strong though not conclusive (Davidson,
1979). Peripheral insensitivity to insulin has been suggested as the
mechanism of glucose intolerance in the elderly (DeFronzo et al., 
1978a) and probably due to a post-receptor or intracellular defect 
rather than a receptor defect (Jackson et al., 1982). A similar 
mechanism has been suggested for the glucose intolerance seen in 
uraemia (Smith et al., 1982; Pedersen et al., 1985) and is discussed 
in Chapter 2. CAPD has been a particularly suitable treatment for the 
elderly (Nicholls et al., 1984), and at least one third of CAPD 
patients are over 60 years of age (Nolph et al., 1985). Hence the 
importance of assessing the effect of CAPD on glucoregulatory hormones 
and intermediary metabolites in the elderly. To date no studies have 
been reported.
2. Diabetes
The effect of diabetes on gluconeogenesis and ketogenesis is well 
documented and is discussed in Chapter 1. Diabetics have deranged 
glucoregulatory hormones and under certain conditions, particularly 
infection and poor blood glucose control, can have disturbances of 
intermediary metabolism, such as lactic acidosis and increased 
ketogenesis. Furthermore, diabetics with end stage renal failure are 
frequently treated by CAPD (Flynn et al., 1983; Khanna et al., 1986). 
Indeed in the U.K. CAPD is the preferred mode of dialysis for 
diabetics (Cameron and Challah, 1986). Thus it is relevant to 
investigate the hormonal and intermediary metabolic effects of 
intraperitoneal glucose absorption, particularly as no studies have 
been previously reported.
3. Peritonitis
Peritonitis is by far the commonest complication of CAPD. Single 
centre studies show an incidence of about 1.7 episode of peritonitis
per year (Smith et al., 1986) and large multicentre registry data 
shows similar results with a 66% risk of patients developing 
peritonitis in 1 year (Nolph et al., 1985). Occasionally, peritonitis 
can be recurrent and is one of the main reasons for failure of CAPD 
therapy (Heaton et al., 1986; Tsakiris et al., 1986). Peritonitis is 
associated with increased glucose absorption from the dialysate (Rubin 
et al., 1981), which can induce loss of ultrafiltration (Verger et_ 
al., 1984) resulting in the need for more hypertonic exchanges to 
achieve adequate fluid balance. Although the effect of increased 
permeability of the peritoneum to glucose is known the hormonal and 
intermediary metabolite status during peritonitis have not been 
studied.
4. Objectives
Thus, the primary objective of the study was to determine the 
glucoregulatory hormone and intermediary metabolite status in CAPD 
patients. This was investigated in several ways. Firstly, fasting 
concentrations were determined in CAPD patients as well as other 
uraemic patients to distinguish the effects of CAPD from those of 
uraemia. Secondly, low and high dextrose dialysate solutions were 
studied to assess the quantitative effect of peritoneal glucose 
absorption. Thirdly, specific categories of CAPD patients were 
investigated, namely, diabetics, the elderly and patients with 
peritonitis to determine if any of these factors had any metabolic 
consequences on glucoregulatory hormone homeostasis and intermediary 
metabolism.
METHODS
1. Patients
Glucoregulatory hormones and intermediary metabolites were 
measured after an overnight fast in a 'mixed uraemic population1. Ten 
healthy subjects acted as controls, 6 non-dialysis patients with 
advanced chronic renal failure were the CRF group, 6 patients on 
haemodialysis were the HD group and 42 patients on CAPD were also 
studied. After a 12 hour overnight fast CAPD patients had hormone and 
metabolite profiles measured during a 6 hour peritoneal dialysis 
cycle.
The CAPD patients were classified into 7 groups, with 6 patients 
in each; isotonic, hypertonic, new, elderly, peritonitis, diabetic and 
overnight peritoneal dialysis. The isotonic group was given low 
dextrose (1.5% or isotonic) dialysis solution during the study. All 
the other groups were given high dextrose (4.25% or hypertonic) 
dialysis solution. The group named 'hypertonic1 (H) was used as the 
reference group during the CAPD profiles. The 'new' (N) group were 
patients recently established on CAPD (for more than 1 month but less 
than 6 months). Most patient had about 3 months of therapy prior to 
the study. The 'elderly' (E) group were patients over the age of 65 
years. The 'peritonitis' (P) group consisted of patients with proven 
bacterial peritoneal infection who were studied within 4 days of the 
onset of peritonitis. The 'diabetic' (D) group were patients who had 
diabetic nephropathy as the cause of their renal failure. All were 
taking insulin supplementation in the form of intraperitoneal insulin. 
Four patients were 'insulin dependent* and 2 were 'insulin treated'. 
The last group, overnight peritoneal dialysis (OPD), were patients who 
continued their peritoneal dialysis prior to the study, i.e. they did 
not omit their overnight exchange and had an isotonic cycle prior to
the metabolic profile.
2. Protocol
All subjects had a 12 hour oral fast and all CAPD patients except 
the OPD group omitted their overnight dialysis cycle. Haemodialysis 
patients were studied on their interdialysis day (18-24 hours after 
their last dialysis). Fasting blood specimens were taken between 0900 
and 1000 hours and CAPD profiles were studied between 0900 and 1500 
hours.
None of the CAPD patients were taking steroids, B-blockers or 
thiazide diuretics prior to the study. Diabetics omitted their 
intraperitoneal insulin during the study and blood glucose was 
monitored regularly with BM stixs (Boehringer). Patients with 
peritonitis also omitted their intraperitoneal antibiotics during the 
study cycle.
An intravenous cannula was inserted into a forearm vein and kept 
patent by heparinised saline flushes after each blood sample. Any 
residual peritoneal fluid was drained from the peritoneal cavity into 
the empty overnight bag which was attached the previous night to keep 
the CAPD system closed and sterile. Body weight and blood pressure 
were recorded and dialysis fluid bags were weighed and an aliquot 
taken for analysis prior to instillation. The exact time of 
instilling the fluid was recorded and the mid-point was taken as zero 
time. Subsequent blood specimens were taken at 15, 30, 45, 60, 90, 
120, 180, 240 and 360 minutes. At the end of the cycle the dialysate 
effluent was drained, weighed and an aliquot was taken for analysis.
During the 6 hour exchange no food or fluids were given except 
water. Most patients consumed between 200 and 400 ml of water. 
Patients remained semi-supine for most of the study. At the end of
the study cycle an isotonic exchange was performed and patients 
continued with their usual CAPD regimen. Intraperitoneal insulin was 
adjusted according to blood glucose estimations and intraperitoneal 
antibiotics were resumed in the peritonitis group. Patients continued 
their usual diets which had a caloric value of 35-45 Kcal/Kg/day and 
protein intake of about 1.2 g/Kg/day.
The study was approved by the Sheffield Hospitals Medical Ethics 
Committee and all subjects gave informed written consent.
3. Assays
Blood for glucose, lactate, pyruvate, alanine, 3-hydroxybutyrate, 
acetoacetate and glycerol was taken into ice cold perchloric acid.
The automated enzymic fluorometric continuous flow assays (Lloyd et_ 
al., 1978) and the manual spectrofluorometric assay for acetoacetate 
and pyruvate are detailed in Chapter 5. Dialysate glucose and lactate 
were measured by the same technique. Blanks were run for all 
metabolites to exclude non-specific (native) fluorescence due to 
uraemia. Blood for hormone assays was kept ice cold until separated 
(within 4 hours). Frozen plasma or serum was stored at -20°C until 
assayed. Serum insulin was measured by double antibody 
radioimmunoassay, a modification of the method of Soeldner and Slone 
(1965). Free insulin in diabetics was measured after antibody 
precipitation with polyethylene glycol. Plasma c-peptide was measured 
by a radioimmunoassay kit (Novo Biolab) and glucagon by c-terminal 
specific radioimmunoassay with wick chromatography (Orskov et al., 
1968). Growth hormone and cortisol were measured by double antibody 
radioimmunoassays from ’in house kits'. Details of all assays are 
described in Chapter 5.
4. Peritoneal dialysis solutions
All CAPD patients used Fresenius standard dialysis solutions 
(Perito-Flex, Fresenius, The Dylade Co. Ltd., Runcorn, U.K.). The 
isotonic fluid contained 1.5% glucose (15 g/1 or 84 mmol/1) and the 
hypertonic solution contained 4.25% glucose (42.5 g/1 or 237 mmol/1). 
The other constituents of the peritoneal fluid were:- 
Sodium 134 mmol/1 (5.786 g/1 NaCl)
Calcium 1.75 mmol/1 (0.257 g/1 CaC^)
Magnesium 0.50 mmol/1 (0.102 g/1 MgC^)
Chloride 103.5 mmol/1
Lactate 35.0 mmol/1 (3.924 g/1 Na lactate)
The isotonic fluid contained glucose in the form of dextrose 
monohydrate 16.5 g/1, equivalent to anhydrous dextrose 15 g/1. The 
hypertonic fluid contained dextrose monohydrate 46.5 g/1, equivalent 
to 42.5 g/1 of anhydrous dextrose. The osmolality of the isotonic 
fluid was 358 mosm/1 and the hypertonic solution was 511 mosm/1.
5. Statistics
Statistical analysis was performed using the paired Tt' test to 
compare changes within a group and by analysis of variance to compare 
changes between groups. Generally parameters had a normal 
distribution but metabolites had a slightly skewed distribution. 
Correlations were sought using linear regression analysis.
RESULTS
Glucoregulatory hormones and intermediary metabolites were 
determined in a mixed uraemic population. In the fasting state 
healthy control subjects were compared with chronic renal failure, 
haemodialysis and CAPD patients. This latter group, CAPD (n=30), was 
an amalgamation of 5 CAPD subgroups (viz: isotonic, hypertonic, new, 
elderly and peritonitis). The CAPD subgroups were abbreviated by the 
letter(s)
I = Isotonic 
H = Hypertonic 
N = New 
E = Elderly 
P = Peritonitis 
D = Diabetic
OPD = Overnight peritoneal dialysis
It should be noted that during the CAPD cycle all patients were 
given a hypertonic (high dextrose) solution except those in the 
isotonic group who were given isotonic (low dextrose) solution.
Results are presented in five sections
1. General data including clinical variables
2. Fasting hormone and metabolite status
3. Hormones and metabolites during a CAPD cycle
4. Hormones and metabolites in diabetics on CAPD
5. Dialysate glucose and ultrafiltration
1. GENERAL DATA
Clinical data for the control and three uraemic groups (CRF, HD, 
CAPD) are shown in Table 7.1 (values are mean and SEM). Age and serum 
creatinine were comparable in the uraemic groups. Fasting serum total
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cholesterol was elevated in the CAPD group (p<0.01), whereas the CRF 
and HD subjects, although they had a high cholesterol level this was 
not significantly different from controls. Fasting serum total 
triglycerides were markedly increased in all the uraemic groups 
(p<0.001). Fasting HDL-cholesterol was significantly decreased in the 
uraemic subjects.
CAPD patients were subgrouped as shown in Table 7.II (values are 
mean and SEM). This classification is used throughout the result 
section of the chapter. More females participated in the study 
reflecting the female predominance in CAPD at the centre. Most 
patients were between 50 and 65 years of age except for the elderly 
group, all of whom were over 65 years. The mean weight in each group 
was comparable and varied between 60 and 75 Kg. Fasting serum total 
cholesterol and triglycerides were increased and HDL-cholesterol was 
decreased in all subgroups.
2. GLUCOREGULATORY HORMONES AND INTERMEDIARY METABOLITES IN THE 
FASTED STATE
a) Glucoregulatory Hormones
Fasting hormone concentrations for each group and CAPD subgroups 
are shown in Table III (values are mean and SEM). Glucose 
concentrations were not significantly different in any of the groups 
or subgroups compared to controls. Fasting serum insulin 
concentrations were similar to controls in all but two CAPD subgroups. 
The hypertonic (H) subgroup had a higher basal insulin concentration 
(p<0.05), although the mean value was in the accepted normal reference 
range (2.5-13.5 mU/1) for the assay. The OPD subgroup also had a 
higher basal insulin concentration but this set of patients were not 
in a true fasted state as they have peritoneal dialysis immediately
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prior to the study. Plasma c-peptide was grossly elevated (pcO.OOl) 
in all uraemic patients with the exception of diabetics on CAPD.
Basal c-peptide in diabetics was similar to controls (p<0.05).
Fasting plasma glucagon was increased in all the uraemic groups 
particularly the CRF and haemodialysis groups (p<0.01). However, in 
CAPD patients basal glucagon was variable and was only significantly 
increased in the I subgroup (p<0.01). Serum growth hormone 
concentrations showed wide variation in the fasting state and although 
increased in some uraemic patients overall there was no difference 
between controls and any of the uraemic groups or CAPD subgroups. 
Fasting plasma cortisol was increased (p<0.01) in the CRF and HD 
groups. However, the main CAPD group and all subgroups, (except the 
OPD subgroup), showed no significant change in basal cortisol 
concentrations.
Figures 7.1 to 7.6 show the fasting glucose and hormone 
concentrations for each main group and the subgroups. Values are mean 
and SEM. The p values are derived from one way analysis of variance 
and compare controls with the appropriate uraemic group or subgroup. 
The CAPD subgroup, N (new), OPD (overnight peritoneal dialysis) and D 
(diabetic) have been omitted. These subgroups were omitted because 
the N group behaved in an identical manner to the H group, the OPD 
group did not represent a true fasted state and the D group is 
presented later in the diabetic section.
b) Intermediary Metabolites
Fasting intermediary metabolites for each main group and CAPD 
subgroups are shown in Table 7.IV (values are mean and SEM). Glucose 
was unchanged as previously stated. Fasting blood lactate, pyruvate 
and alanine were similar to control values and the lactate:pyruvate
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ratio was normal in all groups and subgroups. Fasting 
3-hydroxybutyrate was higher in the uraemic patients but this was only 
significantly different in the CRF group (p<0.05) and the elderly CAPD 
subgroup (p<0.05). Basal acetoacetate was also higher in uraemia but 
was only significantly increased in the CAPD group (p<0.05) and 
largely due to the elderly subgroup (p<0.01). The 
3-hydroxybutyrate:acetoacetate ratio was essentially normal but was 
moderately increased in the CRF group due to a relative increase in 
3-hydroxybutyrate. Fasting glycerol concentrations were generally 
higher in uraemia and this was most marked in the CAPD group (p<0.05) 
and again predominantly due to the elderly subgroup (p<0.01). The 
diabetic and OPD subgroups also had significantly raised glycerol 
concentrations.
Figures 7.7 to 7.12 show the fasting intermediary metabolite 
concentrations for each group and CAPD subgroups. Values are mean and 
SEM. Three subgroups have been omitted for reasons explained above.
In summary, in the fasting or post-absorptive state total 
triglycerides were increased and HDL-cholesterol decreased in all 
uraemic patients. Total cholesterol was significantly increased only 
in CAPD patients. Fasting glucose and insulin were normal but 
c-peptide was grossly elevated in uraemia. Glucagon was increased in 
the CRF and haemodialysis patients and in many of the CAPD subjects. 
Lactate, pyruvate and alanine were normal but the ketone bodies and 
glycerol were increased in uraemic patients, particularly the elderly 
subjects on CAPD.
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3. HORMONE AND INTERMEDIARY METABOLITES DURING A PERITONEAL DIALYSIS
CYCLE
The hormone and metabolite changes with peritoneal glucose 
absorption over a 6 hour dwell period are shown in Figures 7.13 to 
7.24. The mean concentrations are plotted at 10 time intervals but 
the SEM has been omitted from some points for clarity of illustration, 
where there was no significant difference. The new, diabetic and 
overnight peritoneal dialysis groups have been omitted for reasons 
previously stated.
a) Glucoregulatory Hormones
Glucose: Blood glucose (Figure 7.13) significantly increased in
all groups (p<0.01) and especially with hypertonic dialysate. Glucose 
showed a small but significant increase from 5 to 6 mmol/1 with 
isotonic dialysate reaching a maximum at 30 minutes. Hypertonic 
dialysate increased blood glucose from 5 to over 9 mmol/1 and peaked 
at 60 minutes. Patients with peritonitis had a more rapid rise and . 
increased blood glucose concentration which was significantly higher 
than the H (hypertonic) group (p<0.05). The H group had a markedly 
increased blood glucose compared to the I (isotonic) group (p<0.01). 
Blood glucose concentrations returned to their basal levels by 4 
hours.
Insulin: The rise in serum total insulin (Figure 7.14) paralleled
that of glucose. The rapid rise in the first 15 minutes was followed 
by smaller increments over the first hour. All groups showed a 
significant rise in insulin from basal concentrations (0.001<p<0.05). 
The isotonic fluid produced much smaller increments compared to 
hypertonic fluid. There was approximately a 3-fold increase in
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insulin in response to hypertonic solution. The difference in serum 
insulin between the hypertonic (H) group and the isotonic (I) group 
was highly significant throughout most of the cycle (p<0.001). The 
peritonitis (P) group had a higher insulin concentration over the 
first 3 hours of the cycle but this was not statistically different 
from the H group. Insulin concentrations returned to basal level by 4 
hours.
C-peptide: Plasma c-peptide concentrations (Figure 7.15) were
elevated at the start and increased further during peritoneal 
dialysis. The isotonic solution produced a small but significant 
increase (p<0.05) but the 3 groups using hypertonic fluid had a marked 
increase (p<0.01). The rate of rise was slower than that of glucose 
and insulin, reaching a maximum by 2 hours with hypertonic fluid.
There was a very slow decline and c-peptide concentrations did not 
return to their basal levels by 6 hours in groups using the high 
dextrose dialysate. The difference between the H and I groups was 
significant throughout most of the cycle (p<0.05). The peritonitis 
(P) group had a more rapid rise and reached higher concentrations than 
the other groups using hypertonic fluid but the difference was not 
significant.
Glucagon: There was marked variation in plasma glucagon
concentrations within each group (Figure 7.16). The general trend 
showed a fall in glucagon over the first hour of the dialysate dwell. 
Although basal glucagon was high in the isotonic group no significant 
change occurred during the dialysis cycle. The hypertonic (H) and 
elderly (E) groups showed a small but significant fall in glucagon 
(p<0.01), while patients with peritonitis (P), although they had a
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similar trend did not produce a significant fall in glucagon.
Glucagon was significantly decreased (p<0.05) during the first 2 hours 
of dialysate dwell in the H group compared to the I group.
Growth hormone: Serum growth hormone concentrations fluctuated
both within and between groups (Figure 7.17). Overall there was no 
clear trend in response to the peritoneal glucose load. The isotonic 
group showed a fall in growth hormone over the 6 hours (p<0.05) while 
the other groups showed marked variability and no real change. There 
was no difference between any of the groups.
Cortisol: Plasma cortisol concentrations (Figure 7.18) also
showed considerable variation both within and between groups. Overall 
there was no change during the peritoneal dialysis cycle and no 
difference between any of the groups.
b) Intermediary Metabolites
Lactate: Blood lactate (Figure 7.19) increased in all patients
during peritoneal dialysis (p<0.05) reaching a peak by 60 minutes and 
returning to basal concentrations by 4 hours. There was no 
significant difference in lactate concentrations throughout the cycle 
between the isotonic (I) and the hypertonic (H) or elderly (E) groups, 
although the elderly group did have higher levels in the first 2 
hours. However, lactate concentrations were significantly higher 
(p<0.01) in the peritonitis (P) group compared to the others. A rapid 
rise within the first hour of dwell and approximately a 3-fold 
increase from basal concentrations was observed.
Pyruvate: Pyruvate (Figure 7.20) behaved similarly to lactate but
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the increase from basal concentrations was smaller. The rise in 
pyruvate concentration was not significant in the hypertonic (H) 
group, but small and significant changes (p<0.05) were seen in both 
the isotonic and elderly groups. The peritonitis group showed a 
marked increase in pyruvate (p<0.01) which reached a maximum at 60 
minutes and declined to basal levels by 4 hours. The difference in 
peak pyruvate between the hypertonic (H) and peritonitis (P) groups 
was significant (p<0.05).
Lactate:pyruvate ratio: The lactate:pyruvate ratio (Table 7.V)
was essentially normal (10:1) throughout dialysis in most groups. The 
exceptions were in the elderly and particularly in the peritonitis 
group which showed an increased ratio due to the relatively greater 
increase in lactate.
Alanine: Blood alanine concentrations (Figure 7.21) were variable
but remained normal during dialysis. There was a small but 
statistically significant rise in alanine concentrations (p<0.05) in 
the elderly and isotonic groups during the first 2 hours of dwell. No 
change occurred in either the hypertonic (H) or the peritonitis 
groups. Furthermore, there was no difference between any of the 
groups during the cycle.
3-Hydroxybutyrate: Blood 3-hydroxybutyrate (Figure 7.23)
decreased from high fasting concentrations to trough levels between 2 
and 3 hours and then increased over the remainder of the cycle. The 
decrement was generally greater with the high glucose dialysis 
solutions. However, the decrease in 3-hydroxybutyrate was significant 
in the isotonic and elderly groups (p<0.05) but not in the hypertonic
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(H) and peritonitis groups. The increment from the mid cycle trough 
to the end of the dwell was more prominent with the low glucose 
dialysate than with hypertonic fluids. The difference in 
3-hydroxybutyrate concentrations between the isotonic (I) and the 
hypertonic (H) groups was significant (p<0.01) in the latter half of 
the cycle.
Acetoacetate; Acetoacetate (Figure 7.24) responded similarly to 
3-hydroxybutyrate. All groups showed a significant fall from high 
fasting concentrations to trough levels at about 1 hour (p<0.05).
There was no difference between any of the groups, with the exception 
of higher acetoacetate concentrations in the latter half of the cycle 
in the isotonic (I) compared to the hypertonic (H) group (p<0.05).
3-hydroxybutyrate:acetoacetate ratio; The 3-hydroxybutyrate: 
acetoacetate ratio (Table VI) was essentially normal (1:2) throughout 
most of the dialysis cycle in most groups. However, the hypertonic 
(H) and elderly (E) groups had low ratios in mid cycle due to the 
relatively greater decrease in 3-hydroxybutyrate.
Glycerol: Blood glycerol concentrations (Figure 7.22) decreased
(p<0.05) in all groups in the first 60 minutes and then gradually 
returned towards basal levels particularly during the last 2 hours of 
the dialysis dwell. The hypertonic solutions appeared to have a more 
suppressive effect on glycerol but there was no significant difference 
between any of the groups.
A summary of the glucoregulatory hormone and intermediary 
metabolite changes induced by peritoneal glucose absorption during a
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dialysis cycle are shown in Table 7.VII. Generally, greater changes 
were observed with hypertonic than isotonic fluid. The presence of 
peritonitis showed a greater, increase in glucose, insulin, c-peptide, 
lactate and pyruvate compared to other patients given similar 
hypertonic solutions.
4. HORMONAL AND METABOLITE CHANGES IN DIABETICS ON CAPD
a) Post-Absorptive State
Fasting serum total cholesterol and triglycerides were increased 
(p<0.001) and HDL-cholesterol decreased (p<0.01) in diabetics on CAPD 
compared to controls (Table 7.II). Fasting blood glucose was higher 
(7.3+1.5 mmol/1), but due to the wide individual variation this was 
not significantly different from controls. Serum free (unbound) 
insulin was measured in diabetics and, therefore, not directly 
comparable with the total insulin measured in non-diabetics. Fasting 
c-peptide, glucagon, growth hormone and cortisol were not 
significantly different from controls. The mean fasting c-peptide 
concentration was within the normal range but this was due to 2 
patients having high basal levels and 4 having low concentrations. 
Lactate, pyruvate and alanine were normal but the ketone bodies 
(3-hydroxybutyrate and acetoacetate) and glycerol were increased in 
diabetics (p<0.05).
b) During a Hypertonic Dialysate Cycle
Changes in hormone and metabolite concentrations in diabetics 
during a hypertonic exchange are shown in Figures 7.25 to 7.35 (values 
are mean and SEM). It should be noted that no exogenous insulin 
supplementation was given prior to or during the dialysis cycle. The 
non-diabetic group used for comparison with the diabetics was the
hypertonic (H) group.
Glucose: Blood glucose (Figure 7.25) increased from 7.3 to 14.5
mmol/1 in the first 90 minutes (p<0.05) and then reached a plateau 
over the remainder of the cycle. There was no decline in glucose 
during the 6 hour cycle. The difference in glucose concentrations 
were significant between diabetic and non-diabetics from 1 hour 
onwards (p<0.05).
Insulin: Diabetics showed no change in free (unbound) insulin
(Figure 7.26) in contrast to the endogenous insulin release in 
non-diabetics with hypertonic dextrose solution. Accepting the 
limitations of comparing free with total insulin, it can nevertheless 
be seen that there was an obvious difference in insulin response 
between the groups (p<0.05), particularly during the first 2 hours of 
the dialysis exchange.
C-peptide: Plasma c-peptide concentrations (Figure 7.27) remained
unchanged in diabetics throughout the hypertonic exchange. In 
contrast, non-diabetics had a progressive increase in c-peptide in the 
first half of the cycle and then remained persistently elevated in the 
second half of the exchange. Significant differences were found 
between the 2 groups throughout (0.001<p<0.05). The diabetics had a 
mean c-peptide value of about 1 mmol/1. This was due to 2 patients 
having concentrations in excess of 2 mmol/1 and 3 patients having 
negligible concentrations. However, none of the diabetic patients 
showed any tendency to increase their c-peptide with peritoneal 
glucose absorption.
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Glucagon: Plasma glucagon (Figure 7.28) showed no change in
diabetics throughout the dialysis cycle. Although the non-diabetic 
group had a lower concentration of glucagon in the first half of the 
cycle there was no significant difference between the groups.
Growth hormone and cortisol: Serum growth hormone and plasma
cortisol (Figure 7.29) did not show any change during the 6 hour dwell 
and there was no difference in either hormone between diabetics and 
non-diabetics.
Lactate: Blood lactate (Figure 7.30) in diabetics increased
(p<0.05) over the first hour of dialysis and gradually decreased from 
2 to 6 hours. This was similar to non-diabetics and no difference was 
found between the groups.
Pyruvate: Pyruvate (Figure 7.31) did not show any significant
change in diabetics over the 6 hour exchange. There was no difference 
between diabetics and non-diabetics throughout the cycle. The 
lactate:pyruvate ratio was essentially normal in diabetics throughout 
the exchange (Table 7.V).
Alanine: Blood alanine (Figure 7.32) did not show any change
during the dialysis cycle and there was no difference between diabetic 
and non-diabetic patients.
3-hydroxybutyrate: 3-hydroxybutyrate (Figure 7.34) remained
elevated and did not change in diabetics during the hypertonic glucose 
load. In contrast, the non-diabetics showed a decrease from fasting 
concentrations to a trough level in 1 hour, although the decrement was
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not statistically significant due to the large variation in basal 
concentrations. However, diabetics had significantly higher (p<0.05) 
3-hydroxybutyrate concentrations between 1 and 3 hours than 
non-diabetics.
Acetoacetate: Acetoacetate (Figure 7.35) responded similarly to
3-hydroxybutyrate. In diabetics acetoacetate remained persistently 
elevated throughout the hypertonic exchange. In contrast 
non-diabetics showed a decrease (p<0.05) within the first hour. There 
was marked variation in acetoacetate concentrations in the diabetic 
group particularly towards the end of the cycle. Significant 
differences (p<0.05) were found between the groups at 1 to 2 hours of 
dialysis dwell.
The 3-hydroxybutyrate:acetoacetate ratio remained essentially 
normal in diabetics (Table 7.VI). In contrast the non-diabetics (i.e. 
hypertonic H group) showed a decrease in the ratio between 1 and 3 
hours of the cycle due to a relatively greater fall in 
3-hydroxybutyrate.
Glycerol: Glycerol (Figure 7.33) showed no change during the
dialysis cycle in diabetics and concentrations remained persistently 
elevated. In contrast the non-diabetics had a small but significant 
fall (p<0.05) in glycerol in the first half of the cycle. There was, 
however, no significant difference in glycerol concentrations between 
the two groups throughout the dialysis dwell.
A summary of the hormone and metabolite changes in diabetics in 
the post absorptive (fasting) state and during a high dextrose 
peritoneal dialysis exchange are shown in Table 7.VIII. As previously
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stated, the non-diabetics were patients in the hypertonic (H) CAPD 
subgroup.
In the fasting state glucose was increased and c-peptide was 
decreased in diabetics compared to non-diabetics on CAPD. Glucagon 
was marginally increased in both diabetics and non-diabetics though 
not significantly different from healthy subjects. Fasting growth 
hormone, cortisol, lactate, pyruvate and alanine were unchanged in 
both CAPD groups, xrhile basal ketone bodies and glycerol were 
increased in diabetics.
During the hypertonic (42.5 g/1) dextrose peritoneal load the 
changes due to glucose occurred generally in the early part of the 
cycle. Blood glucose increased but serum free insulin, c-peptide and 
glucagon remained unchanged in diabetics. Growth hormone and cortisol 
were unaltered in both groups. Lactate showed a small increase but 
pyruvate and alanine did not change in diabetics. In contrast to 
non-diabetics the ketone bodies and glycerol were not suppressed by 
peritoneal glucose in diabetics.
5. DIALYSATE, GLUCOSE AND ULTRAFILTRATION
The ultrafiltration volume (UFV) was calculated from the 
difference in weight between the pre- and post-dialysis fluid.
Glucose and lactate were also measured in the dialysate pre- and 
post-exchange. The ultrafiltration volumes and dialysate glucose 
concentrations are shown in Figure 7.36 (values are mean and SEM).
The isotonic (15 g/1) solution had a measured pre-dialysis glucose of 
81.0+0.7 mmol/1 and a post-dialysis glucose of 24.3+2.2 mmol/1. The 
ultrafiltration volume was 150+50 ml for the isotonic group. The 
pre-dialysis glucose concentration for the hypertonic (42.5 g/1) 
solution was 224.6+52.4 mmol/1 and the post-dialysis concentration was
DI
AL
YS
AT
E 
G
LU
CO
SE
 
m
m
ol
/l
<_<_ i
UFV
ml
1000
600H
200H
E DPH
150-J
50H
pre
dialysis □  post dialysisFigure 7.36
Ultrafiltration volumes and dialysate glucose 
concentrations in each CAPD sub-group
42.5+2.0 mmol/1. These values were the mean of 30 hypertonic 
solutions. The mean ultrafiltration volume for the hypertonic groups 
varied between 678 ml and 923 ml for the 6 hour dwell. Dialysate 
effluent glucose concentrations were similar in all hypertonic groups 
and although the ultrafiltration volume was lower in the peritonitis 
group this was not significantly different from the others.
It should be noted that a "2 litre" dialysis fluid bag contained 
marginally more than 2000 ml. A 2 litre 1.5% (isotonic) bag weighed 
about 2100g and a 2 litre 4.25% (hypertonic) bag weighed about 2150g. 
This data was derived from over 100 separate bag weighings including 
the 42 bags used in this study. However, the marginal excess does not 
affect the results and was consistent throughout.
The amount of glucose and lactate absorbed from 2 litres of 
dialysis fluid over a 6 hour cycle is shown in Table 7.IX (values are 
mean and SEM). The isotonic fluid (15 g/1 dextrose) resulted in 21g 
(70%) of glucose being absorbed while the hypertonic solutions (42.5 
g/1 dextrose) resulted in absorption of between 65 and 71g of glucose 
(76-84%). Lactate absorption, 6.6-6.9g (84-88%), was uniform in all 
patients.
Changes in total body weight was a relatively insensitive marker 
of ultrafiltration capacity over a single dialysis cycle. The 
decrease in body weight and measured ultrafiltration volume are shown 
in Table 7.X. No significant correlation was found between change in 
body weight and ultrafiltration volume.
Ultrafiltration showed considerable variability within each group. 
Individual ultrafiltration volumes are plotted against the amount of 
glucose absorbed over 6 hours (Figure 7.37). Apart from the obvious 
difference between the isotonic and hypertonic fluids, ultrafiltration 
varied from individual to individual even though the amount of glucose
absorbed was fairly constant (approximately between 60 and 80g with 
hypertonic solutions). No significant linear correlation was found 
between the quantity of glucose absorbed and ultrafiltration capacity 
for any one group or even all groups combined.
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DISCUSSION
The study is discussed in 5 sections in a similar format to the 
results. Firstly, some comments on the design of the study followed 
by discussion of the metabolic variables in the post-absorptive state 
and then during the peritoneal dialysis cycle. The penultimate 
section discusses diabetics on CAPD and finally comments about 
dialysate changes and ultrafiltration.
1. GENERAL
Glucoregulatory hormones and intermediary metabolites were 
investigated in a 'mixed uraemic population' in a fasting state to 
determine if any specific changes were due to the type of dialysis 
rather than uraemia per se. Metabolic variables were assessed in CAPD 
during a 6 hour dialysis cycle to determine the effects of peritoneal 
glucose absorption. The CAPD population was divided to evaluate 
factors such as age, diabetes and peritonitis which might induce 
further metabolic changes.
This work was performed at a large centre for CAPD but the number 
of patients suitable for investigation was nevertheless limited. To 
date no large, in depth, metabolic study has been published on CAPD. 
The few published reports of hormone and/or metabolite changes in CAPD 
have been limited to 5 patients in each study. The variability of 
metabolite and hormone concentrations even in normal healthy subjects 
is well recognised (Foster et al., 1978) and thus some caution is 
needed in interpretating changes in the metabolic variables.
Values of hormones and metabolites tended to have a normal or
slightly skewed distribution but log transformation was not performed
*
in the analysis. Comparison between the groups was done by analysis 
of variance and p values were derived using the pooled standard
deviation for all groups. However, accepting the statistical 
restrictions comparison between the sub-groups was necessary to assess 
specific clinical factors. The possibility of a type I error is 
increased by the numerous variables and patient groups studied.
2. FASTING STATE
Hyperlipdaemia was present in all uraemic patients. Fasting serum 
total triglycerides were markedly increased in all patients, but total 
cholesterol although increased in all was only significantly elevated 
in CAPD patients. HDL-cholesterol was also uniformly suppressed in 
uraemia. These results are in agreement with many previous studies 
(Olefsky et al., 1974; Sanfellipo et al., 1978; Cattran et al., 1976; 
Ramos et al., 1983). In this study higher cholesterol and 
triglyceride concentrations were found in the CAPD population compared 
to other uraemic patients. The difference could not be readily 
explained by age or body weight and there was no correlation with 
duration of CAPD therapy. Cholesterol and triglycerides have been 
reported to fall after 1 year on CAPD (Lindholm et al., 1983), which 
may indicate a metabolic adaption to the glucose load. It has been 
shown that the total carbohydrate intake in some CAPD patients is 
regulated by the spontaneous reduction of the oral carbohydrate intake 
(Von Baeyer et al., 1983). In the present study lipid status was 
assessed at a single point in time and in view of the well known 
individual variability in blood lipids, a longitudinal type study 
would be more appropriate to evaluate the effect of CAPD on 
hyperlipidaemia. Nevertheless, the marked hyperlipidaemia 
particularly in CAPD (partly carbohydrate induced and accompanied by 
glucose intolerance - type IV) is a major risk factor in 
atherosclerosis. If one then considers other factors, such as
hypertension and possibly hyperglycaemia and hyperinsulinaemia (Keen 
et al., 1965), uraemic and particularly CAPD patients are strong 
candidates for ischaemic heart and other vascular diseases.
In the post-absorptive state (after a 12 hour fast) blood glucose 
was normal in uraemic patients. This has been well documented 
(DeFronzo, 1973, 1978b). However, recent studies on CAPD patients 
have shown increased fasting glucose concentrations (Heaton et al., 
1983, 1985), but in these studies the patients were not truly fasted 
for 12 hours as they had peritoneal dialysis overnight prior to the 
study. Glucose absorption from the overnight exchange could explain 
the increased blood concentrations. This was seen in the present 
study in patients who had an overnight exchange. CAPD is normally a 
continuous 24 hour process, but for comparison with other groups a 
basal reference state is necessary and thus CAPD patients had both an 
oral and peritoneal overnight fast prior to the study.
Fasting insulin has been reported as being increased, normal and 
decreased in uraemia. Normal basal levels have been found by many 
(Spitz et al., 1970; Roth et al., 1973; DeFronzo, 1978b), while others 
have recorded basal hyperinsulinaemia (Hutchings et al., 1966; Briggs 
et al., 1967; Horton et al., 1968). In the present study fasting 
serum insulin was increased in all uraemic groups compared to 
controls, but the difference was small and in most cases not 
significant. Haemodialysis patients had marginally higher insulin 
than non-dialysis uraemics and CAPD patients. Recent studies continue 
to show conflicting data. Haemodialysis patients after a 12 hour fast 
had insulin levels higher though not significantly different from 
controls (Dumbauld et al., 1983), while undialysed chronic renal 
failure patients had significantly higher insulin concentrations 
(Ricanati et al., 1983). However, on reviewing these studies the mean
fasting serum insulin concentrations were similar, but control insulin 
levels varied and this may have accounted for the different 
interpretations. In CAPD basal hyperinsulinaemia was found in 5 
patients in each of Heaton et al. (1983, 1985) studies, but these 
patients did not have a true fast as they had peritoneal dialysis 
prior to the study. Interestingly, in the current study one of the 
two subgroups to have a significant increase in basal insulin was the 
group who had overnight peritoneal dialysis. Thus this may, in part, 
explain some of the divergence of data. Normal fasting insulin 
(Armstrong et al., 1985) and low fasting insulin concentrations (Von 
Baeyer et al., 1983) have also been observed in CAPD. Each of the 
above studies in CAPD evaluated only 5 patients. Larger studies are 
obviously needed. The low basal insulin concentrations were explained 
by peritoneal clearance of insulin (Von Baeyer et al., 1983), but in 
the present study no significant difference was found between 
haemodialysis and CAPD patients.
Thus with these conflicting reports what is the basal insulin 
state in uraemia and CAPD? There is certainly individual variability 
and perhaps some patients have normal and some increased basal insulin 
concentrations depending on their degree of glucose intolerance 
(DeFronzo, 1978b). In the present study 30 CAPD patients, in a truly 
fasted state had a mean basal insulin concentration within the normal 
reference range, which was not significantly different from controls. 
Four individuals had basal concentrations just out with the normal 
range. Thus, on balance, basal insulin was normal in CAPD. In 
addition to individual variability, standards of radioimmunoassay are 
important and it is not feasible to simply compare absolute 
concentrations of insulin found in different studies as the quality of 
standard and anti-sera are bound to vary. It is interesting that
earlier studies found hyperinsulinaemia more frequently than later 
ones. Currently available assays are more sensitive, specific and 
precise compared to methods of 10-15 years ago, when cross-reactivity 
with proinsulin was a major problem and tended to overestimate serum 
insulin concentrations. In the present study the assay method used a 
double antibody technique with inter- and intra-assay coefficients of 
variation of between 5% and 8%. The assay was part of the 
supraregional assay service (SAS) and subject to stringent quality 
control procedures. There was no significant cross-reactivity with 
proinsulin.
C-peptide was grossly elevated in all uraemics and confirms the 
findings of Chapter 6 on beta cell function. Elevated c-peptide 
concentrations have been documented in uraemia (Jaspan et al., 1977) 
and increased levels have also been reported in CAPD (Wideroe et al.,
1984). Raised circulating plasma c-peptide concentrations are due to 
impaired renal degradation, the kidney being almost exclusively 
responsible for metabolism and excretion (Jaspan et al., 1977). 
Interestingly, haemodialysis patients had higher concentrations than 
both non-dialysed chronic renal failure and CAPD patients but the 
difference was not significant. It is possible that residual renal 
function and peritoneal clearance of c-peptide may have contributed to 
the small difference between the uraemic groups. It has been 
suggested that CAPD may increase proinsulin production which could 
lead to an increase in c-peptide (Wideroe et al., 1984). However, 
although proinsulin concentrations are increased in uraemia due to 
impaired renal degradation (Katz et al., 1973) increased production is 
unlikely in CAPD as serum insulin concentrations were normal. 
Furthermore, cross-reactivity between c-peptide and proinsulin during 
the assay was less than 10% using the c-peptide antiserum M1230 (see
Chapter 5).
Fasting plasma glucagon was increased in all uraemic groups with 
significant differences observed in undialysed chronic renal failure, 
haemodialysis and some of the CAPD subgroups. Hyperglucagonaemia in 
uraemia has been documented and is largely due to reduced renal 
clearance (Emmanouel et al., 1976; Kuku et al., 1976) as pancreatic 
secretion is normal in uraemia (Lefebvre and Luyckx, 1975). However, 
in uraemia there is also a marked increase in proglucagon and other 
glucagon intermediates which are not biologically active (Emmanouel e£ 
al., 1976). The assay used in this study specifically measured 
c-terminal (pancreatic) glucagon but some interference with the 
biologically inactive 9000 Dalton precursor cannot be excluded. 
Although elevated, relatively lower concentrations of glucagon were 
found in CAPD patients than other uraemics. After overnight dialysis 
basal glucagon was also found to be increased in three small studies 
(Heaton et al., 1983, 1985; Armstrong et al., 1985), in agreement with 
results in this study. The small difference between CAPD patients and 
others may be due to peritoneal clearance of pancreatic glucagon.
Growth hormone concentrations were markedly variable in the 
uraemic population studied. Generally, no significant differences 
were observed in comparison with controls although haemodialysis 
patients and some CAPD patients had raised fasting concentrations. 
Growth hormone has been reported as normal (Marumo et al., 1979) and 
increased (Saaman and Freeman, 1970; Orskov and Christensen, 1971) in 
uraemia. In CAPD normal fasting growth hormone has also been observed 
(Von Baeyer et al., 1983; Heaton et al., 1985). However, the value of 
isolated concentrations is minimal and growth hormone status is best 
assessed by a dynamic test. The differences found in this study 
between haemodialysis and CAPD patients is small and probably
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unimportant, although better middle molecule clearance of growth 
hormone (MW 21000) by CAPD is a possible explanation.
Pasting plasma cortisol was increased in all uraemic patients, but 
significant elevation was found in the chronic renal failure and 
haemodialysis patients but not in CAPD patients. Only a marginal 
increase was found in CAPD in agreement with others (Heaton et al.,
1985). Considerable controversy exists regarding the 
pituitary-adrenocortical axis in uraemia. Although normal diurnal 
variation in plasma cortisol is described, frequent irregular bursts 
of cortisol secretion occurs interspersed with periods of 
non-secretion (Weitzman et al., 1971). Thus major variations in 
plasma cortisol can occur depending on the time of sampling. Cortisol 
conjugates accumulate in the plasma of uraemics and can cross-react 
with cortisol antibodies. This may lead to gross over-estimation 
(Nolan et al., 1981). Changes in cortisol binding protein which is 
reduced in uraemia can also influence plasma cortisol concentrations 
(Rosman et al., 1984). Thus, it is not surprising that conflicting 
results have been reported. Normal (Nolan et al., 1981) and increased 
(Wallace et al., 1980) fasting cortisol have been described. It is 
interesting, but purely speculative, that CAPD patients, who in this 
study had lower cortisols than other uraemics, may be able to clear 
cortisol conjugates via the peritoneum thus lowering the cortisol 
components measured by radioimmunoassay.
Patients new to CAPD had similar hormone concentrations as those 
well established on the technique. Elderly patients and those with 
peritonitis had similar fasting profiles as other CAPD patients. The 
use of an overnight dialysis cycle did affect some variables, such as 
increasing blood glucose, insulin, c-peptide and cortisol.
Non-dialysed chronic renal failure patients differed from CAPD
patients in having higher glucagon and cortisol concentrations, while 
haemodialysis patients tended to have a generally increased profile 
with raised c-peptide, glucagon, growth hormone and cortisol.
Although the difference between CAPD patients and other uraemics was 
usually small peritoneal clearance of middle molecules may have played 
a role.
Data on intermediary metabolites in uraemia are sparse and only 
one group has studied metabolites in CAPD (Heaton et al., 1983, 1985). 
Thus frequent reference is made to these studies which assessed 
metabolic profiles during a dialysis cycle and also 24 hour metabolic 
rhythms in 2 separate groups of 5 patients on CAPD. Values for 
circulating intermediary metabolites in healthy subjects have been 
documented (Alberti et al., 1975; Foster et al., 1978) and the mean 
and normal reference range for the variables measured in this study 
are given in the Appendix 1. The values are similar to those of 
Foster et al. (1978), who used the same semi-automated enzyme 
fluorometric assays as in this study. These authors found 
considerable variation in intermediary metabolites even in overnight 
fasted, resting, apparently healthy subjects. In the present study 
the precision of the assay was good. The inter- and intra-assay 
coefficients of variation were under 5% for all metabolites except 
3-hydroxybutyrate which had a coefficient of variation of about 12%. 
Acetoacetate and pyruvate were assayed by a manual method, within 48 
hours of sampling, due to their relative instability on storage. 
Precision was again satisfactory with coefficients of variation of 
about 5% (see Chapter 5).
The principle behind the assay of intermediary metabolites depends 
on changes in fluorescence resulting from alterations in NADH 
concentrations produced by enzyme action. Fluorescence that is
non-enzymatic must be taken into account to increase the accuracy of 
analysis. Serum from uraemic patients has a 'native* fluorescence, 
which correlates with the level of serum creatinine and can also be 
affected by drugs (Hadjivassiliou et al., 1984). Thus all samples 
were run with blanks (that is, omitting the enzyme-coenzyme stage in 
the assay), to exclude non-enzymatic or native fluorescence due to 
uraemia. Values for healthy control subjects were similar to 
previously reported normals (Alberti et al., 1975; Foster et al., 
1978).
The three gluconeogenic precursors lactate, pyruvate and alanine 
were not significantly different from controls. The lactate:pyruvate 
ratios were also normal. Fasting blood lactate and pyruvate 
concentrations have been widely reported as normal in chronic renal 
failure, haemodialysis, intermittent peritoneal dialysis and after 
renal transplantation (Campanacci et al., 1968; Attman et al., 1979; 
Parrish, 1981; Nakao et al., 1982). In contrast, elevated fasting 
lactate has been observed in haemodialysis and CAPD (Dumbauld et al., 
1983; Heaton et al., 1985) although pyruvate was normal. The reason 
why lactate was increased while pyruvate was normal in these latter 
studies is unclear, as they are theoretically in equilibrium. Fasting 
blood alanine was normal in all uraemic patients in this study and is 
in agreement with others (Randerson et al., 1981; Deferrari et al., 
1983). In contrast, elevated basal alanine has also been reported in 
dialysis patients (Dumbauld et al., 1983; Heaton et al., 1985). 
However, in the study by Dumbauld et al. the control group had 'low' 
alanine concentrations compared to the usually accepted normal values. 
The circulating concentration of alanine depends on the balance 
between production and uptake. Increased hepatic uptake has been 
reported by some (Rubenfeld et al., 1978) and normal uptake by others
(DeFronzo and Felig, 1980). Thus, it is possible that both normal and 
increased alanine can occur in renal failure depending on the balance 
between production, utilization and uptake as well as other metabolic 
and hormonal events.
The ketone bodies, 3-hydroxybutyrate and acetoacetate, as well as 
glycerol which was used as an index of lipolysis, were generally 
increased in the fasting state in uraemia. 3-Hydroxybutyrate was 
higher in all uraemic patients compared to controls, but significant 
increases were observed only in the non-dialysis chronic renal failure 
group and the elderly CAPD patients. Data in the literature is again 
conflicting. 3-Hydroxybutyrate was increased in chronic renal failure 
(Ricanati et al., 1983), normal in haemodialysis (Dumbauld et al.,
1983) and decreased in CAPD (Heaton et al., 1985). It is also 
documented that fasting ketone bodies increase with age (Foster e£ 
al., 1978) and in the present study the elderly patients had higher 
basal concentrations than the other CAPD patients. The effect of 
overnight dialysis in one study (Heaton et al., 1985) may have 
contributed to suppression of ketogenesis as the patients were not in 
a 'true' fasted state, thus explaining the lower basal ketone body 
concentrations. Acetoacetate was found to be normal in CAPD (Heaton 
et al., 1985) and decreased in haemodialysis (Dumbauld et al., 1983). 
Like 3-hydroxybutyrate, acetoacetate in the present study was higher 
in uraemic patients, but significant increases were found only in CAPD 
patients and primarily due to the elderly subset of patients. 
Acetoacetate is elevated in healthy elderly subjects (Foster et al., 
1978). Bearing in mind the possible suppressive effect of overnight 
peritoneal glucose absorption on ketone bodies, the basal 
concentrations of both 3-hydroxybutyrate and acetoacetate observed by 
Heaton et al. are not too disimilar from the data in the present
study. Fasting glycerol concentrations in the current study were not 
significantly different between either chronic renal failure or 
haemodialysis patients and controls. CAPD patients tended to have 
higher glycerol concentrations particularly the elderly. Glycerol was 
found to be normal in CAPD (Heaton et al., 1985) but increased levels 
are documented in healthy elderly subjects (Foster et al., 1978; 
Davidson et al., 1979; Jackson et al., 1982). Allowing for possible 
suppression of lipolysis due to overnight peritoneal glucose 
absorption, the difference between the ’normal1 glycerol 
concentrations found by Heaton et al. and the ’increased’ glycerol 
found in the present study is small, particularly if the age factor is 
also considered.
Patients new to CAPD had similar metabolite profiles as those well 
established on CAPD. Peritonitis did not have any specific influence 
on basal levels but elderly patients tended to have higher ketone 
bodies and glycerol, which is well recognised in healthy elderly 
subjects.
3. PROFILES DURING CAPD
Glucoregulatory hormones and intermediary metabolites during a 
peritoneal dialysis cycle has been studied to date by only two groups. 
Hormone (Heaton et al., 1983; Armstrong et al., 1985) and intermediary 
metabolites (Heaton et al., 1983) were measured during low and high 
glucose exchanges in 5 patients in each study. The possible effect of 
age, peritonitis and diabetes has not been reported. Diabetics will 
be discussed in the next section.
The change in blood glucose in response to both low and high 
dextrose dialysis solutions in this study confirms the findings of 
others (Heaton et al., 1983; Armstrong et al., 1985). Isotonic
solutions induced only a marginal increase in blood glucose over 6 
hours, while hypertonic solutions caused a significant increase in the 
first hour of dwell and blood glucose returned to basal values by 4 
hours. Elderly patients behaved similarly to younger patients and new 
patients produced the same response as those established on CAPD. 
Patients with peritonitis had an exaggerated increase in blood 
glucose. There was an increase in the rate of blood glucose elevation 
and a higher peak due to the increased permeability of the peritoneum 
due to infection. This increase in permeability has been previously 
documented by several groups (Rubin et al., 1981a; Verger et al.,
1984). However, the total net amount of glucose absorbed from the 
dialysate was similar to non-infected patients using hypertonic 
solutions by the end of the 6 hour cycle. Thus during peritonitis the 
rate of glucose absorption, but not the quantity of glucose absorbed 
is increased. This may reduce the ultrafiltration capacity by 
decreasing the osmotic gradient across the peritoneum, resulting in 
the need for more hypertonic or more frequent exchanges to control 
fluid balance. Furthermore, the increased permeability of the 
peritoneum can affect the pharmacokinetics of intraperitoneal drugs 
(McIntosh et al., 1984) and can also lead to greater protein losses 
(Rubin et al., 1981b).
The serum insulin response mimicked that of glucose, reaching a 
maximum within 1 hour and returning to basal concentrations by 4 
hours. Small increments were seen with 1.5% dextrose solutions but a 
3-fold rise in insulin occurred with the 4.25% dextrose fluid. This 
data is in agreement with others (Heaton et al., 1983; Armstrong 
al., 1985). Elderly and patients new to CAPD did not differ from 
those established on the technique, but the insulin response was 
further increased during peritonitis though not significantly. The
relatively higher insulin response in peritonitis corresponds to the 
increase rate of glucose absorption. The effect of other hormones and
peptides of the 'enteroinsular axis1 such as somatostatin and
gastrointestinal polypeptide are unknown in CAPD.
Hypertonic solutions induced a marked increase in c-peptide due to 
pancreatic stimulation by the peritoneal glucose load. The rate of 
rise was slower than that of glucose and insulin in keeping with the 
lower metabolic clearance rate (Jaspan et al., 1977). The maximum 
response was obtained by 2 hours in agreement with c-peptide kinetic 
studies (Wideroe et al., 1984). The rate of decline of c-peptide was
slow, in comparison with insulin, due to the lower metabolic clearance
rate and its almost exclusive renal degradation. C-peptide did not 
return to basal concentration with hypertonic solutions by the end of 
the 6 hour cycle. This might suggest accummulation of c-peptide, but 
peritoneal clearance does occur (Wideroe et al., 1984) and during 
isotonic exchanges c-peptide returns to basal levels by 4 hours. 
Elevated c-peptide appears to have no metabolic effect (Faber and 
Binder, 1977; Jaspan et al., 1977). In peritonitis both the rate of 
rise and peak response was greater, though not significantly 
different, from other non-infected patients using hypertonic 
solutions. This exaggerated response is due to increased pancreatic 
stimulation caused by the increased rate of glucose absorption due to 
increased permeability of the peritoneum. Elderly patients had a 
similar c-peptide response suggesting that beta cell function, 
assessed by both the insulin and c-peptide response, is no different 
from younger uraemics. This is in agreement with data from 
non-uraemic elderly subjects (Jackson et al., 1982).
During the dialysis cycle hyperglucagonaemia persisted, although 
there was an initial fall in the first hour of dwell corresponding to
the period of maximum glucose absorption and insulin secretion. This 
transient fall in glucagon, although small, was more marked during 
high dextrose cycles. This is in agreement with the findings of 
others (Heaton et al., 1983; Armstrong et al., 1985). Elderly 
patients and those with peritonitis had a similar response to other 
CAPD patients. Thus despite the increased rate of glucose absorption 
and beta cell stimulation glucagon was not suppressed further. In the 
study by Armstrong et al. (1985) higher glucagon concentrations were 
observed in all his 5 patients. This may reflect the presence of 
proglucagon. In the present study a c-terminal specific assay was 
used which measured pancreatic glucagon and concentrations were 
similar to those of Heaton et al. (1983).
The normal response of a fall in growth hormone concentration 
following glucose administration is not seen in uraemia. A 
paradoxical rise during glucose tolerance testing has been observed 
(Wright et al., 1968; Saaman et al., 1970). In haemodialysis high 
levels persist (Spitz et al., 1970) and a paradoxical rise is found 
after a glucose challenge (Swenson et al., 1974). During the 
procedure of haemodialysis growth hormone concentrations fall (Hansen 
et al., 1979), possibly due to the absorption of acetate from the 
dialysis fluid, as i.v. infused acetate inhibits growth hormone 
secretion (Schmitz et al., 1982). In CAPD patients during a dialysis 
exchange there was considerable variation in growth hormone 
concentrations, but levels were essentially normal and did not 
significantly change despite both glucose and lactate absorption.
This is in agreement with others (Von Baeyer et al., 1983), but 
contrasts with the paradoxical rise reported in intermittent 
peritoneal dialysis (Gahl et al., 1980). The reason for the latter 
difference is unclear. Theoretically, CAPD might affect growth
hormone secretion and clearance. The constant glucose absorption over 
24 hours may lead to suppression of growth hormone secretion (Heaton 
et al., 1985). Alternatively, protein losses from the dialysate may 
lead to malnutrition. Malnutrition is associated with raised growth 
hormone (Pimstone et al., 1968) and an inverse relationship between 
serum albumin and growth hormone has been observed (Wright et al., 
1968). Furthermore, growth hormone (MW 21,000) is likely to cross the 
peritoneal membrane and may contribute to lower concentrations in 
CAPD. Whether a balance between the tendency to hypersecretion and 
increased excretion exists is not clear, but in CAPD no paradoxical 
rise in growth hormone has been reported.
Plasma cortisol did not change during the CAPD cycle and 
concentrations were essentially normal. Little is known about 
cortisol secretion in CAPD, but a higher 24 hour secretion was found 
by Heaton et al (1985) due largely to reduced nocturnal suppression. 
This is, in contrast, to observations found in chronic renal failure 
and haemodialysis patients who maintained a normal circadium rhythm 
(Wallace et al., 1980). As previously discussed, CAPD may clear 
cortisol conjugates via the peritoneum, reduced cortisol binding to 
albumin and relative hypoalbuminaemia may also contribute to lower 
cortisol in CAPD than in other forms of uraemia. Interpretation of 
cortisol concentrations in uraemia remains complex. In this study no 
apparent change occurred in response to hyperglycaemia and 
hyperinsulinaemia, suggesting that cortisol is not involved in the 
glucoregulatory hormone control during CAPD, although a ’permissive* 
role for cortisol cannot be ruled out.
Blood lactate increased significantly from normal fasting 
concentrations to peak levels in 1 hour in all CAPD patients. A 
similar rise was seen with both low and high dextrose solutions and,
therefore, was independent of glucose concentration. The blood 
lactate increase was most likely due to the dialysate lactate, which 
was similar in both isotonic and hypertonic solutions, rather than 
secondary to increased glycolysis. The blood lactate profile in new 
and elderly patients was similar to the other non-infected CAPD 
patients and returned to baseline by 4 hours. In peritonitis blood 
lactate increased markedly in the first hour of dwell. This could be 
explained by, either a greater rate of lactate absorption from the 
peritoneal fluid due to increased permeability of the peritoneum, or 
from increased glycolysis due to the greater rate of glucose 
absorption and exaggerated hyperinsulinaemia. Possibly both 
mechanisms play a role, although the increased rate of dialysate 
lactate absorption was probably the major factor. The amount of 
lactate absorbed during the 6 hour cycle was constant, in all groups, 
at about 7g or 28g per day which is much less than the estimated 
endogenous production of 120g per day and maximum utilising ability of 
330g per day (Krebs et al., 1975). Thus dialysate lactate is unlikely 
to have any significant clinical effect on lactate homeostasis. 
Furthermore, the blood lactate rise was relatively transient and 
values of greater than 3 mmol/1 were observed only in a few 
individuals with peritonitis. These levels are not high enough to 
induce lactic acidosis. (>5 mmol/1). Lactate normally increases 
temporarily after exercise but is readily metabolized and utilized 
particularly by the liver. Higher lactate concentrations after 
exercise have been found in uraemics compared to healthy controls by 
some (Parrish et al., 1981), while others (Nakao et al., 1982) 
observed lower concentrations in uraemic patients. However, it is 
unlikely that either lactate or glucose in dialysis fluid per se could 
induce lactate acidosis under normal conditions. A recent case report
of lactic acidosis (Conte et al., 1986), the first documented in CAPD, 
cited lactic acid coma, but this patient had concomitant hepatic 
failure, which was the most likely predisposing factor. In the 
present study, all patients had normal liver function and blood 
lactate concentrations returned to basal levels within 4 hours, again 
evidence that lactate was not accumulating.
Pyruvate, which theoretically is in equilibrium with lactate, 
increased in the first hour of the cycle and was also independent of 
the dialysate glucose concentration. In peritonitis a more marked 
increase in pyruvate occurred in parallel with changes in blood 
lactate. It is more likely that dialysate lactate absorption was 
responsible for the rise in blood pyruvate, but again stimulation of 
glycolysis and suppression of gluconeogenesis by hyperinsulinaemia 
cannot be excluded. The lactate:pyruvate ratio was normal in all 
patients except those with peritonitis. In the latter group the ratio 
increased due to a relative increase in lactate. The only other data 
on blood lactate and pyruvate during CAPD (Heaton et al., 1983) showed 
that basal blood lactate was high but remained unchanged during the 
dialysis cycle, while normal basal pyruvate became elevated during 
hypertonic dialysis. These results are not easily explained.
Blood alanine did not show any significant overall change during 
the peritoneal exchange. There was a small rise in the isotonic, 
elderly and peritonitis groups. This is not surprising as 
hyperinsulinaemia can induce endogenous production by glycolysis and 
suppress utilization by gluconeogenesis. However, this small rise was 
seen with low glucose solutions but not x*ith all high glucose 
solutions. Nevertheless, although the alanine profile did not alter 
significantly a suggested trend similar to the other gluconeogenic 
precursors was observed. Alanine, in theory, is in equilibrium with
lactate, through its equilibrium with pyruvate (Krebs et al., 1975; 
Alberti and Nattrass, 1979). Thus dialysate lactate might also induce 
a rise in alanine. Patients with peritonitis had a small but 
marginally greater relative rise than the other patients using 
hypertonic solutions. This could be explained by,either increased 
glycolysis and suppression of gluconeogenesis by raised ambient 
insulin levels, or secondary to raised blood lactate induced by 
dialysate lactate absorption. It is not possible to clarify which was 
the most important pathway. Blood alanine concentrations, although 
higher, were unchanged with CAPD in the study of Heaton et al. (1983). 
Alanine production and utilization have been observed to be increased 
(Rubenfeld et al., 1978) and also normal (DeFronzo and Felig, 1980) in 
renal failure. In the present study blood alanine showed no obvious 
change despite the ambient hyperinsulinaemia and dialysate lactate 
absorption.
Ketone bodies, 3-hydroxybutyrate and acetoacetate were suppressed 
by peritoneal glucose absorption, the effect being more marked with 
high glucose dialysate. Dialysate induced hyperglycaemia stimulates 
insulin release and suppresses gluconeogenesis and ketogenesis.
During the latter half of the dialysis cycle, when blood glucose was 
returning to basal concentrations, suppression of ketogenesis was less 
marked with isotonic than hypertonic dialysate. The
3-hydroxybutyrate:acetoacetate ratio was essentially normal during the 
CAPD cycle as both ketone bodies fell in parallel, but in the middle 
of the cycle at the point of maximum suppression of ketogenesis the 
ratio increased due to a relatively greater suppression of 
acetoacetate. Similar though less obvious changes were observed by 
Heaton et al. (1983). Although elderly patients had higher basal 
levels of ketone bodies the decrement was similar to other groups
using hypertonic exchanges. The presence of peritonitis despite 
increasing the rate of glucose absorption and did not induce any 
further change in ketone body concentrations.
Glycerol, an indicator of free fatty acid status, was suppressed 
during the dialysis cycle in all patients in a similar manner to the 
ketone bodies. The changes were mainly in the early part of the cycle 
corresponding to the period of maximum hyperinsulinaemia which 
inhibited lipolysis. The suppression of glycerol and free fatty acids 
in response to oral glucose has been long recognised in uraemia (Roth 
et al., 1973). In CAPD, non esterified fatty acids, glycerol and 
ketone bodies correlated with each other, although glycerol did not 
significantly differ from controls in the study of Heaton et al. 
(1983).
'4. HORMONE AND METABOLITE CHANGES IN DIABETICS ON CAPD
No data on hormone or metabolite changes in diabetics on CAPD have 
been reported. The metabolic consequences of diabetes, uraemia and 
peritoneal glucose absorption may be superimposed on each other. In 
this study exogenous insulin (normally given by addition to the 
peritoneal fluid bag immediately prior to instillation) was omitted 
during the dialysis cycle. Thus, this study gave the opportunity to 
investigate the metabolic changes unopposed by insulin. Although all 
6 patients were insulin treated diabetics, 2 did have some residual 
pancreatic function manifested by high basal c-peptide concentrations.
Hypercholesterolaemia, hypertriglyceridaemia and low 
HDL-cholesterol were found in the diabetics but it was not possible to 
conclude whether uraemia, CAPD or diabetes was responsible, as each is 
a predisposing factor to abnormal lipid metabolism.
a) Fasting state
In the fasting state (that is, no overnight dialysis, a 12 hour 
oral fast and no insulin for 12 hours) blood glucose was as expected 
higher than both healthy controls and non-diabetic CAPD patients.
Serum free (unbound) insulin, although not strictly comparable with 
total serum insulin (Nakagawa et al., 1973) was quantitatively similar 
to the 'hypertonic* CAPD group, which was used as the control CAPD 
group in this study. Fasting c-peptide was higher than expected for 
type I diabetics and this can be explained by the presence of 2 
patients who were 'type II-insulin treated' diabetics. Type II 
diabetics frequently have normal or raised c-peptide concentrations 
(Unger and Foster, 1985) and in the presence of uraemia impaired renal 
degradation can markedly increase the c-peptide concentration (Jaspan 
et al., 1977). Hence caution is needed in interpreting isolated 
c-peptide concentrations which may be elevated due to uraemia rather 
than significant residual beta cell function (see Chapter 6). Fasting 
plasma glucagon concentrations were higher, though not significantly, 
than healthy controls but similar to non-diabetic CAPD patients. 
Absolute and relative hyperglucagonaemia are recognised in diabetes 
(Unger and Foster, 1985), but it is unclear from the study whether the 
raised fasting glucagon was due to diabetes or uraemia. However, it 
is interesting that diabetics and uraemics on CAPD had very similar 
concentrations. The role of growth hormone in diabetes is still 
uncertain, but raised growth hormone concentrations are seen in poorly 
controlled diabetes and can cause hyperglycaemia and hyperketonaemia 
(Press et al., 1984). Increased growth hormone may also induce 
insulin resistance in non-diabetics, by impairing both insulin 
supression of hepatic glucose and peripheral utilisation (Rizza et 
al., 1982). However, in this study fasting growth hormone did not
significantly differ from non-diabetic uraemics.
Although cortisol is capable of increasing blood glucose, cortisol 
infusion in healthy subjects failed to increase glucose production and 
even during prolonged fasting plasma cortisol remained normal (Shamoon 
et al., 1981). In this study fasting plasma cortisol concentrations 
were normal in diabetics as well as non-diabetics on CAPD. It is 
suggested that cortisol has no direct short term role in the control 
of glucose in diabetics (Cryer, 1984).
The gluconeogenic precursors lactate and pyruvate have been 
reported to be normal (Nosadini et al., 1985) and increased (Alberti 
et al., 1975) in diabetics on insulin. In type II diabetics improved 
glycaemic control by diet has resulted in lowering fasting lactate 
pyruvate and alanine (Sheppard et al., 1983). In the present study, 
in the relative absence of insulin, fasting lactate and pyruvate were 
similar to both healthy controls and non-diabetic uraemic patients. 
Fasting values were similar to those observed by Sheppard et al. 
(1983). Fasting alanine is usually normal in diabetics (Capaldo et^  
al., 1984; Nosadini et al., 1985) and basal concentrations in this 
study confirmed that diabetics on CAPD were not any different from 
either healthy controls or non-diabetic uraemics. The fasting alanine 
concentrations were similar to those found by others (Potter et al., 
1982; Sheppard et al., 1983). Fasting ketone bodies and glycerol are 
significantly elevated in both type I and II diabetics (Alberti et^  
al., 1975; Sheppard et al., 1983; Nosadini et al., 1985). The 
cardinal factor affecting lipolysis and ketogenesis in the fasting 
state is the balance between insulin and glucagon. In this study 
elevation of 3-hydroxybutyrate, acetoacetate and glycerol were 
observed in diabetics compared to healthy subjects. However, ketone 
body concentrations in diabetics on CAPD were similar to non-diabetic
uraemics and fasting glycerol was also similar to non-diabetic CAPD 
patients although higher than other uraemics. Thus, it is not clear 
whether the rise in ketone bodies and glycerol, due to augmentation of 
ketogenesis and lipolysis, in the post absorptive state was due to 
diabetes or uraemia.
b) During CAPD
Diabetics had a progressive rise in blood glucose over the first 
90 minutes of dialysate instillation and then reached a plateau, the 
hyperglycaemia being unopposed due to the lack of insulin. Serum free 
insulin remained unchanged throughout the period of peritoneal glucose 
absorption. Two patients (type II insulin treated diabetics) did show 
a small, but insignificant rise in free insulin which might have 
suggested some residual pancreatic function. This is, in contrast, to 
the non-diabetic CAPD patients who had a significant rise in total 
serum insulin. Mean c-peptide concentrations were relatively 
increased but remained unchanged during the dialysis cycle. Raised 
mean concentrations were due to 2 patients having high c-peptide 
levels, while the others had negligible concentrations. The elevated 
levels of c-peptide may be explained, in part, by some residual 
pancreatic function, but largely by impaired renal degradation of the 
peptide. However, as c-peptide concentrations did not change despite 
the dialysis induced hyperglycaemia it can be concluded that no 
clinically significant beta cell reserve existed in any of the 
diabetics.
A pure carbohydrate meal normally causes suppression of glucagon 
and stimulation of insulin but signals other than the absorbed glucose 
may be responsible for the alpha and beta cell peptide changes. 
Somatostatin is a strong suppressor of glucagon and may play a role in
response to an oral carbohydrate load (Unger and Foster, 1985). 
Gastrointestinal polypeptide, which is released during a carbohydrate 
meal, is a stimulus to insulin secretion. When the insulin response 
is adequate (as in non-diabetics) the stimulating effect of 
gastrointestinal polypeptide upon glucagon is not apparent because of 
concomittant suppression of glucagon by insulin. However, in 
diabetics the insulin response is blunted and the glucagon response to 
an oral carbohydrate load becomes paradoxically positive. This may be 
a consequence of the unoppossed actions of gastrointestinal 
polypeptide on the acells of the pancreas (Unger and Foster, 1985).
In this study diabetics showed no change in glucagon while 
non-diabetics had a fall in response to the dialysate glucose 
absorption. It is not known whether peritoneal glucose absorption 
stimulates the enteroinsular axis although most of the glucose is 
absorbed into the portal circulation. The actions of somatostatin and 
gastrointestinal polypeptide are unknown in CAPD.
As previously discussed, the role of growth hormone in diabetes is 
unclear but several reports link increased plasma growth hormone with 
poorly controlled diabetes (Vigneri et al., 1976; Press et al., 1984). 
The small group of diabetics in this study had good glycaemic control, 
assessed by glycosylated haemoglobin measured colorimetrically.
Growth hormone did not show any change during the dialysis cycle in a 
similar manner to non-diabetics. Thus, neither raised concentrations 
due to the presence of diabetes or a paradoxical rise due to uraemia 
(Orskov et al., 1971) were observed during peritoneal glucose 
absorption. Whether prior good glycaemic control or the specific 
effect of CAPD prevented changes in growth hormone is unclear. Growth 
hormone probably has a permissive rather than glucoregulatory role in 
diabetes (Cryer, 1984).
Cortisol, like growth hormone, probably has a permissive rather 
than regulatory role in diabetes (Cryer, 1984). Thus, it is not 
surprising that no change in cortisol occurred during peritoneal 
glucose absorption, even in the absence of exogenous insulin. Normal 
plasma cortisol concentrations were observed in both diabetics and 
non-diabetics throughout the dialysis cycle. It is possible, though 
speculative, that peritoneal removal of cortisol conjugates could 
explain the normal values found in all CAPD patients, in contrast to, 
elevated concentrations in non-dialysed chronic renal failure and 
haemodialysis patients.
Lactate concentrations are usually normal (Nosadini et al., 1985) 
or slightly increased (Capaldo et al., 1984) in diabetics with 
'average* glycaemic control. The normal response after oral glucose 
or a meal would be to increase lactate due to increased glycolysis 
modulated by insulin release. However, in this study despite the lack 
of insulin, blood lactate had a small, though significant increase in 
diabetics during the first hour of dwell similar to non-diabetics.
The most likely explanation for the rise in blood lactate was 
dialysate lactate absorption rather than an increase in endogenous 
lactate via glycolysis. It was also observed that the decline in 
blood lactate was slower in diabetics suggesting suppression of 
lactate utilization due to insulin deficiency.
Pyruvate was marginally but not significantly higher in diabetics 
in the fasting state in agreement with Nosadini et al. (1985).
However, during peritoneal glucose absorption pyruvate did not change 
in diabetics although increased in non-diabetics. The lack of change 
in pyruvate may be explained by the failure to suppress 
gluconeogenesis. and inhibition of glycolysis due to insulin 
insufficiency. Although, theoretically, lactate and pyruvate are in
equilibrium the dialysate lactate absorption would explain the greater 
change in lactate than pyruvate.
Alanine is usually normal in well controlled diabetics (Potter e£ 
al., 1982; Capaldo et al., 1984; Nosadini et al., 1985) but several 
reports of raised blood alanine have been documented, particularly 
after pancreatectomy (Barnes et al., 1975; Del Prato et al., 1985).
In this study diabetics had normal alanine concentrations which did 
not change with peritoneal glucose absorption. This might be due to 
lack of insulin stimulation with failure to increase glycolysis and 
suppress gluconeogenesis, but the non-diabetics who had a significant 
hyperinsulinaemia also failed to induce a significant increase in 
alanine, although some patients did show a small rise compatible with 
insulin mediated glycolysis.
Ketogenesis and lipolysis are under integrated control and 
represent a link between carbohydrate and lipid metabolism. Ketone 
bodies accumulate in plasma during fasting and uncontrolled diabetes 
and the initiating event is a change in the molar ratio of glucagon to 
insulin. Insulin deficiency triggers the lipolytic process liberating 
free fatty acids and glucagon appears to be the primary hormone 
involved in fatty acid oxidation and the formation of ketone bodies 
(Miles et al., 1980; Foster and McGarry, 1982).
Normally ketone bodies and glycerol are suppressed by glucose 
loading, but in this study diabetics in contrast to non-diabetics 
failed to suppress 3-*hydroxybutyrate and acetoacetate. This can be 
explained by insulin deficiency and relative glucagon excess.
Glycerol did not change from fasting concentration in diabetics 
despite glucose absorption whereas non-diabetics had a significant 
fall in the early part of the cycle. Again, the imbalance between 
insulin and glucagon explains the failure to suppress lipolysis in
diabetics.
5. DIALYSIS FLUID AND ULTRAFILTRATION
In view of the potential hazards from excessive dialysate glucose 
absorption, such as hyperlipidaemia and accelerated altherosclerosis 
it is prudent to limit the number of hypertonic exchanges, but many 
patients require at least one high dextrose cycle per day. On a 
typical regimen of 3 isotonic (1.5% dextrose) and 1 hypertonic (4.25% 
dextrose) cycles, it is estimated from this study that 130g of glucose 
is absorbed per day from the peritoneal cavity. This is in agreement 
with data from others (Nolph et al., 1979; Grodstein et al., 1981). 
Although the rate of glucose absorption varies between individuals, 
reflecting individual peritoneal characteristics the total amount of 
glucose absorbed was quite uniform. In 30 CAPD patients using 4.25% 
dextrose solutions (2 litres) glucose absorption was between 60 and 
80g over a 6 hour dwell, but the ultrafiltration volume varied 
considerably.
Ultrafiltration depends on many factors such as the state of 
hydration, residual renal function, catheter mechanics, integrity of 
the peritoneum and the osmotic gradient between blood and dialysate 
(Nolph, 1983). Nolph et al. (1981) postulated that ultrafiltration 
takes place at the proximal side of the peritoneal capillary network 
and glucose absorption at the distal end of the network. The proximal 
end has a higher hydrostatic pressure and there is low solute 
permeability due to 'tight* (10A°) cell junctions. The distal end has 
lower hydraulic pressure and wider cell separation (40A°). This 
theory suggests different sites for glucose absorption and water 
removal. It has also been shown that ultrafiltration capacity can be 
severely reduced while solute (glucose) transfer remains unaffected
(Manuel, 1983). Thus, it is not surprising that no significant 
correlation was found between the amount of glucose absorbed from the 
dialysate and net ultrafiltration.
Hyperglycaemia per se may reduce the osmotic glucose gradient and 
decrease the ultrafiltration capacity, but in this study diabetics who 
had persistent hyperglycaemia did not show reduced ultrafiltration.
In contrast, patients with peritonitis had reduced ultrafiltration.
In peritonitis the rate of dialysate glucose absorption increased and 
this had been previous verified by others (Rubin et al., 1981a; Verger 
et al., 1984). However, the total amount of glucose absorbed over the 
6 hour cycle was the same as in other patients using similar dextrose 
solutions. Overall, glucose absorption and ultrafiltration were 
similar in new and established patients, as well as the elderly and 
diabetics using the same concentration of glucose in the dialysate. 
Thus the rate of glucose absorption as well as the concentration of 
glucose is important in respect to ultrafiltration. The method of 
assessing ultrafiltration in this study was crude, but easily 
applicable to any patient, especially at an out-patient clinic. More 
accurate kinetic models for solute transfer and ultrafiltration 
measurement have been designed (Spencer and Farrel, 1986). Although 
more applicable for research purposes, further information on the 
viability and integrity of the peritoneum needs to be obtained to 
determine the durability of CAPD.
Dialysate volume measurements based on dilution of high molecular 
weight marker molecules have shown that with a 2 litre hypertonic 
exchange (3.86% dextrose) the ultrafiltration volume peaked at 3.0-3.3 
litres at 3 hours and, thereafter, reabsorption took place and the 
ultrafiltration rate varied between 25 ml/min and -1.5 ml/min (Pyle et^  
al., 1981). Thus at the start of the dialysis cycle the glucose
gradient and ultrafiltration rate are highest. These fall as the 
dwell time lengthens and after long dwells glucose may diffuse back to 
the dialysate and water may be reabsorbed.
Peritoneal lactate absorption was constant in all groups and 
amounted to 6.8g during a 6 hour cycle or about 28g per day. As 
previously discussed, this adds little to the normal endogenous 
lactate production of about 120g/day (Krebs et al., 1975). During 
peritonitis, the rate of lactate absorption increased but the rise in 
blood concentration was not sufficient to induce lactic acidosis and 
the effect was only temporary. Thus dialysate lactate, in the 
presence of normal liver function, does not adversely affect lactate 
homeostasis. Lactate in commercial dialysis solutions is present in a 
racemic configuration. The lactate measured in this study did not 
distinguish between the L(+) and D(-) species, but the clearance of 
lactate from the peritoneal cavity is relatively stereospecifc. The 
L(+) isomer has a greater clearance from the peritoneum than the D(-) 
and the latter is less readily metabolised (Rubin et al., 1982). 
However, the difference in clearance between the two isomers is only 
about 2.5 ml/min and probably not clinically significant.
SUMMARY
Hyperlipidaemia was observed in all uraemic patients, but 
hypercholesterolaemia and hypertriglyceridaemia were most marked in 
CAPD and particularly diabetics on CAPD. This emphasises the role of 
glucose intolerance, hyperinsulinaemia and carbohydrate induced 
hyperlipidaemia and the risk of coronary heart disease in patients 
with end stage renal disease.
In the fasting state glucose and insulin were normal although 
haemodialysis patients tended to have marginally increased insulin 
concentrations. C-peptide was grossly elevated in uraemia due to 
impaired renal degradation. Glucagon was generally increased, while 
cortisol was normal in CAPD patients though increased in other 
uraemics. Growth hormone was essentially normal in most uraemic 
patients. The gluconeogenic precursors, lactate, pyruvate and alanine 
were normal in the post-absorptive state, but ketone bodies and 
glycerol tended to be higher in uraemia particularly in the elderly 
CAPD patients.
Hormone and intermediary metabolite profiles during a peritoneal 
dialysis cycle generally showed greater changes with the higher 
dextrose solutions. Peritoneal glucose absorption produced 
hyperglycaemia which induced hyperinsulinaemia and an increase in 
c-peptide. Glucagon decreased while growth hormone and cortisol were 
unchanged. Lactate and to a lesser extent pyruvate increased during 
the cycle. This was largely due to absorption of dialysate lactate as 
the increase appeared to be independent of dialysate glucose 
concentration, although some endogenous production of lactate and 
pyruvate from glycolysis cannot be excluded. Alanine was unchanged 
throughout the cycle. Ketone bodies and glycerol were suppressed 
during peritoneal glucose absorption. Thus dialysate glucose
absorption causes hyperglycaemia and the concomitant hyperinsulinaemia 
stimulates glycolysis, inhibits gluconeogenesis and suppresses 
ketogenesis and lipolysis. Peritonitis increases the permeability of 
the peritoneum and enhances the rate of glucose absorption which 
induces a more marked hyperinsulinaemia, although glucagon was not 
further suppressed. The elevated lactate and pyruvate during 
peritonitis was most likely due to increased dialysate lactate 
absorption, but increased endogenous production due to 
hyperinsulinaemia cannot be excluded. Ketogenesis and lipolysis were 
not further suppressed by peritonitis. Elderly patients who had 
higher basal concentrations of ketone bodies and glycerol had similar 
profiles as other patients.
Hormones and intermediary metabolites in diabetics on CAPD were 
deranged with the deprivation of exogenous insulin. Peritoneal 
glucose absorption produced persistent hyperglycaemia and no beta cell 
response. Glucagon, growth hormone and cortisol were unchanged. 
Lactate increased despite the absence of hyperinsulinaemia due to 
dialysate lactate absorption, while pyruvate and alanine were 
unaltered during the cycle. Ketone bodies and glycerol were not 
suppressed despite the ambient hyperglycaemia due to the lack of 
endogenous and exogenous insulin. Thus insulin deficiency and 
relatively normal or increased glucagon failed to stimulate 
glycolysis, while gluconeogenesis, ketogenesis and lipolysis were 
maintained.
Glucose absorption from the peritoneal dialysate in general terms 
is similar to an oral glucose load, although the role of the 
entero-insulin axis is not known in CAPD. The essential role of 
insulin in controlling metabolic substrates during CAPD is clearly 
shown. During CAPD hyperinsulinaemia stimulates glycolysis and
inhibits gluconeogenesis, ketogenesis and lipolysis. It should be 
noted that normally the CAPD patient is never truly fasted as dialysis 
normally continues 24 hours per day, every day. It is estimated that 
about 130g of glucose per day is absorbed from the dialysis fluid, in 
addition to the oral carbohydrate intake. It is, therefore, important 
that caloric and dietary intake is regularly reviewed and ideally an 
individual dietary prescription should be formulated to minimise 
obesity and hyperlipidaemia.
The long term sequelae of the metabolic consequences remain to be 
seen, but the risks, particularly of vascular disease have to be 
balanced against the alternatives. Although renal transplantation is, 
undoubtedly, the preferred mode of treatment for end stage renal 
disease it is not suitable or available for all patients.
Haemodialysis is also not suitable or available for all patients and 
hypertension and fluid balance are usually better controlled by CAPD. 
The other alternative is CAPD, thus the metabolic effects and 
potential consequences of CAPD need to be assessed in perspective.
CHAPTER 8
GLYCOSYLATED AND CARBAMYLATED HAEMOGLOBIN IN URAEMIA
INTRODUCTION
Glycosylated haemoglobin, as an indicator of integrated long term 
blood glucose control, in diabetics with normal renal function is well 
established clinically and biochemically (Gabbay et al., 1977; Jovanic 
et al., 1981). Recently, a possible pathophysiological significance 
has been suggested between the formation of non-enzymatic 
glycosylation of proteins and the complications of diabetes mellitus 
(Cohen, 1986). This has been discussed in Chapter 4. Glycosylated 
haemoglobin status in uraemia is complex and controversial with 
reports of elevated, normal and reduced concentrations.
Elevated concentrations of haemoglobin A-^ (HbA^ ) and HbA^c in 
non-diabetic uraemic patients has been frequently documented (De Boer 
et al., 1980; Graf et al., 1980; Kovarik et al., 1981; Fluckiger et_ 
al., 1981). Normal concentrations of total glycosylated haemoglobin 
in the red cell have been reported (Fluckiger et al., 1981; Nath et 
al., 1982) in renal failure. Reduced concentrations of HbA-^  have also 
been observed in uraemia (Dandona et al., 1979; Freedman et al.,
1982). Haemoglobin A-^ has been reported to be higher in uraemic 
diabetics than non-uraemic diabetics (Kumar et al., 1983), but others 
have found no difference between similar groups (Panzetta et al.,
1983).
Several explanations have been forwarded to account for the 
elevation of glycosylated haemoglobin in renal failure such as 
co-existing hyperglycaemia and glucose intolerance (Casparie et al., 
1977; Stanton et al., 1978). However, many more recent studies have 
found no association with impaired glucose metabolism in non-diabetic 
uraemic patients (Graf et al., 1980; Kovarik et al., 1981; Nath et 
al., 1982; 0'Regan et al., 1982; Saloranta et al., 1986). Evidence 
that a direct effect of uraemia is responsible, is supported by the
correlation between HbA^ and plasma creatinine (Kovarik et al., 1981) 
and urea (DeMarchi et al., 1983a), although the latter authors favour 
the role of acidosis as the cause of increased glycosylated 
haemoglobin. Interference in the measurement of HbA^ by some 
non-glucose adduct such as urea has been demonstrated (Fluckiger e£ 
al., 1981). These authors suggest that haemoglobin carbamylation 
results from urea-derived cyanate and this may be responsible for the 
rise in glycosylated haemoglobin in uraemia. Reduced concentrations 
of glycosylated haemoglobin in renal failure have been postulated to 
be due to the reduced red cell life span (Freedman et al., 1982).
Objectives
In view of the complex and conflicting data in the literature this 
study aimed to reassess and clarify the subject of glycosylated 
haemoglobin in uraemia. The objectives of the study were:-
1. To evaluate glycosylated haemoglobin in a large uraemic 
population including non-dialysis, dialysis and transplant 
patients, as well as diabetics with and without renal failure.
2. To compare different methods of measuring glycosylated 
haemoglobin (from the same blood sample);
a) by cation chromatography to detect HbA^ and specific 
components HbA^Q and HbA^a+ .^
b) by a specific chemical method using colorimetry to detect the 
total glycosylation in the red cell.
3. To measure carbamylated haemoglobin simultaneously with 
glycosylated haemoglobin and to investigate the possible 
associations.
4. To clarify the role of glycosylated haemoglobin in uraemia and in 
diabetics with renal failure.
METHODS
1. Patients
Over 200 subjects were studied to evaluate glycosylated and 
carbamylated haemoglobin in a wide spectrum of renal disease. Nine 
groups of subjects were investivated. The abbreviations for each 
group are used throughout the Chapter.
Group
1 Control (healthy volunteers)
2 PRD (primary renal disease)
3 CRF (chronic renal failure)
4 CAPD (continuous ambulatory peritoneal dialysis)
5 HD (haemodialysis)
6 Tx (transplants with normal renal function)
7 Tx-RF (transplants with renal failure)
8 D (diabetics with normal renal function)
9 D-RF (diabetics with renal failure)
A further 9 haemodialysis patients were studied pre- and 
post-dialysis to assess the effects of the procedure. Patients in the 
PRD group had proven underlying renal disease (mainly 
glomerulonephritis, polycystic kidney disease or tubulointerstitial 
disease) with normal blood urea and creatinine. Impairment of 
glomerular filtration rate and proteinuria were not excluded. The CRF 
group consisted of patients with wide degrees of renal impairment from 
mildly elevated creatinine to end stage renal disease, but none of the 
group were on dialysis. The CAPD and HD groups comprised patients 
established on dialysis for at least 6 months. Transplant patients
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with normal renal function had normal blood chemistry but impairment 
of the glomerular filtration rate and proteinuria were not excluded. 
Transplants with renal failure had persistently elevated urea and 
creatinine but were managed without dialysis. Diabetics with normal 
renal function (14 type I, 8 type II) had normal urea and creatinine 
but milder degrees of diabetic nephropathy, such as abnormal 
glomerular filtration and proteinuria, were not excluded. Diabetics 
with renal failure (20 type I, 4 type II) had elevated urea and 
creatinine and 8 patients in this group were on dialysis.
2. Study criteria
None of the patients had a blood transfusion within 3 months of 
the study or any detectable haemoglobinopathy. Liver disease, 
alcoholism, jaundice and recent alcohol ingestion were all exclusion 
criteria. Some of the patients had hyperlipidaemia but this was not 
formerly screened or excluded. Drug therapy was not altered for this 
study. All transplant patients took prednisolone and either 
cyclosporine A or azathioprine. Uraemic patients were taking many 
drugs but the only exclusion was aspirin or antibiotic medication at 
the time of the study. None of the patients were diabetic other than 
the two diabetic groups.
3. Protocol
Random venous blood samples were taken from subjects usually 
during out-patient clinic visits and after informed consent. Blood 
was taken for the simultaneous measurement of glucose, full blood 
count, urea, electrolytes, creatinine, liver function tests, 
glycosylated and carbamylated haemoglobin. Blood for glycosylated 
haemoglobin was allowed to stand for 24 hours at 4°C to reduce the
’labile' fraction in diabetics. None of the diabetics had severe 
hyperglycaemia at the time of sampling. To assess the effect of 
haemodialysis blood was taken immediately pre-dialysis (i.e. 48 hours 
after last dialysis) and post-dialysis (after a 4 hour session). 
Arterial blood for H+ ion concentration and bicarbonate was taken from 
the arterial line in the 9 patients investigated during haemodialysis. 
Ethical committee approval was obtained for this study.
4. Assays
Glycosylated haemoglobin was measured by 2 distinct methods. 
Firstly, total glycosylation in the red cell by the thiobarbituric 
acid - colorimetric method (Fluckiger and Winterhalter, 1976) with 
modifications as described in Chapter 5. Red cells were washed, lysed 
and hydrolysed to split off the glycosyl moiety which converts to 
5-hydroxymethylfurfural (5HMF) (as shown in Figure 4.2). The 5HMF was 
then measured colorimetrically following reaction with thiobarbituric 
acid. Within and between batch coefficients of variation were 3.5% 
and 6% respectively.
Secondly, cation chromatography using minicolumn commercial kits 
estimated HbA-^  and the specific components HbA-^ c and HbA-^ a+ .^ The 
kits were from BioRad laboratories and the methods are fully described 
in Chapter 5. The chromatographic methods used whole blood 
haemolysate which was applied to a weakly acidic cation exchange 
resin. An elution/developing reagent was then added to the column 
which separated the fast moving components. By using specific buffers 
the components were separated. The within and between batch 
coefficients of variation were approximately 3% and 6% respectively.
Carbamylated haemoglobin was estimated by quantifying the amount 
of valine (isopropyl) hydantoin released from the acid hydrolysis of
globin. Valine hydantoin was then measured by gas liquid 
chromatography. The method was adapted from Manning et al. (1973) and 
Fluckiger et al. (1981) with modifications as described in Chapter 5. 
The reaction is represented in Figure 8.1. All samples were assayed 
in duplicate and between assay variation was 12%.
5. Statistics
Parametric tests were used as glycosylated and carbamylated 
haemoglobin had a normal distribution. In view of the multiple groups 
investigated analysis of variance was used for comparison between 
groups. In calculating the ' t' statistic the "combined standard 
deviation" was employed. Comparison between pre- and post-dialysis 
data was done using the paired ftf test. Correlations were sought by 
linear regression analysis. Analysis of ratios were done by the 
Mann-Whitney non-parametric test.
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RESULTS
1. General data
Sex and age (mean and SD) are shown for each group in Table 8.1. 
The control group were the youngest and the CAPD group the oldest, but 
most of the other groups were, of comparable age, between 40 and 50 
years. Haemoglobin, packed cell volume (PCV) and serum albumin are 
shown in Table 8.II (mean and SEM). Haemoglobin and PCV were 
decreased in all groups with renal failure (p<0.001) compared to 
controls, while diabetics and transplants with normal renal function 
had similar values to controls. Albumin was normal in all groups 
except the CAPD group which had a lower albumin concentration 
(p<0.05).
Blood urea, serum creatinine and plasma bicarbonate (mean and SD) 
are shown in Table 8.III. The primary renal disease (PRD), transplant 
(Tx) and diabetic (D) groups had normal urea and creatinine 
concentrations while all the other groups had increased urea and 
creatinine (p<0.001). Bicarbonate was statistically reduced in all 
the renal failure groups compared to controls (p<0.01).
Random blood glucose (mean and SEM) values are shown in Table 
8.IV. Glucose concentrations were normal in all but the 2 diabetic 
groups which had significantly increased concentrations (p<0.001).
Most diabetics with or without renal failure had random glucose 
concentrations under 12 mmol/1 and all were below 16 mmol/1.
2. Glycosylated haemoglobin
Glycosylated haemoglobin measured by the colorimetric method was 
evaluated in about 100 patients prior to this study. This confirmed 
that glycosylated haemoglobin by this technique (GHb) was elevated
Group n Sex
M F
Age
1 C 20 9 11 33.1 ( 7.4)
2 PRD 22 13 9 41.7 ( 8.9)
3 CRF 40 25 15 52.2°( 8.3)
4 CAPD 24 12 12 57.7C (11.8)
5 HD 31 18 13 44.0b( 7.9)
6 TX 16 7 9 38.8 ( 9.7)
7 TX-RF 14 12 2 40.6 (10.9)
8 D 22 9 13 46.5b( 9.9)
9 D-RF 24 16 8 49.8b(10.2)
Age - values are mean and (SD) 
p values refer to comparison with controls 
b - p <0.01
Table 8 . I c - p <0.001 Clinical Data
Sex and Age
Group n Haemoglobin
g/dl
PCV
%
Albumin
g/1
1 C 20 14.6 (0.3) 43.8 0.9) 47 (0.6)
2 PRD 22 14.7 (0.2) 43.9 0.6) 42 (1.2)
3 CRF 40 10.^ (0.3) 32.4° 1.0) 40 (0.7)
4 CAPD 24 9.6° (0.3) 28.8° 0.9) 36a (0.9)
5 HD 31 9.0° (0.4)
c
27.7 1.2) 43 (1.0)
6 TX 16 14.0 (0.5) 42.0 1.3) 43 (1.0)
7 TX - RF 14 12.5b(0.5) 37.0 1.4) 41 (0.8)
8 D 22 14.0 (0.3)
c
42.1
c
1.0) 41 (1.4)
9 D-RF 24 11.0 (0.5) 33.7 1.5) 38 (1.2)
Values are mean and (SEM) 
p values refer to comparison with controls 
Table 8. II a - p <0.05 . . ~
b - p <0.01 Clinical Da
c - p <0.001
Haemoglobin 
and Albumin
Group n UREA
(mmol/1)
CREATININE
(pmol/1)
BICARBONATE
(mmol/1)
1 C 20 5.1 (1.1) 89 ( 20) 27.7 (6.2)
2 PRD 22 5.8 (1.2) 97 ( 21) 27.8 (5.9)
3 CRF 40 24.7° (3.9) 521° ( 82) 22.3k(3.5)
4 CAPD 24 20. 3C ( 4.1) 998° (204) 23.7^ (4.8)
5 HD 31 21.3°(3.8) 967° (174)
b
23.4 (4.2)
6 TX 16 6.9 (1.7) 111 ( 28) 26.6 (6.7)
7 TX-RF 14 13.0°(3.5) 277° ( 74)
b
24.3 (6.5)
8 D 22 5.6 (1.2) 87 ( 19) 26.7 (5.7)
9 D-RF 24 20.1° (4.1) 466° ( 95) 25.2 (5.1)
Table 8. Ill
Values are mean and (SD) 
p values refer to comparison with controls
k ~ n’m  Clinical Datab - p< 0.01
c - p< 0.001 Urea, Creatinine, Bicarbonate
Group n Glucose (mmol/1)
1 C 20 4.0 (0.2)
2 PRD 22 3.8 (0.1)
3 CRF 40 4.1 (0.1)
4 CAPD 24 4.5 (0.2)
5 HD 31 4.4 (0.2)
6 TX 16 4.1 (0.2)
7 TX - RF 14 4.1 (0.3)
8 D 22 9.4C (0.8)
9 D-RF 24 7.2F (0.7)
Table 8. IV
Values are mean and (SEM) Clinical Data
p values refer to controls
c - p <0.001 Glucose
GLYCOSYLATED HAEMOGLOBIN - COLORIMETRIC METHOD
Subjects n GHb (mmol HMF/mol Hb)
A) Controls 17 35.9 (0.7)
B) Uraemia 60 37.0 (0.4)
CRF 13 38.3 (0.9)
CAPD 31 35.8 (0.9)
HD 16 37.1 (0.8)
C) Diabetes 22 50.6 (2.2)
No Uraemia 4 55.8 (4.2)
CRF 5 55.0 (3.3)
CAPD 9 49.3 (3.8)
HD 4 43.5 (4.7)
Values are mean and (SEM)
A v B NS
A v C p < 0.001
B v C p < 0.001
Table 8 . V
Glycosylated Haemoglobin measured by the TBA - colorimetric 
method in pilot study.
only in diabetics. Results are shown in Table 8.V (mean and SEM). 
Non-diabetic uraemic patients and healthy controls had similar GHb 
concentrations, whereas diabetics had significantly higher 
concentrations (p<0.001).
Glycosylated and carbamylated haemoglobin (CHb): Table 8.VI shows the 
values of glycosylated haemoglobin (GHb, HbA^, HbA^c, + )^ and
carbamylated haemoglobin for 6 groups. The PRD, Tx and Tx-RF groups 
are discussed later. Values are mean, (SEM) and [95% confidence 
intervals]. Comparison of these results are shown below.
HbA :^ Figure 8.2a shows the scatter of HbA-^  values for each group 
(transplants are shown later) and Figure 8.2b shows the mean, 95% 
confidence interval and statistical difference between the groups.
HbA^ was elevated in all 3 non-diabetic uraemic groups and in both 
diabetic groups. The haemodialysis (HD) group had a lower HbA^ than 
the other non-diabetic uraemic groups. Both diabetic groups had 
significantly higher HbA^ than non-diabetics (p<0.001). The mean 
level of HbA^ was similar in both diabetics groups.
HbA-j^ : Figure 8.3a shows the scatter of HbA^c values and Figure 8.3b 
shows the mean, 95% confidence interval and statistical difference 
between the groups. The 3 non-diabetic uraemic groups (CRF, CAPD, HD) 
had increased HbA^c values compared to controls although there was 
some overlap. Statistically there was no difference between the HD 
group and controls although the other non-diabetic uraemic groups had 
significantly increased HbA^c concentrations. The diabetic groups had 
significantly increased HbA^c compared to controls and non-diabetic 
uraemic subjects (p<0.001). There was no difference between the
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diabetic groups.
HbAia+b: Figure 8.4a shows the scatter of HbA^a+  ^values and Figure 
8.4b the mean, 95% confidence interval and statistical difference. 
HbA^a^  was significantly increased in all uraemic and diabetic groups 
compared to controls (p<0.001). The scatter of HbA^a+  ^values was 
similar in both uraemia and diabetics. The HD group had the lowest 
mean HbA^a+  ^concentration of the uraemic groups and was significantly 
lower than the CAPD group (p<0.001) but not significantly different 
from the CRF group. Diabetics with renal failure had a marginally 
higher mean than diabetics with normal renal function but the 
difference was not significant. Diabetics with renal failure had 
similar HbA^a+  ^concentrations as the CAPD group and both were higher 
than the CRF group.
GHb: Figure 8.5a shows the scatter of GHb values and Figure 8.5b the 
mean, 95% confidence interval and statistical difference.
Glycosylated haemoglobin measured by colorimetry was elevated only in 
the presence of diabetes (p<0.001). There was no difference between 
diabetics with normal or impaired renal function. GHb was similar in 
non-diabetic uraemics and controls.
CHb: Figure 8.6a shows the scatter of CHb values and Figure 8.6b the 
mean, 95% confidence interval and statistical difference. Although 
there was a wide scatter of CHb concentrations there was no overlap 
between individuals with renal failure and normal renal function. All 
uraemic groups including diabetics with renal failure had gross 
elevation of CHb (p<0.001). The HD group had a lower mean CHb 
concentration than the CRF and CAPD groups (p<0.01), but this was not
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statistically different from diabetics with renal failure.
3. Comparison of glycosylated haemoglobin methods
Glycosylated haemoglobin measured by colorimetry (GHb) and by the 
minicolumn cation chromatographic techniques (HbAp HbA^c, HbA^a+ )^ 
were compared and are shown in Figures 8.7, 8.8 and 8.9. Figure 8.7a 
shows the correlations of HbA-^  and GHb and Figure 8.7b the correlation 
of HbA^c and GHb in diabetics with normal renal function. A strong 
and significant positive linear correlation was found in both 
comparisons. Linear regression analysis was carried out in diabetics 
with renal failure comparing HbA-^  (Figure 8.8a) and HbA^c (Figure 
8.8b) with GHb. A strong linear correlation was found for both 
methods. Comparison between HbA-^ a+  ^and GHb in diabetics with normal 
renal function is shown in Figure 8.9a and Figure 8.9b shows the 
correlation between HbA^a+  ^and GHb in diabetics with renal failure. 
Linear regression analysis shows that the correlation was less strong 
in both diabetic groups with the HbA^a+  ^fraction compared to the HbA^ 
and HbA-^ c fractions, although a significant correlation was found in 
all. No significant correlations between GHb and HbA^ or HbA^c or 
HbAia+b were found in any of the non-diabetic uraemic groups.
Comparison of the microcolumn methods for each fraction are shown 
in Table 8.VII. The correlation coefficients for each patient group 
are shown with the strongest correlation in diabetics with and without 
renal failure. Generally the best correlation was found in comparing 
the HbA-^  component with the HbA^c fraction.
The ratio of HbA^a+ /^HbA-^ c for each group is shown in Table 
8.VIII. The values are mean and (SD). The ratio ®>A^ ^/HbA^ was 
significantly increased in all non-diabetic uraemics compared to the 
control group due to a relatively greater increase in the HbA^a+^
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Table 8. VII 
C o r r e l a t i o n  c o e f f i c i e n t s  (r) of
HbA-] and s u b f r a c t i o n s
GROUP A 1 v A 1c A 1 v A 1 a+b A 1 c v A 1 a + b
C 0.731 0 . 7 0 7 0 . 7 4 9
CRF 0 . 5 1 8 0 . 5 3 9 0 . 7 1 2
CAPD 0 . 7 2 4 0 . 6 9 5 0 . 5 5 5
HD 0 . 4 7 5 0 . 3 8 8 0 . 3 1 8
DIAB 0 . 8 5 7 0 . 8 2 9 0 . 6 7 5
DI A B - R F 0 . 8 8 9 0 . 7 6 3 0 . 7 9 9
Comparison of ion exchange chromatographic methods
Rat i o
Table 8. V I I I  
of HbA-j a+b/H^A-] c
GROUP n H b A 1 a + b / H b A lc P
C 20 0 . 2 9 2  (0.021)
CRF 40 0 . 3 2 8  (0.049) < 0 . 0 1
CAPD 24 0 . 3 6 8  (0.039) < 0 . 0 0 1
HD 31 0 . 3 4 7  (0.046) < 0 . 0 0 1
DIAB 22 0 . 2 5 7  (0.033) < 0 . 0 1
DIAB -RF 24 0.301 (0.042) NS
V a lu es are m e a n and (SO)
p valu es r e f e r  to c o m p a r i s o n  w i t h  c o n t r o l s
Identical le v e l s  of s i g n i f i c a n c e  w e r e  o b t a i n e d  
by both M a n n  W h i t n e y  t e s t  and A n a l y s i s  of 
V a r i a n c e
fraction. Diabetics with normal renal function had a significantly 
lower ratio due to a relatively greater increase in the HbA^c 
components. Diabetics with renal failure had a ratio similar to 
controls, even though the absolute quantities of both HbA^a+  ^and 
HbA^c increased.
4. Glycosylated haemoglobin and renal function
Comparison of glycosylated haemoglobin (HbA-^ , HbA^c, HbA^^^, GHb) 
and both urea and creatinine were sought by linear regression 
analysis.
HbA-^  and urea showed no significant correlation in any of the 
groups except for the HD group (r=0.502, p<0.01). All the other 
groups had an r value below 0.2. HbA^ and creatinine showed no 
correlation in any of the groups except controls (r=0.710, p<0.001).
HbA^c and urea showed no correlation in any of the groups with the 
exception of a modest correlation with the CAPD group (r=0.460, 
p<0.05). HbA^c and creatinine did not show any correlation in any of 
the groups.
HbAia+b an£* urea were observed to have a correlation in the CRF 
(r=0.331, p<0.05) and CAPD (r=0.422, p<0.05) groups but not in any of 
the others. HbA-^ a+  ^and creatinine were correlated in the CAPD group 
(r=0.473, p<0.05) but not in the others. Neither urea nor creatinine 
showed any correlation with GHb in any of the groups. Overall none of 
the glycosylated haemoglobin components consistently correlated with 
urea or creatinine in any of the groups.
Glycosylated haemoglobin did not correlate with random blood 
glucose, total haemoglobin, sex or age in any of the groups.
5. Carbamylated haemoglobin and renal function
Carbamylated haemoglobin (CHb) expressed as isopropyl hydantoin 
(IPH) was similar in controls (Table 8.VI) to both diabetics and 
patients with primary renal disease (Table 8.XIII). The 'normal1 
concentration of CHb was 26 (range 23-29) in 20 healthy controls. 
Combining the above 3 groups a non-uraemic reference range was 
determined in 64 patients: mean=27, range 22-32 ng IPH/mg globin.
Comparison of CHb concentrations and renal function are show in 
Table 8.IX and Figures 8.10 and 8.11. The correlation coefficients 
and p values between CHb and both urea and creatinine are shown in 
Table 8.IX. A stronger correlation was found between CHb and urea 
than between CHb and creatinine. The strongest correlation was found 
in undialysed patients with chronic renal failure. Controls showed a 
weak correlation but diabetics with normal renal function showed no 
correlation. Figure 8.10a displays a significant positive linear 
correlation between CHb and urea in the CRF group and Figure 8.10b 
shows the correlation between CHb and creatinine in the CRF group.
The comparison between CHb and urea for diabetics with renal failure 
is shown in Figure 8.11. The CAPD group was found to have a stronger 
correlation between CHb and both urea and creatinine than the 
haemodialysis (HD) group.
CHb and bicarbonate: No significant correlation was found between CHb 
and bicarbonate in any of the groups with the exception of the CAPD 
group (r=-0.411, p<0.05), which had a mean bicarbonate level within 
the normal range.
Table 8. IX
C o r r e l a t i o n  of C a r b a m y l a t e d  H a e m o g l o b i n  
and Renal F u n c t i o n
GROUP U R E A C R E A T I N I N E
n r P r P
C O N T R O L 20 0.551 <0.0 5 0.521 < 0.0 5
CRF 40 0 . 7 5 2 <0.001 0 . 6 2 4 <0.001
CAPD 24 0 . 5 5 2 <0.01 0 . 4 6 7 <0. 0 5
HD 31 0 . 4 4 0 <0.0 5 -0 . 0 2 2 NS
DIAB 13 0 . 4 8 3 NS 0 . 4 4 5 NS
D I AB -RF 22 0 . 5 8 2 <0.001 - 0 . 0 6 5 NS
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CHb and haemoglobin: There was no correlation between CHb and total 
haemoglobin (or PCV) in any of the groups.
CHb and glucose: No correlation between CHb and random blood glucose 
was observed in any of the groups.
6. Carbamylated and glycosylated haemoglobin
CHb and HbA :^ Plots showing the correlation between HbA-^  and CHb are 
shown in Figure 8.12. In the CRF group (Figure 8.12a) and the CAPD 
group (Figure 8.12b) a significant positive linear correlation was 
found between the 2 variables. A weak correlation (r=0.355, p<0.05) 
was found in the HD group but no significant correlation was found 
between HbA^ and CHb in diabetics with renal failure (Figure 8.13).
CHb and HbA^g: HbA^c and CHb showed a significant linear correlation 
in CRF patients (r=0.605, p<0.001) as displayed in Figure 8.14. A 
moderate correlation was found in the CAPD group (r=0.434, p<0.01).
No correlation was found between the variables in either the HD 
(r=0.042) or the diabetic renal failure groups (r=0.178).
CHb and HbA^ +^ :^ HbA-^ a+  ^and CHb showed a significant positive 
correlation in CRF and CAPD patients as seen in Figures 8.15a and 
8.15b. The HD and diabetic renal failure groups showed no correlation 
(HD: r=0.233; D-RF: r=0.248).
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CHb and GHb: There was generally no correlation between glycosylated 
haemoglobin measured by colorimetry and CHb. The only exception was a 
weak correlation in the CRF group (r=0.341, p<0.05). No correlation 
was observed between GHb and CHb in diabetics with renal failure 
(r=0.174).
Overall there was a correlation between CHb and the 
chromatographic measured components of glycosylated haemoglobin but 
not with the colorimetric measured species. This relationship was 
seen in non-diabetic uraemic patients, particularly the CRF and CAPD 
groups, but not in diabetics with renal failure.
The absolute values for glycosylated and carbamylated haemoglobin 
were shown in Table 8.VI and a summary of the relative change, in each 
variable for each patient group, compared to the control group is 
shown in Table 8.X. HbA-^  increased by about 12 to 20% in the 
non-diabetic uraemic patients compared to a 50% increment in 
diabetics. HbA^c showed more variation but less relative change in 
uraemics while diabetics had a rise of about 50%. was
increased by over 50% in uraemic diabetics but all the uraemic groups 
showed a relatively greater increase in the HbA^a+  ^fraction than the 
HbAic. GHb showed negligible change in non-diabetics while both 
diabetic groups showed an increment of 35 to 40%. CHb had a 2 to 
4-fold increase in all uraemic patients including diabetics with 
uraemia.
7. The effect of haemodialysis
Several variables were measured in 9 haemodialysis patients 
immediately pre- and post- a 4 hour dialysis session. The paired * t' 
test was used to compare the changes. The results are shown in Table
Table 8. X
R e l a t i v e  c h a n g e  in g l y c o s y l a t e d  and 
c a r b a m y l a t e d  h a e m o g l o b i n
HbA']
%
H b A 1c
%
H b A 1a+b
%
G H b
%
CH b
%
CRF 2 2 . 4 18.1 3 3.3 3.0 427
CAP D 21.6 16.8 47.1 <1 385
HD 12.9 3.8 2 2.9 <1 285
D 51.9 57.5 3 8.6 4 0.3 4
D-RF 52.0 47.2 51. 0 35.1 3 0 4
T x - R F 1 1.4 9.3 19.0 4.6 235
V a l u e s  are the p e r c e n t a g e  c h a n g e  (inc r e a s e )  in c o m p a r i s o n  
to cont rols.
Table 8. XI 
The effect of haemodialysis
Pre Dialysis Post Dialysis P
Glucose 4.2 ( 3.9 - 4.6) 6.9 ( 5.6 - 8.1) < 0.001
A1 9.0 ( 8.3 - 9.8) 9.1 ( 8.6 - 9.6) NS
Alc 5.3 ( 4.9 - 5.7) 5.3 ( 4.9 - 5.7) NS
Ala+b 1.9 ( 1.7 - 2.1) 2.0 ( 1.7 - 2.2) NS
GHb 38.3 (35.2 - 41.4) 36.8 (34.7 - 38.9) NS
CHb 111 (84 - 139) 100 (79 - 120) NS
Urea 26.9 (23.3 - 30.5) 12.9 (9.2 - 16.5) < 0.001
Creatinine 1043 (928 - 1159) 568 (516 - 622) < 0.001
H+ 43.4 (40.1 - 44.6) 36.1 (32.4 - 39.8) < 0.01
Bicarb 22.2 (21.4 - 23.1) 25.8 (24.5 - 27.0) < 0.001
n = 9
Values are mean and (95% C.I.)
P-comparison between pre and post dialysis
Table 8. XII
Correlation between Glycosylated/Carbamylated 
Haemoglobin and Bicarbonate/H+ concentrations
GROUP n r P
HbA'i vBic C 20 0.238 NS
HbA-| vBic CRF 40 0.141 NS
HbA-j vBic CAPD 24 -0.545 < 0 . 0 1
HbA-j vBic HD 31 -0.425 < 0.05
HbA1vH+ HD 8 0.221 NS
HbA-] vBic DIAB-RF 24 -0.044 NS
H b A ^ v B i c . CRF 40 0.033 NS
H b A ^ v B i c CAPD 24 -0.441 < 0 . 0 5
H b A ^ v B i c HD 31 -0.191 NS
HbAlc vH+ HD 8 -0.086 NS
H b A ^ v B i c DIAB-RF 24 0.205 NS
HbA1a+bvBic CRF 40 0.094 NS
HbA1a+bvBic CAPD 24 -0.576 <0.01
HbA1a+bvBic HD 31 0.026 NS
HbA1a+bvH+ HD 8 -0.396 NS
HbA1a+bvBic DIAB-RF 24 -0.197 NS
GHbvBic CRF 40 -0.070 NS
GHbvBic CAPD 24 -0.386 NS
GHbvBic HD 31 -0.095 NS
GHbvH+ HD 8 0.282 NS
GHbvBic DIAB-RF 24 -0.160 NS
CHbvBic CRF 40 -0.234 NS
CHbvBic CAPD 24 -0.411 <0.05
CHbvBic HD 31 -0.254 NS
CHbvH+ HD 8 0.232 NS
CHbvBic DIAB-RF 24 0.102 NS
8.XI (values are mean and 95% Cl). Blood glucose (random) and plasma 
bicarbonate increased (p<0.001), while hydrogen ion concentration 
(p<0.01), blood urea and serum creatinine decreased (p<0.001). 
Glycosylated haemoglobin (HbA-p HbA-^, HbA^a+fc, GHb) and carbamylated 
haemoglobin did not change.
8. The effect of acidosis
Comparison between plasma bicarbonate and both glycosylated 
haemoglobin and carbamylated haemoglobin in general showed no 
significant correlation. Correlation coefficients are shown in Table
8.XII. A weak but persistent correlation was found in the CAPD group 
but the bicarbonate concentration was essentially normal. As a group 
the CRF patients were more 1acidotic' but no correlation was found. 
There was no correlation between H+ ion concentration in the HD group 
and either glycosylated or carbamylated haemoglobin.
9. Glycosylated and carbamylated haemoglobin in renal transplantation 
This part of the study evaluated 4 groups of subjects: controls
(as previously described), patients with underlying renal pathology 
but normal renal function i.e. primary renal disease (PRD), renal 
transplant subjects with normal renal function (Tx) and renal 
transplants with failing graft function (Tx-RF).
a) General data
Age and sex are shown in Table 8.1; total haemoglobin, PCV and 
albumin in Table 8.II; and urea, creatinine and bicarbonate in Table 
8.III. Patients in the PRD group were similar to controls for all 
variables. Transplants with normal renal function had normal total 
haemoglobin, PCV, albumin, urea, creatinine and bicarbonate.
Transplants with renal failure had reduced total haemoglobin, PCV and 
bicarbonate and increased urea and creatinine. Random blood glucose 
(Table 8.IV) was normal in all groups.
b) Glycosylated and carbamylated haemoglobin
Glycosylated haemoglobin (HbA^ , HbA-^ c, HbA-^ a+ ,^ GHb) and 
carbamylated haemoglobin are shown in Table 8.XIII. Values are mean 
(SEM) and [95% Cl]. Figure 8.16 shows the chromatographic measured 
components of haemoglobin A-^, i.e. HbA^, HbA^c and HbA^a+  ^for each of 
the 4 groups. Values are mean and 95% Cl, and statistical differences 
are also shown. The PRD group had similar HbA^, HbA^c and HbA^^-^ 
values as the control group. Transplants with normal renal function 
had an increase in HbA^ concentration (p<0.05) but HbA^c and HbA^a+  ^
were similar to controls. Transplants with renal failure had an 
increase in HbA^ (p<0.01), HbA-^ c (p<0.05) and HbA^a+  ^(p<0.01).
Glycosylated haemoglobin measured by colorimetry (GHb) is shown in 
Figure 8.17 (values are mean and 95% Cl) for each of the 4 groups. 
There was no change in GHb and all groups were similar to controls.
Carbamylated haemoglobin is shown in Figure 8.18 with the scatter 
of values, mean, 95% Cl and statistical difference between the groups. 
The control and PRD groups were similar but transplants with normal 
renal function, although they generally overlapped with the control 
group, had a few individuals with elevated concentrations of CHb and 
the mean of the Tx group was significantly increased (p<0.05). 
Transplants with renal failure showed a wide scatter and the mean CHb 
concentration was grossly elevated (p<0.001).
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c) Renal function and other associations
HbAp HbA^c and GHb did not correlate with either urea or 
creatinine in any of the groups. HbAia+b showed a significant 
correlation (r=0.602, p<0.05) with urea but not with creatinine in the 
Tx-RF group. The other groups showed no correlation with HbA^a+ .^
CHb was found to have a strong positive linear correlation with urea 
in the transplants with renal failure (r=0.874, p<0.001) and is 
plotted in Figure 8.19. The other groups did not show any correlation 
between CHb and urea. Transplants with renal failure also showed a 
correlation between CHb and creatinine (r=0.589, p<0.05) but this was 
not observed in the other groups.
Comparison of bicarbonate with HbA^ , HbA^c or HbA^a+  ^did not show 
any correlations between the variables in any of the groups.
In transplants with renal failure CHb and HbA-^ a+  ^showed a strong 
correlation (r=0.761, p<0.01) but correlations of CHb with HbA^ 
(r=0.471, p-NS) or HbA-^ c (r=0.634, p<0.05) were less obvious. The 
other groups did not show any correlation between CHb and glycosylated 
haemoglobin.
The ratio of HbA^a+ /^HbA-^ c in transplants with renal failure was 
significantly higher than controls (p<0.01). The other groups showed 
no change in the HbAia+b/HbA^c ratio.
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DISCUSSION
The aims of this study were to evaluate glycosylated and 
carbamylated haemoglobin in uraemia and attempt to clarify the 
confusing and conflicting data in the literature. In this large 
study, over 200 patients with varying degrees of renal impairment were 
studied. Different methods of measurement and several components of 
glycosylated haemoglobin were assessed and the association with 
carbamylated haemoglobin examined.
This study showed elevation of chromatographically determined 
glycosylated haemoglobin (HbAp HbA^c and HbA^a+ )^ and normal 
colorimetrically measured glycosylated haemoglobin in non-diabetic 
uraemic subjects. The increased formation of carbamylated haemoglobin 
was confirmed and showed a parallel rise with HbA-^  and its 
sub-fractions. This investigation provides strong evidence that this 
non-glucose adduct of haemoglobin is responsible for the interference 
and 'false' elevation of glycosylated haemoglobin measured by 
ion-exchange column chromatography. Carbamylation of haemoglobin was 
strongly influenced by the degree of uraemia but was detectable in 
non-uraemic subjects. Diabetics with renal failure had elevated 
glycosylated haemoglobin independent of assay method and increased 
carbamylated haemoglobin, but the latter did not correlate with 
glycosylated haemoglobin.
1. Study design
This study was designed to measure simultaneously, i.e. from the 
same blood specimen, the chromatographic components of HbA^, total 
glycosylation of the red cell, carbamylated haemoglobin and other 
biochemical variables in a population of uraemic and diabetic 
patients. This enabled a comparison to be made between the components
of glycosylated haemoglobin and carbamylated haemoglobin in 
individuals.
A number of situations can cause interference with the measurement 
of chromatographically determined glycosylated haemoglobin (Gabbay e£ 
al., 1983) and these have been discussed in Chapter 4. In the study 
protocol several exclusion criteria were implemented to reduce 
interfering factors. None of the subjects had a recent blood 
transfusion (within 3 months of the study), haemoglobinopathy, 
jaundice or had recent alcohol, antibiotic or aspirin ingestion. The 
presence of hyperlipidaemia was, however, not excluded and as most 
subjects were uraemic or diabetic or both, interference from 
lactescence cannot be ruled out. Lactescent plasma due to 
hyperlipoproteinaemia has been shown to elute with the HbA^ fraction 
(Dix et al., 1979a). In reality, it would be very difficult to find a 
population of uraemic or diabetic patients without some degree of 
hyperlipidaemia. The determination of total glycosylation in the red 
cell by a direct chemical method (colorimetry) circumvents most 
interfering factors, but shortened red cell life span can reduce the 
concentration of glycosylated haemoglobin independent of methodology. 
In uraemia red cell survival is generally accepted to be reduced in 
undialysed chronic renal failure (Shaw, 1967), haemodialysis (Fried at 
al., 1978) and CAPD patients (Hefti et al., 1983). However, by the 
simultaneous measurement of both chromatographic and colorimetric 
determined glycosylated haemoglobin the net effect of reduced 
erythrocyte life span should be minimised.
In view of the multiple groups of patients investigated and the 
numerous variables measured the risk of a type-I error is increased 
and thus some caution has to be used in the statistical interpretation 
of the results.
2. Methodology
Much of the confusion about glycosylated haemoglobin is related to 
nomenclature and methodology. This has been discussed in Chapters 4 
and 5. In this study two separate cation exchange minicolumn 
chromatographic methods were used. One measured HbA^ (i.e. total 
HbA-^ a+ j^_c) and the other measured the specific fractions HbA^c and 
HbAfa+b* These methods based on the principle of a net change in 
charge were quite similar, with different fractions being eluted by 
changing the buffer solution. The assays used whole blood 
haemolysates, were sensitive to temperature changes, required a high 
degree of operator skill to achieve reproducibility and precision, and 
were relatively expensive. All assays were performed in a water bath 
with a constant ambient temperature of 26°C. Glycosylated haemoglobin 
was also measured by the thiobarbituric acid - colorimetric method, 
whereby furfural compounds are generated from the ketoamine linked 
carbohydrate moieties upon acid hydrolysis and quantified 
colorimetrically after reacting with thiobarbituric acid. This direct 
chemical method measures the total glycosylation in the red cell and 
has the advantages of being unaffected by non-glucose adducts, 
aldimine intermediates and is inexpensive to run, but has the 
drawbacks of having no universally accepted standard, hydrolysis 
conditions must be carefully controlled for precision, and is a 
time-consuming, labour intensive procedure compared to the minicolumn 
kits.
3. Haemoglobin glycosylation
In this study HbA^ was significantly increased in non-diabetic 
uraemic patients. This is in general agreement with many others 
(DeBoer et al., 1980; Graf et al., 1980; Kovarik et al., 1981). HbA^
was found to be increased by 13 to 20% in uraemics compared to 
controls. The increment was greater in non-dialysed chronic renal 
failure and CAPD patients than haemodialysis patients. By comparison 
diabetics independent of renal function had a greater rise in HbA^, 
showing a 50% increase.
HbA-^ c has been less frequently measured in non-diabetic uraemics, 
but the elevated concentrations found in this study are in agreement 
with others (Graf et al., 1980; O’Regan et al., 1982; Saloranta eit 
al., 1986). HbA-^ c increased proportionately less in uraemics (less 
than 20%), in contrast to increments of 40 to 50% in diabetics.
The HbA-^ a+k fraction was increased in diabetic and uraemic 
patients. HbA-^ a+  ^has been reported to be increased in uraemia 
(Fluckiger et al., 1981; Lantz et al., 1981) but no elevation of this 
fraction was found in diabetics with uraemia (Saloranta et al., 1986). 
In the present study HbA^a+  ^increased by between 20 and 50% in 
non-diabetic uraemic patients, by about 40% in diabetics with normal 
renal function and by 50% in diabetics with renal failure.
Glycosylated haemoglobin measured by colorimetry was unchanged by 
uraemia, both in this study and in the pilot study (unpublished data) 
and was only increased in the presence of diabetes. This is in 
agreement with the findings of others (Fluckiger et al., 1981; Nath e_t 
al., 1982). Thus differences in methodology can explain some of the 
confusion regarding glycosylated haemoglobin in uraemia. Furthermore, 
the effect of reduced red cell life span, which could conceivably 
suppress glycosylated haemoglobin concentration independent of 
methodology, was not seen in the colorimetric estimation as 
non-diabetic uraemic patients had similar values to control subjects. 
Colorimetrically measured glycosylated haemoglobin (GHb) was, by 
chance, similar in both diabetics with and without renal impairment.
This finding allows further comparison between the methods and renal 
function in diabetics.
Comparison of the methods of measuring glycosylated haemoglobin 
showed an excellent correlation between the colorimetric and 
chromatographic techniques for diabetics, independent of renal 
function, and particularly for the HbA-^  and HbA-^ c components. ^^ia+b 
was found to have a strong correlation with the colorimetric method in 
diabetics with renal failure, while diabetics with normal renal 
function showed a weaker, though statistically significant 
correlation. No correlation was found between the 2 different methods 
in non-diabetic uraemic patients. This latter finding is in agreement 
with others (Fluckiger et al., 1981; Oimomi et al., 1981).
The data from this investigation suggests that either method of 
estimating glycosylated haemoglobin can be used to monitor blood 
glucose control in diabetics with renal failure. The colorimetric 
method is unaltered by uraemia and may be the preferred method, but it 
has other limitations as previously discussed. The excellent 
correlation between colorimetry and chromatography suggests that HbA-^  
or HbA^c is still useful and its rapid estimation does allow the 
result to be available more readily and is particularly suitable for 
out-patient management. The assumption that since uraemic patients 
have elevated HbA-^  or HbA^c then diabetic uraemic patients would have 
false elevation of glycosylated haemoglobin must be questioned. There 
is little data in the literature specifically on glycaemic control in 
uraemic diabetics, but data extracted from 2 studies show conflicting 
results. Kumar et al. (1983) found HbA-^  to be higher in uraemic 
diabetics than non-uraemic diabetics, but clinically the latter were 
better controlled and the number of patients studied was small. Thus 
the difference may be due to the glycaemic rather than the uraemic
effect. In contrast, Saloranta et al. (1986) found no difference 
between uraemic and non-uraemic diabetics in HbA-^  or HbA^c
concentrations measured chromatographically. In the present study the
similar GHb measurements by colorimetry in the uraemic and non-uraemic 
diabetics gave an independent assessment that both groups had similar 
glycaemic control uninfluenced by uraemia. Comparison of the 
chromatographic components showed that HbA^ and HbA^c were also 
similar. This provides further evidence that chromatographically 
measured glycosylated haemoglobin is still a useful clinical measure 
of glycaemic control in uraemic diabetics.
The ratio of chromatographically determined HbA^ components 
demonstrated that the HbA^a+  ^fraction was more influenced by uraemia 
and the HbA^c fraction by diabetes. This has been previously 
suggested by others (Fluckiger et al., 1981; Oimomi et al., 1981). In
diabetics with renal failure both fractions were proportionately 
raised and thus the ratio was unchanged.
HbA^ and components had a weak, but significant correlation with 
urea in some of the non-diabetic uraemic groups, but the relationship 
was quite variable. The HbA^a+  ^fraction correlated with urea in 
non-dialysed chronic renal failure and CAPD patients but not in 
haemodialysis subjects. Diabetics with renal failure showed no 
association between glycosylated haemoglobin concentration and renal 
function. Thus, overall no consistent significant correlation was 
found between either random (at time of sampling for glycosylated 
haemoglobin) urea or creatinine and glycosylated haemoglobin. A weak 
but significant correlation between HbA-^  and creatinine (Graf, 1980; 
Kovarik et al., 1981), between HbA-^  and urea (Oimomi et al., 1984; 
Saloranta et al., 1986) have been reported, while others have found no 
correlation (Nath et al., 1982; 0'Regan et al., 1982). Furthermore,
others have reported a significant correlation between both urea and 
the time-averaged concentration of urea and HbA-^  in non-dialysed 
chronic renal failure patients but no correlation in haemodialysis 
patients (DeMarchi et al., 1983a; DeMarchi et al., 1983b). This 
variable response was seen in the present study and may be explained 
by the difference in uraemic status between haemodialysis patients, 
who have wide fluctuations in urea concentration, and other uraemics 
who tend to have a more stable level of blood urea. This will be 
discussed later in relation to carbamylated haemoglobin.
All glycosylated species of haemoglobin showed no correlation with 
random glucose, total haemoglobin, age or sex in any of the groups 
including diabetics. It is well recognised in diabetes that 
glycosylated haemoglobin reflects the time-averaged concentration of 
glucose rather than random glucose estimations. However, as 
previously discussed, there is ample evidence against glucose 
intolerance or hyperglycaemia being the explanation of elevated 
glycosylated haemoglobin in uraemia.
4. Haemoglobin carbamylation
Carbamylated haemoglobin was estimated by detecting the amount of 
isopropyl hydantoin released after hydrolysis of globin. Increased 
concentrations of carbamylated haemoglobin were demonstrated in all 
patients with renal impairment. Non-uraemic diabetics and patients 
with underlying renal pathology but normal urea and creatinine, had 
similar concentrations as control subjects. These results confirm the 
only previous report of direct measurement of haemoglobin 
carbamylation in uraemia (Fluckiger et al., 1981). These workers 
detected valine hydantoin from the eluate of three haemoglobin peaks 
(HbAp HbA^a+k anc* HbA^ ) of a uraemic haemolysate chromatographed on
a macrocolumn. Although they did not detect valine hydantoin in 
non-uraemic haemolysate a highly significant correlation was found 
between the amount of valine (isopropyl) hydantoin released from 
haemoglobin and the time-averaged urea concentration in uraemic 
patients.
In the present study modification of the assay, (detailed in 
Chapter 5) increased its sensitivity and isopropyl (valine) hydantoin 
release was detected in non-uraemic subjects. A normal range can now 
be established. In 64 patients with normal renal function a mean 
value of 27 ng IPH/mg globin with a 95% confidence interval of 22 to 
32 ng IPH/mg globin was found. Patients with overt renal failure had 
gross elevation with increases of 200 to over 400% and there was no 
overlap between uraemics and non-uraemics. Carbamylated haemoglobin 
had a significant correlation with urea and creatinine in uraemic 
patients. Urea estimations in this study were taken from a single 
random sample, whereas Fluckiger et al. found a strong correlation 
using time-averaged urea concentrations in a small group of patients. 
Carbamylated haemoglobin has been more extensively studied in Sickle 
Cell disease and the carbamylation mechanism is represented by an 
irreversible covalent second-order kinetic reaction (Uvelli et al., 
1978; Uvelli et al., 1980). Most studies report in vitro 
carbamylation characteristics, but it is likely that in vivo the urea 
derivative isocyanate forms a stable adduct with the N-terminal amino 
group on the haemoglobin chain (Manning et al., 1974), analogous to 
the non-enzymatic glycosylation reaction. Although there are some 
differences in the biochemical characteristics and binding sites 
between carbamylated haemoglobin and glycosylated haemoglobin they, 
nevertheless, share several common features. Thus one can postulate 
the analogy, between urea and carbamylated haemoglobin in uraemia and
glucose and glycosylated haemoglobin in diabetes. In both situations 
low molecular weight reactants, urea-derived isocyanate and glucose, 
are present in limited amounts, but as both reactions with haemoglobin 
are irreversible the modified haemoglobin accumulates in the red cell 
throughout its life span. Hence in both conditions haemoglobin 
behaves as a reporter molecule.
In this investigation carbamylated haemoglobin significantly 
correlated with chromatographically determined glycosylated 
haemoglobin in uraemic patients. This is in agreement with the in 
vitro findings of raised HbA-^  in normal erythrocytes incubated with 
cyanate (Oimomi et al., 1984). Non-dialysed chronic renal failure and 
GAPD patients showed the strongest correlation with HbA^, HbA^a+  ^and 
HbAfc, but haemodialysis patients tended to have a weaker and more 
variable correlation and diabetics with chronic renal failure showed 
no correlation. The generally weaker association in haemodialysis 
patients can be explained by the fluctuating concentrations of urea, 
which reach a peak pre-dialysis and trough post-dialysis. These 
oscillations will influence the time-averaged urea concentration and a 
random urea estimation is not representative. In contrast, most of 
the non-dialysed chronic renal failure and CAPD patients had a 
relatively more stable urea concentration which was more 
representative of the time-averaged urea. The lower carbamylated 
haemoglobin in haemodialysis patients also explains the lower HbA^, 
HbA-^ c and HbA^a+  ^concentrations generally observed in relation to 
other uraemic patients. It is possible that reduced red cell life 
span, due to haemolysis in the extracorporeal circulation, may have 
contributed to lower values in haemodialysis patients. However, there 
was no direct evidence to support this and colorimetrically measured 
glycosylated haemoglobin which is equally dependent of red cell life
span was also normal.
The combination of glycosylation and carbamylation of haemoglobin 
was observed in diabetics with renal failure. In these patients 
carbamylated haemoglobin correlated with urea but not with HbA^ and 
sub-fractions. HbA^ and sub-fractions correlated with 
colorimetrically determined glycosylated haemoglobin (the latter 
reflecting time-averaged glucose concentrations and unaffected by 
uraemia). From the molecular point of view, it is possible for both 
reactions to occur together and although they share the common binding 
site at the N-terminal valine residue, the glycosyl moiety is attached 
predominantly to the 3 chain (Bunn et al., 1979) while the carbamyl 
moiety is distributed to both a and 3 chains with a slight preference 
for the a chain (Manning et al., 1974; Nigen et al., 1974). Several 
other binding sites for both adducts have been identified but this 
detail is beyond the scope of this discussion.
The combination of both reactions in uraemic diabetics may
initially appear antagonistic. However, the colorimetrically
determined glycosylated haemoglobin was similar, in both diabetics
with and without renal failure and the similar HbA.. and HbA, values1 lc
confirm that the latter measurements reflect the glycaemic rather than 
the uraemic effect in diabetics with renal failure. The marginal 
difference in HbA^a+  ^between the diabetic groups would be in keeping 
with a small carbamylation effect. In non-diabetic uraemic patients 
all 3 components HbAp HbA^c and HbA^a+  ^were increased, but the 
HbA-^ a+k sub-fraction was relatively more increased, which is in 
partial agreement with Fluckiger et al. (1981) who detected most of 
the carbamylated haemoglobin (valine hydantoin) from the HbA^a+  ^
fraction. Carbamylated haemoglobin did not show any correlation with 
age, sex or total haemoglobin concentration.
The effect of reducing urea and creatinine concentrations and
correcting the metabolic acidosis during a 4 hr haemodialysis session
did not induce any acute change in either glycosylated or carbamylated 
haemoglobin. The latter are formed by a non-enzymatic process taking 
weeks or months and dependent on the life span of the red cell as well 
as the ambient glucose or urea concentration.
It has been suggested that uraemic acidosis plays a major role in
the elevation of glycosylated haemoglobin (DeMarchi et al., 1983a; 
DeMarchi et al., 1983b). This was based on data showing correlations 
between HbA-^  and either arterial blood pH or plasma bicarbonate. In 
this present study no correlation was found between glycosylated 
haemoglobin and either H+ concentration or plasma bicarbonate and is 
in agreement with others (Panzetta et al., 1983).
Generally, patients with a primary renal disease or a renal 
transplant but normal renal function, showed the same features as 
control subjects. However, carbamylated haemoglobin was elevated in a 
few transplant individuals who had rejection episodes or were 
recovering from post-transplant acute tubular necrosis over the 
preceding 3 months. This reflects the retrospective marker effect of 
carbamylated haemoglobin. Transplant patients with failing graft 
function were similar to other chronic renal failure patients and 
demonstrated elevation of carbamylated haemoglobin, HbA^, HbA^c an(* 
particularly HbA^a+ .^ The association between carbamylated 
haemoglobin and HbA^a+k was reaffirmed and both variables showed a 
strong correlation with both urea and creatinine.
5. Red cell life span
Reduced concentrations of HbA-^  in uraemia have been reported by 
one group (Dandona et al., 1979; Freedman et al., 1982) who explained
their findings by assuming shortened red cell life span was 
responsible. However, this was not measured in the study. As 
previously discussed, reduced erythrocyte survival is well documented 
in uraemia, but no studies have been published that directly measure 
red cell life span in conjunction with glycosylated haemoglobin in 
uraemia. Glycosylated haemoglobin measured by colorimetry is 
dependent on red cell life span and the finding that all uraemic 
patients had normal values is evidence, albeit indirect, that red cell 
survival in uraemia does not have a significant effect on the 
measurement of glycosylated haemoglobin. Decreased glycosylated 
haemoglobin has been demonstrated in haemolytic but not non-haemolytic 
anaemia (Panzer et al., 1982). Thus the normochromic normocytic 
anaemia of uraemia should not affect glycosylated haemoglobin 
concentrations. There is no data available on carbamylated 
haemoglobin and erythrocyte survival in uraemia, but it is interesting 
that in Sickle Cell disease cyanide was used therapeutically and the 
resultant carbamylated haemoglobin prolonged sickled red cell life 
span and increased oxygen affinity (Cerami et al., 1971; Gillette et 
al., 1974). The increase in red cell life span reflected the degree 
of carbamylation (Milner and Carache, 1973; Gillette et al., 1974).
It might be postulated that the formation of carbamylated haemoglobin 
could prolong red cell survival in uraemia and this may also directly 
affect glycosylated haemoglobin. However, this is purely speculative 
and further studies are necessary to elucidate any relationship 
between carbamylated haemoglobin and red cell life span.
The analogy between non-enzymatic carbamylation in uraemia and 
non-enzymatic glycosylation in diabetes should create further avenues 
of research. The possible clinical and pathophysiological role of 
non-enzymatic carbamylation warrants further investigation. Data from
this study suggests that carbamylated haemoglobin could be a useful 
clinical indicator of the 'uraemic state* as it appears to reflect the 
time-averaged urea concentration. This could be clinically valuable 
in several situations such as differentiating acute from chronic renal 
failure, detecting the timing and progression of chronic renal 
failure, assessing compliance in protein diet restriction therapy and 
evaluating the efficiency of dialysis procedures. The 
pathophysiological role of non-enzymatic carbamylation could have 
wider implications, if it can modify other proteins analogous to 
non-enzymatic glycosylation. Diabetes and uraemia share several 
common pathological complications, such as vascular disease, 
lipoprotein abnormalities and neuropathy and it is tempting to 
speculate that non-enzymatic modification of proteins may be 
implicated. Thus non-enzymatic carbamylation warrants further 
investigation in uraemia to assess both its potential clinical 
usefulness and possible pathophysiological significance.
SUMMARY
In a large number of patients with a wide spectrum of renal 
disease glycosylated haemoglobin was increased in uraemia when 
measured chromatographically but not colorimetrically. All components 
of HbA^ increased, particularly HbA^a+ .^ Carbamylated haemoglobin was 
detected in all subjects, but was grossly elevated in renal failure 
and paralleled the rise in HbA^a_c and correlated with the severity of 
uraemia. Glycosylated haemoglobin increased in both assay methods in 
diabetics independent of renal function, but carbamylated haemoglobin 
was elevated only in uraemic diabetics. HbA-^ c appeared to be more 
influenced by diabetes and HbA^a+  ^by uraemia. Although the 
colorimetric assay may in some situations be the method of choice 
being unaltered by uraemia, it is suggested that HbA^ or HbA^c is 
still useful in monitoring glycaemic control in uraemic diabetics.
The role carbamylated haemoglobin requires further study, but the 
current findings suggest that it may reflect the recent mean uraemic 
state and thus analogous to diabetes and glycosylated haemoglobin. 
Thus, carbamylated haemoglobin may act as a retrospective indicator of 
integrated uraemic control. The concept of non-enzymatic 
carbamylation of proteins may also have some pathophysiological 
significance and warrants further investigation.
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APPENDIX 1
NORMAL VALUES AND REFERENCE RANGE
Mean Reference Range Source
INSULIN 5.0 2.8-13.5 mu/1 1
C-PEPTIDE 0.18-0.52 nmol/1 1
GLUCAGON 70 60-80 pg/ml 2
GROWTH HORMONE 2-10 <10 mu/1 3
CORTISOL 140-610 nmol/1 3
GLUCOSE 5.0 2.2-6.7 mmol/1 4
LACTATE 0.638 0.041-1.136 mmol/1 4
PYRUVATE 0.064 0.029-0.144 mmol/1 4
LACTATE/PYRUVATE RATIO 10.8 7.0-14.5 4
ALANINE 0.304 0.206-0.449 mmol/1 4
3-HYDROXYBUTYRATE 0.046 0.010-0.217 mmol/1 4
ACETOACETATE 0.032 0.007-0.160 mmol/1 4
3-HYDROBUT/ACACETATE RATIO 1.3 0.4-4.8 4
GLYCEROL 0.053 0.031-0.093 mmol/1 4
TOTAL CHOLESTEROL 3.8-7.0 mmol/1 5
TOTAL TRIGLYCERIDES 0.5-2.2 mmol/1 5
HDL-CHOLESTEROL 1.0-1.7 mmol/1 5
GLYCOSYLATED HAEMOGLOBIN (colorimetry) 29-39 mmol HMF/molHb 5
HbA1 7.6 7.3-8.0 % 6
HbAic 6.1 5.9-6.3 % 6
HbAla+b 1.5 0.9-2.3 % 6
CARBAMYLATED HAEMOGLOBIN 27 22-32 ng IPH/mg globin 6
Values from sources 1, 2, 4 and 5 refer to normal subjects after an 
overnight fast
Source
1. Department of Medical Biochemistry, University of Newcastle: 
values are for normal subjects after overnight fast.
2. Prof. Orskov, Kommune Hospitalet, Aarhus, Denmark.
3. Supraregional Assay Service, Royal Victoria Infirmary, 
Newcastle: cortisol values are for 9 am specimens.
4. Adopted by Department of Therapeutics, University of Sheffield, 
from Forster, K.J., Alberti, K.G., Hinks, L. et al., 1978. 
Values are for whole blood.
5. Department of Clinical Chemistry, Royal Hallamshire Hospital, 
Sheffield.
6. Work from this thesis: a) Values for HbAp A^c and A^a+^ are
similar to Biorad Ltd. reference ranges, b) carbamylated 
haemoglobin values have not been previously published: values 
taken directly from this thesis.
APPENDIX 2
1. Free Insulin Concentrations:
Polyethylene Glycol Solution (PEG)
The measurement of free insulin in diabetics was performed after 
removal of insulin antibodies by precipitation with PEG solution,
a) Buffer 3.1g/l Boric Acid
b) Take 200 ml buffer and add lg Bovine Serum Albumin (BSA) 
(Armour) and make up to 400 ml with deionised water.
c) Polyethylene glycol (PEG) 6000 (British Drug Houses). Add 
30 g PEG to 70 g of the buffer/BSA solution (pH 7.2-8.0) to 
give the final PEG solution.
Specimen: 0.25ml fresh serum was added to 0.25ml PEG/buffer
solution, centrifuged at 3000 rpm for 30 minutes at 0°C and 
the supernatant was stored at -20°C until assayed.
2. Due to the instability of pancreatic glucagon, blood was taken 
immediately into the proteinase inhibitor, aprotinin. The 
’preservative’ solution contained:
Disodium EDTA (Sigma) 372 mg, Aprotinin (Trasylol, Bayer) 5ml 
(100,000 Kallikrein Inactivator Units) made up to 10 ml with 
fresh deionised water.
Specimen: 0.25ml of EDTA/Aprotinin was added to a plain glass 
tube and kept at 0°c prior to the addition of 2.5ml of whole 
blood. After separation the serum was stored at -20°C.
3.7g KCL
0.24g/l Thiomersal
39.7ml 0.1 M NaOH
and made up to 1 litre with deionised water
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Work from this thesis has been published, mainly in abstract form, but 
several papers have or are being currently submitted for publication:
1. Pancreatic Beta Cell Function in Non-Diabetics with Renal Failure. 
Scottish Renal Association, Glasgow, April 1985.
2. Pancreatic Beta Cell Function in Non-Diabetics with Renal Failure.
XXII Congress of the European Dialysis Transplant Association, Brussels, 
June, 1985. Published in Proceedings of EDTA 1985;22:1067-1070.
3. Glycosylated and Carbamylated Haemoglobin in Uraemia. XXIII Congress
of the European Dialysis Transplant Association, Budapest, June 1986. 
Abstract in Nephrology, Dialysis and Transplantation 1986; 1(2) :p88.
4. Glucose and Intermediary Metabolism in CAPD. XXIII Congress of the 
European Dialysis Transplant Association, Budapest, June 1986. Abstract 
in Nephrology, Dialysis and Transplantation 1986; 1(2) :pll5.
5. Glycosylated and Carbamylated Haemoglobin in Uraemia. Scottish Renal
Association, Glasgow, October 1986. Abstract in Nephrology, Dialysis 
and Transplantation 1987;2(1) :p59.
6. Hormones and Metabolites in CAPD. IV Congress of the International
Society for Peritoneal Dialysis, Venice, June 1987. Abstract in Peritoneal 
Dialysis Bulletin 1987;7(supp) :S71.
7. Glycosylated Haemoglobin in CAPD. IV Congress of the International
Society for Peritoneal Dialysis, Venice, June 1987. Abstract in Peritoneal 
Dialysis Bulletin 1987;7(supp) :S70.
8. Pancreatic Beta Cell Function in CAPD, submitted to Nephrology, Dialysis
and Transplantation, July 1987.
9. Glucoregulatory Hormones and Intermediary Metabolism in Diabetics
on CAPD. Xth International Congress of Nephrology, London, July 1987.
Abstract in Congress Abstract Book, pl99.
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